OBI & OTRADI April 2024 Newsletter

OBI Client Company Recent Wins

PDX Pharmaceuticals

  • PDX Pharma’s CEO, Dr. Wassana Yantasee, was among eight OHSU researchers inducted into The National Academy of Inventors for 2024.
  • PDX Pharma filed a new provisional patent application on their new asset class, which is based on the nanoparticle delivery of cytokines for treating cancer and autoimmune diseases.
  • PDX Pharma welcomes a new Research Assistant II, Peter Chang, who received his MS, at UC Berkeley, and worked at ReCode Therapeutics before joining the company.

ProMedix

Learn more about OBI’s 31 startups by visiting our website!


Life Science Innovation Northwest
April 17-18

Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This one-and-a-half-day event will bring our life sciences community to discuss and feature some of the most compelling life science breakthroughs of our time.

Registration is open!


Webinar: Understanding How Business
Operations + FDA Regulations Overlap
May 8

In addition to starting and running a typical manufacturing business, MedTech products have additional regulatory requirements such as Quality Management systems, development phases, risk management, document control, and design controls.

In this webinar, Travis Rappleye from Think B Squared will provide an overview of the typical MedTech development process, overlaid on a traditional manufacturing business lifecycle. He will also identify how business and MedTech product development workstreams interplay.

In the startup world, we rarely have the luxury of managing one simple project at a time. Register for this free webinar and learn how to use the overlap strategically to keep your business on track!


OBI Startup Spotlight Expo
September 12

Join us for an evening of innovation and discovery at our inaugural OBI Startup Spotlight Expo! Explore the latest advancements in biotech and life sciences as we showcase the cutting-edge work of OBI’s talented resident company startups.

Enjoy refreshments while mingling with industry leaders, investors, and legislators. The event will take place in our beautiful new event center, providing the perfect backdrop for networking and learning about the future of biotech.

Don’t miss this opportunity to be inspired and connect with the leaders shaping tomorrow’s world. Get your tickets now.

If your company would like to help support this event, please view available sponsorship opportunities.


Bend Venture Conference 2024

BendVenture conference logo with brown mountain in background

Mark your calendars now for Bend Venture Conference, October 17-18, 2024!

Bend Venture Conference (BVC) takes place in beautiful downtown Bend and creates a high level of entrepreneurial activity and energy. For over two decades, BVC has served as a pillar of Central Oregon’s robust entrepreneurial culture that has transformed this small timber community into a mecca for startups. Throughout the conference, attendees hear company pitches, participate in multiple networking activities and listen to inspiring presenters from across the United States.


Upcoming Events

VertueLab’s NSF SBIR/STTR
Proposal Preparation Series
April 10, 17, 24, and May 1, 2024 | 10:30-11:30 a.m.
Virtual
Free to attend – registration

 

OHSU Innovates Speaker Series:
Promoting Inventor Equity in Patenting
April 17, 2024 | 10:00-11:00 a.m.
Virtual
Free to attend – registration

 

ITHS Biomedical Innovation Fireside Chat Series
April 18, and May 2 | 2:00-3:00 p.m.
Virtual
Free to attend – registration

 

OBI Quizzy Business Trivia Night!
April 25, 2024 | 5:30-8:00 p.m.
OBI Event Space, Portland
Space is limited – get tickets now!

 

OBI Accelerate Happy Hour Networking
May 2, 2024 | 5:30-7:00 p.m.
OBI Event Space, Portland
Free to attend – registration required

 

OHSU Innovation Day
May 9 | 10:00 a.m.-2:00 p.m. and 4:00-5:00 p.m.
Virtual for daytime sessions
Late afternoon at OHSU Auditorium, Portland
Free to attend – registration

 

OBI Startup Spotlight Expo:
Featuring the Innovative Startups within OBI

September 12, 2024 | 5:00-8:00 p.m.
OBI Event Space, Portland
Tickets on sale now

OBI & OTRADI March 2024 Newsletter

OTRADI is Granted $2.5M from Business Oregon as a Center of Innovation Excellence

Centers of Innovation Excellence (CIEs) are a key strategy of Business Oregon’s 10-Year Innovation Plan, and OTRADI has been working diligently over the past two years to transition from the now-dissolved Signature Research Center program into to this new CIE program.

OTRADI was created to help startup companies and researchers in Oregon find funding partners with the goal of attracting, growing, and keeping bioscience companies and jobs in Oregon. In addition to providing incubation for fledgling bioscience companies, OTRADI operates the Oregon Bioscience Incubator (“OBI”) which has also developed a collection of programs that provide essential entrepreneurial education, mentorship, and networking opportunities for both OBI client companies and other bioscience and digital health entrepreneurs across the state of Oregon. These programs target the specialized needs of entrepreneurs working across a range of bioscience fields including therapeutics, diagnostics, devices, digital health, health IT, and wearables technologies.

In the 2023 – 2025 biennium, OTRADI will continue to operate the OBI as a Bioscience Center of Innovation Excellence. We are grateful to Business Oregon and the Oregon Innovation Council for supporting the bioscience sector and OTRADI as a new Center of Innovation Excellence. This Project was funded in part by the Oregon State Lottery and administered by the Oregon Business Development Department.


OBI Startup Spotlight Expo

Join us for an evening of innovation and discovery at our inaugural OBI Startup Spotlight Expo! Explore the latest advancements in biotech and life sciences as we showcase the cutting-edge work of OBI’s talented resident company startups.

Enjoy refreshments while mingling with industry leaders, investors, and legislators. The event will take place in our beautiful new event center, providing the perfect backdrop for networking and learning about the future of biotech.

Don’t miss this opportunity to be inspired and connect with the leaders shaping tomorrow’s world. Get your tickets now.

If your company would like to help support this event, please view available sponsorship opportunities.


OBI Client Company Wins

Veana Therapeutics

  • In February, Veana closed on an additional $400,000 tranche in our Seed 2A Round.
  • We also hired Dr. Patricia Beckmann as the new CEO, Dr. Emmanuel Akporiaye will remain with Veana as CSO, appointed Dr. Sandy Shotwell as Board Chair and attracted a new seasoned biotech Board member (Stephen Malaska, J.D., General Counsel at Karius).
  • In January we also expanded our clinical trial from U. Washington/FHCRC to now include Providence Cancer Center, Portland, too.  We also enrolled our first Oregon patient in the trial.

Sirona Dx

  • Grants received: Working on an SBIR for spatial biology.  We are also focused on applying for state funded grants.
  • New hires: Retained a consultant (Eric Breuning, Ph.D.) to drive our effort in applying for government grants.
  • New board members: We are excited to have Dr. Carlo Bifulco, Chief Medical Officer @ Providence Genomics, Translational Molecular Pathology, joining our Scientific Advisory Board.
  • Recent contracts and partnerships: Sirona is the process of signing a master collaboration agreement with Providence Clinical Research to advance the Sirona cutting-edge technologies which allow us to provide insights and analytical capabilities that were previously unimaginable, offering our clients a comprehensive understanding of the complex interactions within the tumor microenvironment and the immune system.

Velanidi Technologies

Hemex Health

  • Progress on India’s National Health Mission to eliminate sickle cell disease: Hemex has made significant progress since winning its first tender in the Indian state of Odisha. Gazelle has been deployed across 20 districts, involving 520 sites in the state. We’ve successfully trained over 700 doctors and technicians.
  • Establishment of the Coimbatore Design Center (CDC): Hemex has opened a new engineering design center, the Coimbatore Design Center, in Coimbatore, India. The CDC is now fully operational with a leadership team in place.
  • Hemex awarded a Phase I grant from the National Heart, Lung, and Blood Institute: Hemex Health Inc. has been awarded a Phase I grant to support the development of a 2-minute test for hemoglobinopathies and a test for oxygen affinity.
  • Dr. Sulatha Dwarakanath Appointed as VP of Assay Development: With over 25 years of experience in the biotech and diagnostics industry, Dr. Sulatha Dwarakanath joins Hemex and will help speed up assay development, focused on tests that cater to the needs of our growing market.

HTI

  • CryoFast™ update and demo to two leading Cryo-EM scope vendors received strong endorsement. GTM (go-to-market) and business planning underway. CryoFast data collection architecture uses deep learning to fully automate Cryo-EM data collection and processing workflow to improve the throughput, accuracy, and cost of structure determination.
  • CryoFast will be presented at the April NIH by invitation only event.
  • HTI is confirmed to attend the June BIO2024 conference in Oregon Bioscience Association’s Oregon Pavilion.

EndoSound

  • Our early launch continues as United Medical Doctors becomes our first, in the state of California, to adopt the EVS at two of their centers. We are honored to be on this journey with such a passionate team; they are dedicated to expanding EUS access with a more affordable EUS system for their patients across several SoCal communities.

Rewire AI

 

Learn more about OBI’s 32 startups by visiting our website!


Angel Oregon Life & Bioscience Program

Back for its third year, Oregon Entrepreneurs Network‘s Angel Oregon Life & Bioscience (AOBIO) presents its education and investment program for life and bioscience startups. OBI is a proud partner of this program, which combines:

  • 3-week educational series focused on investment readiness for bio startups
  • Live pitch practice
  • Investment mixer
  • Equity investment opportunity

The format has changed slightly from past years, with an even stronger focus on investment readiness.

Registration is open and the first session is March 21 at 8:30 a.m. Don’t miss it!


University Summer Investment Opportunity 2024

 

Oregon State University, Oregon Health Sciences University, University of Oregon, and Portland State University are excited to announce the University Summer Investment Opportunity 2024!

This opportunity is open to OSU, OHSU, UO, and PSU affiliated companies, defined as:

  • Graduates of one of the above university’s accelerator program.
  • Companies with intellectual property owned by one of the universities.

Successful applicants will go through a due diligence process and finalists will make a public presentation to the assembled group of investors. Investors will make their own investment decisions and may join with others to pool an investment.

Potential investments are estimated to be in the $25,000 – $250,000 range. Learn more and apply by May 10, 2024.


Pitch Opportunities

Pitch Oregon

Pitch Oregon in 2024 comprises of three distinct pitch competitions, each tailored to cater to the unique needs and challenges faced by entrepreneurs in Washington, Multnomah, Clackamas, and Clark counties. In addition to mentorship, and networking opportunities, entrepreneurs participating in Pitch Oregon can expect equity investments, cash prizes, and access to service providers to support their specific needs.

Entrepreneurs and investors interested in participating in Pitch Oregon can find more information, including eligibility criteria and competition details, on the Pitch Oregon website.

 

Pegasus Angel Accelerator

Startup Founders! Are you ready to take your startup to the next level? Pegasus Angel Accelerator is thrilled to announce the Lightning Round Pitch Competition. This hybrid event is your chance to win a $500,000 partner package, secure significant funding, and pitch at our investor-only event!

Don’t miss this unparalleled opportunity to accelerate your startup’s growth in 2024. Apply now and show us what makes your startup stand out!

 

Do you have pitch opportunities or other events to share with our
newsletter subscribers and on our events calendar?
Submit them here!


Science Talk ’24

Registration is now open for Science Talk ‘24, the annual conference of the Association of Science Communicators. At ASC, we believe that science is a human right. Connecting the multifaceted world of science communicators is critical for building a strong and knowledgeable society.

SCIENCE TALK ’24 is taking place as a hybrid conference April 11-12 in person in Portland, Oregon, and with real-time online participation. Conference registration is now open! We are also accepting abstracts for the poster/art session.

The conference theme for 2024 is Opening Doors, which invites a diverse and inclusive community of science communicators to expand their communication potential and impact the world. We look forward to seeing you at Science Talk ’24.


Upcoming Events

TiE Oregon: Panel at the Pub
Funding Stages and Options for Startups
March 12, 2024 | 5:00 p.m.
Golden Valley Brewery, Beaverton
Registration

 

USPTO Women Entrepreneur
Mentoring Program Webinar
March 13, 2024 | 9:00-10:00 a.m.
Virtual
Free to Attend – Registration

 

OEN March Pubtalk:
The FoundHER Panel
March 13, 2024 | 5:00-7:30 p.m.
Trova Trip, Portland
Get Tickets

 

OBI Virtual Lunch & Learn:
Oregon Entrepreneurial Resources Panel

April 3, 2024 | 12:00-1:00 p.m.
Virtual
Free to Attend – Registration

 

ITHS Biomedical Innovation Fireside Chat Series
April 4, April 18, and May 2 | 2:00-3:00 p.m.
Virtual
Free to Attend – Registration

 

Angel Oregon Life & Bioscience
Investment-readiness Education Series
March 21, April 4, April 11, 2024 | 8:30-10:00 a.m.
Virtual
Registration

 

OBI Startup Spotlight Expo
September 12, 2024 | 5:00-8:00 p.m.
OBI Event Space, Portland
Tickets on Sale Now

OBI & OTRADI February 2024 Newsletter

OBI Client Company Wins

stacked rocks

Sirona Dx

  • Expanded headcount with 5 full time new hires in 2023
    • Monica Richmond: Quality Control Manager
    • Matthew Anstett: VP, Business Development
    • Teresa Pham: Director of Global Sales, Biopharma
    • Erik Gerdtsson, PhD: Director of Bioinformatics
    • Kristina Baker, MSc: Principal Scientist
  • Sirona secured a government contract (> $500K) with the US Department of Defense to develop a custom ultra-deep immune profiling panel to accelerate the development of vaccines against viral and bacterial pathogens. Great demonstration of the depth of knowledge and dedication of our scientific team.
  • Secured contracts for our specialized single cell multi omics and spatial biology capabilities with numerous leading pharma and biotech companies including a $1.4M contract to support a phase 2 clinical trial.
  • Sirona is leader in profiling complex biology with single-cell resolution to reveal the next generation of precision biomarker signatures. Our team has developed multiple, propriety immune oncology profiling panels which can accelerate immunotherapy development and distinguish responders vs non-responders. Our team’s leading edge expertise in single cell biology and digital pathology has attracted 9 out of the top 20 global pharma companies (J&J, Gilead, Amgen, Eli Lilly, Pfizer, Boehringer Ingelheim, Merck, AstraZeneca, and Moderna). We are initiating new contracts in 2024 that will triple revenue compared to 2023.
  • In addition to maintaining our CLIA accreditation and passing the last 3 audits with Zero Deficiency, our QA team developed and implemented an advanced Quality Management System enabling us to operate under GCLP guidelines and support two Phase 2 clinical trial studies in 2024.  An important aspect of this includes the development of leading edge, validation strategies, enabling our clients to submit single cell biology readouts in FDA submissions.

PDX Pharmaceuticals

  • PDX Pharmaceuticals has been selected to receive a $100,000 SBIR (Small Business Innovation Research) Matching Grant award from Business Oregon. The award will be used for our IP protection, marketing campaign, and fundraising activities.

Hemex Health

  • Gazelle was used in an important study in Haiti, published in Blood Advances, that demonstrated that the rate of follow-up visits improved when parents received their child’s sickle cell diagnosis at the point of care.
  • Last month, our founders, Patti White and Peter Galen, had the valuable opportunity to present Gazelle to the Chief Minister of Gujarat, a state in India with a high prevalence of sickle cell disease, at India’s prestigious Vibrant Global Investment Summit.
  • India’s Sickle Cell Elimination Mission, aimed at screening 70 million people and eliminating sickle cell disease by 2047, has reached a significant milestone. As of now, 10 million people have been screened under the mission. Hemex Health is proud to be a part of the contribution to this achievement.

HTI

  • HTI’s  CryoFast™, an ML based solution for cryo-em workflow automation, being tested at PNCC/OHSU with great progress. Getting ready for more testing at NYSBC and other sites.
  • Presented HTI investment pitch to few investors with good feedback at JPM2024. Also met few CROs for potential cryo services partnership.
  • Dr. Leah Frye joined HTI advisory as Senior Advisor.  Dr. Frye has 40 years of experience in drug discovery with an emphasis on medicinal and computational chemistry.
    • Currently, she is the sole owner of LLFrye Consulting.  In 2001, she co-founded the therapeutics group at Schrödinger. She led the group for 18 years and rose to the level of Vice President before returning to a focus on science as a senior drug designer and scientific advisor for the team. Under Dr. Frye’s leadership, the Schrödinger Therapeutics Group worked with collaborators to put numerous compounds into clinical trials resulting in 2 FDA-approved drugs to date.  Recently, Schrödinger has developed its own internal drug discovery pipeline and currently has 2 compounds in clinical trials.
    • Dr. Frye left Schrödinger in 2023 to form LLFrye Consulting. Prior to Schrödinger, she was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and before that, she was an Associate Professor of Chemistry with tenure at Rensselaer Polytechnic Institute.
    • Dr. Frye holds a Ph.D. in Synthetic Organic Chemistry from Johns Hopkins University and a B.S. Professional degree in Chemistry from the University of Idaho.  She was an Individual Research Service Award postdoctoral fellow in the Department of Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine.
    • Dr. Frye is an inventor on 20 issued US patents plus a number of recent patent applications.

Learn more about OBI’s 32 startups by visiting our website!


Angel Oregon Life & Bioscience

Back for its third year, Oregon Entrepreneurs Network‘s Angel Oregon Life & Bioscience (AOBIO) presents its education and investment program for life and bioscience startups. OBI is a proud partner of this program, which combines:

  • 3-week educational series focused on investment readiness for bio startups
  • Live pitch practice
  • Investment mixer
  • Equity investment opportunity

The format has changed slightly from past years, with an even stronger focus on investment readiness. More details can be found on Oregon Entrepreneurs Network website –> Registration is now open. Don’t miss it!


Startup Business Essentials

Oregon Entrepreneurs Network has brought back its popular Startup Business Essentials program for entrepreneurs. Enroll in the 5-part series to gain support, insight, and guidance from thought leaders and successful founders.

You may be wondering if your startup is a good fit for this program. All the details are available here, including who might benefit most from Startup Business Essentials.

Registration for the cohort starting March 4 is now open.


Pacific Northwest Pitch Opportunities

Life Science Innovation Northwest

Poster Presentations are an excellent opportunity for early-stage entrepreneurs, research teams, and startups to have one-on-one conversations with other experts in your industry, get feedback about your ideas, and answer questions about your research or work. It could even lead to finding your next investor, employee, or employer!

Seattle Angel Conference

The Seattle Angel Conference (SAC) is a program for growing the startup and angel investor ecosystems in the greater Seattle area. Attend workshops, register your startup in the conference, or inquire about whether Angel Investing is for you. Offers startup workshops, investor conferences, or participate with your company.

Flywheel Investment Conference

Don’t miss out as hundreds of investors, founders, and professionals come together to connect, learn, and develop resources for building companies.

Pitch Oregon

The deadline has passed to apply for the Pitch Oregon investment, but show your support and meet other entrepreneurs and investors by attending Pitch Oregon in April.

Do you have pitch opportunities or other events to share with our
newsletter subscribers and on our events calendar?
Submit them here!


Upcoming Events

NIH, OCTRI, and OBI Webinar: Entrepreneurial Support
to Advance Your Small Business Health Innovations
February 21, 2024 | 9:00-11:00 a.m.
Virtual
Free – register here

 

ITHS Biomedical Innovation Fireside Chat Series
February 22, March 7, April 18, May 2 | 2:00-3:00 p.m.
Virtual
Free – register here

 

OBI Lunch & Learn: IP Law for Scientists
March 6, 2024 | 12:00-1:00 p.m.
Virtual
Free – register here

 

OBI Accelerate Happy Hour Networking + 
Fireside Chat: Bioethics and Healthcare Decision-Making
March 7, 2024 | 5:30-7:30 p.m.
OBI Event Space – Portland
Space is limited – register soon!

OBI & OTRADI End-of-Year 2023 Newsletter

Ringing in the New Year!

Welcome 2024! But before we leave 2023 behind, this end-of-year newsletter features a recap of some of the outstanding and innovative work that our client companies are doing, and their successes along the way. We hope you enjoy sharing in their wins as much as we do.

This end-of year edition of the OBI & OTRADI newsletter also welcomes a returning client company, delivers a special thank you, and lists some awesome upcoming events. Please feel free to share.

We hope you have a peaceful and prosperous 2024.


Client Company Wins in 2023

AirOmatix

  • Joined the OBI in June, 2023.
  • In September, 2023, AirOmatix was Runner-Up in the Cascadia CleanTech Accelerator Pitch Competition. Their pitch focused on how their oxygen concentrating technology could reduce global greenhouse gas emissions by eliminating the need for transporting metal cylinders of oxygen.
  • They received the Judge’s Award in the Early Stage Startup category of the Oregon Bioscience Association’s 2023 Innovation Showcase. Their pitch touted the benefits of AirOmatix’s small, quiet, high-flow oxygen concentrating technology over the larger, louder, and lower-flow products on the market.

CANX

  • CANX hired Felix Cohen and Killian Anreise to their staff.
  • They are developing therapeutics to address iron-related health conditions such as iron overload disease and certain forms of cancer which depend on iron for their growth.

Caravel 

  • Caravel won the Tufts University $100k Startup Competition and were semi-finalists for the MIT Climate & Energy Prize in Spring 2023.
  • Caravel Bio joined the OBI in August, 2023 with an office and a lab.
  • They hired Arushi Kalia as an Engineering Research Associate. Arushi is working on strain engineering and bioprocess development.
  • Caravel has joined the SQM Lithium Ventures Accelerator. The Caravel team will be exploring applications of their protein engineering platform in lithium mining, aided by scientists and engineers from SQM. SQM, headquartered in Chile, is a global leader in lithium mining and chemical production.
  • They were one of 6 startups selected for the Greentown Go Make with Shell 2023 Program. The Caravel team is proud to announce the company was selected from over 100 applicant companies from around the world to work with Greentown Labs and Shell to develop products for CO2 capture and utilization. As a part of the program, Caravel received $15,000 in non-dilutive funding and will work with mentors and subject matter experts from the Greentown Labs community and Shell to advance Caravel’s Catalytic Biotechnology platform.
  • In December, Caravel closed their pre-seed round with a total raise of $1.012M in dilutive and non-dilutive funding.

Endosound

  • Received an investment from AGA’s GI Opportunity Fund. Read Business Wire press release here.
  • EndoSound Inc., a privately held medical device company developing an endoscopic ultrasound platform to diagnose and treat diseases of the gastrointestinal tract, today announced the initial closing of its Series A round financing.
  • The round is being led by GEO Medtech Venture Fund, a leading healthcare venture capital firm that invests in transformative medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery.
  • The financing will support EndoSound’s ongoing research and development and preparations for commercial launch. The EndoSound Vision System (EVS) is designed to eliminate the financial burden of expanding access to care for patients who require an endoscopic ultrasound (EUS) procedure.  By attaching the EVS Transducer to a standard upper endoscope found in all hospitals and GI surgery centers, this critical technology becomes available and affordable in more areas of care.
  • They successfully closed their series A round of funding, raising $5M, which closed in October.
  • EndoSound is now pursuing a Series B round with the goal of raising an additional $12M in funding in anticipation (pending regulatory clearance) of first sales in 1st Q 2024.
  • NEW! EndoSound is proud to announce the FDA 510(k) clearance of our EndoSound Vision System® (EVS®) on December 27, 2023. This novel and innovative device enables endoscopists to convert upper GI endoscopes into an endoscopic ultrasound (EUS) device. The EVS converts flexible endoscopes from any of the leading manufacturers into a fully functional EUS system providing high quality imaging consistent with today’s leading technology. Moreover, the EVS is significantly less expensive compared to conventional EUS systems.

ESG Brands

  • Joined the OBI in June, 2023 and moved into a lab in OBI’s recently built-out suite.
  • ESG Brands was awarded acceptance into the Germany supported Global Entrepreneurship Centre (GEC) for scaling start-ups which includes €25,000 in-kind contribution and 10 weeks of supported programming to facilitate growth. The GEC scales innovative companies with sustainable technologies, processes, and business models for impact.
  • Raised $200,000 out of the $500,000 goal for 2nd round funding. Targeting to close before the end of July to support scale-up and further development.
  • Accomplished successful repeatability trial for their accelerated degumming process.
  • Accomplished 90/10 blended silver: a precursor to yarn spinning, and a key milestone in the development process.
  • Selected for German-funded impact accelerator, Global Entrepreneurship Centre (GEC) Summer Cohort. 1 of 15 global start-ups chosen by GEC to accelerate scale and funding in order to unlock global impact.
  • Successfully online and operating out of OBI Lab space kicking off local Portland IP development at the intersection of farms x chemistry x fashion.
  • Ideaship has successfully completed a $100,000 patent equity investment in ESG Brands. Ideaship has been instrumental in supporting their intellectual property (IP) applications and will continue to play a pivotal role in shaping their IP strategy, thereby establishing a robust foundation to facilitate their growth backed by venture capital.
  • Secured first customer within the industrial textiles space.
  • Successfully consolidated the fiber supply chain to afford faster processing times and expedite the scale-up of their Tempo™ technology.
  • ESG Brands was a finalist at Bend Venture Conference in the Impact Competition.
  • Recognition for Revitalizing Portland’s Start-up Scene: they’ve gained recognition as a key contributor to the resurgence of the Portland start-up landscape — scaling the world’s next natural fiber to fight climate change, and enable the textile industry to meet climate targets. Check out their feature in the Business Journal: Read more.
  • Cover Story and 2-Page Spread: Thrilled to share that their success has been showcased prominently in Portland Business Journal showcasing 2 out of their 5 teammates! They’ve secured a headline cover story and an extensive 2-page spread, amplifying impact and reach.
  • Successful Completion of First Scale-Up Trial: Celebrating a major milestone, they have completed ESG’s first scale-up trial with a prominent factory group, demonstrating capability and confidence from within the industry.
  • Innovation Highlight: Potable Water MVP from Process Waste: Thrilled to announce the successful creation of their first Minimum Viable Product (MVP): potable water derived from process waste. This breakthrough not only showcases their commitment to sustainable innovation but also highlights the circularity capabilities within their process. Additionally, it demonstrates their ability to create potable water from ESG’s natural fiber banana plant feedstock—an achievement not replicated with any other natural fiber.
  • ESG Brands was featured in the “13 Startups to Watch in 2024” special report in the December 15 issue of the Portland Business Journal.
  • BANEX™ Yarn! ESG Brands ended the year with their first yarn trial, and it was successful! Immediately after and in an industrial setting, further improvements were seen with impressive results. Next up: more yarn will be run and textile made. For a preview or interest in supporting the growth, please contact ESG Brands.
  • Naturally Fire-Retardant Nonwovens! The team tested their most recent nonwoven product and received impressive results: with no fire retardant additives their first nonwoven product is self-extinguishing well under the FMVSS 302 test standard (FMVSS -Federal Motor Vehicle safety standard, flammability test for interior materials on vehicles).

Gamma Diagnostics

  • The TAO awards committee nominated Gamma Diagnostics as a finalist for the Technology Company of the Year, Emerging category. The 2023 Oregon Technology Awards was held on May 16, 2023.
  • They published a 103-patient COVID-19 study showing that their diagnostic test for gamma prime fibrinogen (GPF) can differentiate between mild/moderately ill patients, severely ill patients, and non-patients better than six other widely-used diagnostic tests. The paper is published here.
  • They are thrilled to announce an exclusive distribution agreement and the SAHPRA approval of GammaCoeur™ CVD Risk ELISA Test System with Afri Grow (Pty) Ltd. For more information, see the press release.
  • Gamma Diagnostics was awarded a Phase I STTR of $277,710 by the NIH to develop antisense oligonucleotides to regulate GPF levels.

Hemex Health

  • Major Successes
    • Gazelle, Hemex Health’s diagnostics platform, was installed in a blood bank of Rotary Blood Bank near Delhi. This is a new application for Gazelle to test donated blood for beta thalassemia.
    • They obtained the first government tender for the National Sickle Cell Anemia Elimination Program from the state of Odisha, one of the 17 states under the program. The Program aims to screen 70 million people and to eliminate sickle cell disease in India by 2047.
    • Gazelle made its debut in Vietnam. Their distributor in Vietnam, Biomedical Vietnam, collaborated with Nghia Lo Regional General Hospital for beta thalassemia screening. Biomedical Vietnam conducted screenings with Gazelle for 48 schoolchildren and individuals of marriage age. The debut was an exciting start for the distributor to showcase Gazelle to subject experts ahead of the nationwide rollout.
  • Product Development
    • Hemex is collaborating with MUJN Diagnostics Inc., to develop a diagnostics system that can be used to support patients being treated with alternative therapies for brain health.
    • CEO, Patti White, and Gerrit van Roekel, VP of Business Development, traveled to Ghana to to get input from clinical partners at Korle Bu Teaching Hospital on their new, easy-to-use cartridge that will simplify sample preparation for their sickle cell test.
  • New VP of Finance
    • Josh Cyphers has joined Hemex Health as the new VP of Finance at Hemex Health. Josh has held senior roles in both large and startup companies and brings a passion for making a positive social impact.
  • Awards and Recognition
    • The company was featured on Business Oregon’s Innovation landing page, under “Oregon Business Solves Challenging Global Disease Testing Issue.”
    • Patti White, CEO of Hemex Health, received an award from Alliance Indus and Fiona Ma (CA State Treasurer) for the strong partnerships with Indian businesses that brought Gazelle, an innovative decentralized point-of-need testing solution, to the market. The award also recognizes Hemex’s significant contribution to the Make in India initiative.
    • Hemex Health won a 3-year $3M NIH grant from the NHLBI to commercialize their Hb Variant test for the US market. Read the press release to learn more about the grant.
  • Conferences
    • Hemex Health participated in the 25th MTAR Labcon 2023 Conference in Alibaug, India where sickle cell disease is highly prevalent. It was a valuable chance for the company to interact with delegates from the Raigad region and to gather feedback from those delegates on Gazelle.
    • Patti White, CEO and co-founder of Hemex Health, was asked to speak at the IFC (International Finance Corporation) Global Private Health Conference in Cape Town, South Africa. White talked about the innovation that small companies can bring to global health problems and the potential market opportunities.
    • Peter Galen, Chief Innovation Officer, served as a panelist at Davos Worldwide Summer 2023, a conference focused on designing and implementing global impact initiatives. During the panel, Galen discussed the crucial role that healthcare companies play in eradicating Sickle Cell Disease.
    • Pinecrest Healthcare Ltd, Hemex Health’s distributor in Nigeria, presented Gazelle at the Nigeria Society for Haematology and Blood Transfusion conference, outlining Gazelle’s role in facilitating sickle cell disease (SCD) testing in the country to subject matter experts.
    • Peter Galen, Hemex Health’s Chief Innovation Officer, was honored with an invitation to speak at the American Medical Device Summit. Galen ignited discussions on propelling innovation and prioritizing patient-centricity in the global medical device landscape.
    • Patti White, CEO of Hemex Health, participated in the 18th Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in London. Throughout the conference, Gazelle garnered significant interest from KOLs and field experts due to its capability to facilitate affordable and accessible SCD diagnosis in low-resource areas.
    • Hemex Health participated in the 64th Annual Conference of the Indian Society of Haematology & Blood Transfusion, a prominent event in the field of hematology. They were invited to present Gazelle during the lecture on “Next-Generation Integrated, Affordable Point-of-Care Solution for Haemoglobinopathy.” This provided them with a valuable opportunity to engage with hematologists and demonstrate the capabilities of Gazelle.

HTI

  • Intel Corp. has asked HTI to benchmark their new Xeon platform with CryoDiscovery™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing.
  • Dr. Gabriella Kiss joined the HTI Advisory Board as Senior Advisor. Dr. Kiss brings extensive experience in life science and Business Development to HTI.
  • A leading cryo-EM instrument vendor has provided an LOI for integrating CryoDiscovery™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing, with their product.
  • The Pacific Northwest Computing Center (PNCC) and OHSU have approved for CryoDiscovery™ field testing.
  • ADRx, a drug discovery vendor, has initiated another project for cryo-EM analysis.
  • HTI is excited to announce that Dr. Santi Adavani is joining HTI Advisory Board as Senior Advisor. Dr. Adavani brings extensive experience in AI/ML and software product development to HTI.  Read full press release here.
  • Attended BIO23 as a co-sponsor of the Oregon Bioscience Association‘s Oregon Pavilion. BIO2023,  BIO International Convention | BIO, is the premier international conference with over 17K attendees representing biotech, pharma and investment companies. Meetings set with over 30+ partners to advance cryo-EM service and software business.
  • Successfully finished early CryoDiscovery™ testing at OHSU/PNCC.
  • Successfully submitted the Phase 2 matching grant final report to Business Oregon.
  • Submitted application, per NSF invitation,  for TCEP, Technology Enhancement for Commercial Partnerships (TECP) supplemental funding.
  • Signed Cryo-EM MSA with BASF.
  • Advanced partnership project with ADRx toward full completion into 3D model building stage.
  • Successfully delivered CryoDiscovery™ presentation at ACA23 (American Crystallographic Association) on July 9 with over 200 attendees.
  • Signed MSA (master services agreement) for cryo-EM nanoparticles analysis with path.org, the non-profit funded by the Gates Foundation in Seattle.
  • Had over 30 partner meetings at BIO 2023 which resulted in few good sales leads.
  • Successfully presented CryoFast™ – an AI-based platform for automating cryo-EM image collection at ACA’23 and M&M’23 – two international microscopy conferences. Met with industry partners and received strong product support from the cryo-EM community.
  • Received NSF Phase II supplemental funding to integrate CryoFast™ with the leading cryo-EM camera vendor’s data collection application.
  • Welcome Leo Crowder and welcome back Ryan Dehart – two great additions to our development team.
  • Signed MSA with a major European chemicals company for cryo-EM structure determination services for agricultural crop protection chemicals project.
  • Embarked on a new project using cryo-EM to assess Lipid Nanoparticles with mRNA for a leading non-profit working on scaling Coronavirus vaccine production to developing lower-income countries.
  • Due to strong demand for structure-determination services, HTI signed agreement with Kansas University Medical School as the 2nd cryo-EM imaging partner site. The first partner site is U. of Washington cryo-EM center.
  • OSU selected HTI for their M.S. AI Capstone project.
  • Signed agreement with Miller Nash as HTI legal counsel.
  • CryoFast™ alpha testing at OHSU in its final stage with results to be shared with our industry/pharma partners.

Keliomics

  • Keliomics was a finalist at the 2023 Oregon Technology Awards which was held on May 16, 2023.
  • They were also a finalist at Angel Oregon Life & Bioscience in May at Amaterra Winery.
  • They kicked off their OncoScreen pilot study in partnership with Legacy Health and enrolled their first patient. This marks the first time an intact breast tumor has been cultured in breast adipose tissue from the same patient.
  • Keliomics won a $100,000 investment from ONAMI and a $100,000 investment from Ideaship at the Angel Oregon Life & Bioscience finale in May.
  • Keliomics was featured in the Portland Business Journal for their novel approach to targeted cancer treatment.
  • New Hire:  Shane Sweeney, Lab Technician.
  • New Advisory Board Member:  Andreas Penk, Former President of Pfizer China; Pfizer Oncology EMEA.
  • Capital raised in October:  $400k in seed round convertible notes.
  • Projects Completed:  McDonnell Lab – Duke, Olzmann Lab – UC Berkeley, Scherer Lab – UT Southwestern.
  • Keliomics was featured in the “13 Startups to Watch in 2024” special report in the December 15 issue of the Portland Business Journal.

Madorra

OmnEcoil Instruments

  • OmnEcoil received FDA approval to initiate a clinical trial of their device for simultaneous MRI imaging and biopsying of the prostate.
  • They have also subsequently received IRB approval from OHSU for this trial and expect to initiate patient recruitment in the near future.

PDX Pharmaceuticals

  • PDX Pharma received continued Phase II SBIR funding from the National Cancer Institute (NCI) to support a novel lung cancer treatment, ARAC-02. Read more here.
  • They have received a fast-track SBIR award from the National Cancer Institute, which focuses on development of a drug candidate named PETTRA (PLK1 and EGFR Targeted Therapy and Radiation sensitizer) for lung cancer treatment. The budget is about $2.4M over 3 years. Read more here.
  • They have been selected as one of six semi-finalists for the 2023 AIM-HI Women’s Venture Competition.
  • They were granted a new US patent (11,679,082) on nanoparticle co-delivering broad ranges of mitotic kinase inhibitors and immune checkpoint inhibitors.
  • Their EU patent application (16765662.8) on the core Pdx-NP delivery platform received the notice of allowance.
  • They received a fundable score on their pending Commercialization Readiness Pilot (CRP) grant application at the NCI. The budget is about $250,000 over 2 years.
  • Their drug candidate, ARAC-02, was selected into the Nanotechnology Characterization Lab (NCL)’s collaborative program funded by the NCI.
  • They published a review article at SMALL (impact factor 13.3) on the topic of ‘Nanotechnology Applications in Breast Cancer Immunotherapy,’ in a special issue of Nanomedicine for Women’s Health.’ Read more here.

ProMedix

  • ProMedix Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $250,000.00 to conduct research and development (R&D) work on improving outcomes from sepsis through active digital monitoring of peripheral blood flow.
  • They were selected to advance to the final round of Creative Destruction Labs.
  • ProMedix was the winner of Oregon Entrepreneurs Network‘s entrepreneurial education and angel investment program Angel Oregon Life & Bioscience in May! They received the $185,000 AOBIO angel investment, as well as an additional $75,000 investment from ONAMI.
  • They published an important paper in the American Journal of Emergency Medicine, entitled Evaluation of electronic measurement of capillary refill for Sepsis screening at ED triage.
  • They were invited to attend the Creative Destruction Lab Super Session in Toronto, Canada after graduating from their Vancouver, Canada accelerator program.
  • ProMedix was featured on page 13 of the OHSU Innovates 2023 Impact Report. Read the report here.

Rewire AI

  • Rewire Neuro is now Rewire AI. This change comes as part of a re-energized effort from Rewire to more fully embrace their position as a premier AI company with technology that has application in more markets than just
    neuroscience.
  • CSciO, Kristy Lawton, was an invited speaker on OBA’s Bio On The Rocks Artificial Intelligence panel.
  • CEO, John Harkness, was an invited speaker on TAO’s Generative AI in Healthcare panel.
  • John Harkness was honored to meeting with Senator Ron Wyden and Business Oregon to discuss Oregon’s role in the international marketplace and how we can support trade from Oregon businesses, like Rewire AI.
  • Rewire launched the next generation of their image analysis platform, called Polygon AI. This milestone marks the addition of new AI capabilities, advanced multiplex analysis, and 3D image processing.
  • They were awarded a Phase I SBIR from NIH NIGMS to develop their patented “AutoML” platform for automated generation of custom AI models.
  • Rewire AI was selected as a finalist to pitch in the Life Science Washington Institute “Startup Showcase” and was selected as an NIH SBIR funded startup to pitch and present in the NIH booth at the 2023 HLTH conference in Las Vegas. Additionally, they were invited to pitch at the MedInvest AI conference in Silicon Valley.
  • John Harkness was invited to speak with Senator Ron Wyden in the TAO AI Town Hall executive session.
  • They secured an additional contract to provide AI capabilities to their largest device partner to-date.
  • John Harkness was invited to speak on the “If I Knew Now” panel about challenges faced as a startup founder at the Oregon Bioscience Association Biotech Summit.
  • John was also interviewed on the Darwoft “Dare” podcast about Rewire’s efforts to innovate in the biomedical AI space.

Senju Pharmaceutical

  • They welcomed Samantha Munoz to their team.
  • Senju’s manuscript has been accepted but still in press. They found a cysteine protease, calpain, specific cleaved alpha-spectrin in soft and hard drusen from human donors. This suggests calpain=induced proteolysis participates photoreceptors and RPE cell degeneration during aging and AMD.

 

Sonivate Medical

  • Sonivate Medical, Inc. was invited to SEASON Aesthetic Conference held at George Washington University, Washington, DC in April 2023. This was a gathering of key opinion leaders in dermatology and plastic surgery to discuss the application of ultrasound for cosmetic procedures e.g., facial fillers.
  • Besides discussions, there was hands-on using a cadaver lab for injections and several stations for the participants to rotate through including Sonivate’s next generation product.  Sonivate was one of a very few companies invited to present at this research oriented, technical symposium.  The presentation is titled SonicEye Finger Probe Ultrasound System – Meeting Customer Needs through Disciplined Research.

StoneStable

SUTUREGARD Medical

  • They released a new product this year called HEMIGARD Interlock, which allows surgical incision closure/support without sutures. A proprietary hook and loop technology from 3M has been incorporated into their existing HEMIGARD design and allows for considerable tension relief at the incision healing edge. This protects skin edge blood flow and optimizes healing and scarring outcomes.
  • Their Classic HEMIGARD ASRD (Adhesive Suture Retention Device) is used now in over 230 hospitals in the USA and helps surgeons close high tension or at risk wounds. They envision HEMIGARD Interlock for gentler support in elective surgeries such as joint replacement, bunion correction, cosmetic surgery and other.
  • Q1 2023 was their first profitable quarter and hope to build on this momentum and continue to their goal of being self-funding through sales revenue.

Trace Biosciences

  • Trace Biosciences welcomed four new team members:
    • Nathan McMahon, Ph.D. – Clinical Project Manager
    • Bryce Timm, Ph.D. – Staff Scientist
    • Grace Hubbel, Ph.D. – Staff Scientist
    • Ge Huang, Ph.D. – Senior Research Associate
  • Trace Biosciences was a finalist at Angel Oregon Life & Bioscience held in May at Amaterra Winery.
  • They won a $125,000 investment from ONAMI at the Angel Oregon Life & Bioscience finale.
  • Received an investment from the Elevate Innovation Gap Fund.
  • Received a $4.1M SBIR award from ARPA-H covering development and clinical translation of their technology for nerve-specific imaging intraoperatively.
  • Completed two pre-IND meetings with the FDA and preparing IND package for first-in-human trials spring 2024.
  • Presented at Intraoperative Imaging Society meeting in Deer Valley, Utah.
  • Won judge’s choice best pitch at OBA Innovation Showcase in the Later Stage category.
  • Trace Biosciences was featured on page 8 of the OHSU Innovates 2023 Impact Report. Read the report here.

Vaginal Biome Science

  • Joined the OBI in April, 2023 with an office in our brand new office suite. They expanded into two additional office spaces in January, 2024.
  • From their website: Together with our strong alliance of partners, we are broadening and accelerating groundbreaking studies into the vaginal biome, pioneering new understanding of the role of the biome as a determinant of vaginal and overall health, and developing new products, solutions, and protocols – redefining decades-old and tired approaches to women’s health.

Veana Therapeutics

  • Veana received a $50,000 competitive matching grant from Business Oregon to leverage their Phase 1 SBIR grant.
  • Pleased to announce publication of a proof-of-concept study demonstrating that its oral drug, a-TEA-LS (aka VIMO) improves the anti-tumor efficacy of immune checkpoint blockade antibody in pre-clinical models of triple negative breast cancer.
  • Veana welcomed Patricia Beckman as CEO.

VitalFlo

Vivifi Medical

  • Vivivi Medical joined the incubator in December 2023.
  • Founded in Houston, Texas, they are looking forward to making Oregon their headquarters. Vivivi Medical is developing a permanent solution that reverses Benign Prostate Hyperplasia (BPH) through a robotic/laparoscopic procedure.

OBI Alumni Updates

 

Absci

  • Absci recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody as a potential new cancer treatment. Read about it in the Portland Business Journal.
  • They’ve also recently partnered with PrecisionLife to work together to discover and develop a shared pipeline of biotherapeutics.

Aronora

  • Erik Tucker, PhD, founder and CEO of Aronora received a National Academy of Inventors Fellow award at the National Academy of Inventors Annual Winter Warmer: Celebrating Innovation Excellence in Oregon.
  • Aronora recently raised a funding round with investment from New York Blood Center’s venture fund to support their anti-coagulant drug development.

Sparrow Pharmaceuticals

  • Endocrine Society announced that their Outstanding Innovation Award will recognize Sparrow’s work on a potential new medicine for patients with Cushing’s syndrome, autonomous cortisol secretion, or who rely on long-term glucocorticoid (e.g., prednisone) to control autoimmune diseases and other conditions. Read about the 2024 Laureate Recipients here.
  • First patient has been dosed in Sparrow’s Phase 2 clinical trial for autonomous cortisol secretion treatment.
  • Dr. David Katz, CSO, was featured on the “If We Knew Now” panel discussion at the Oregon Bioscience Association Biotech Summit.

Synergic Medical Technologies

  • Synergic has initiated a clinical trial for the vibrotactile treatment they developed for people with Parkinson’s. The study is posted on clinicaltrials.gov (NCT05881460) and their partners at OHSU will start enrolling people soon. They expect the data from this study to enable them to submit to FDA for market clearance.

Congratulations on your hard work and successful endeavors! You’re creating wonderful innovations for healthcare.


Captis Biotechnology Rejoins the OBI

Welcome back to Captis Biotechnology, who rejoined the OBI this month with space in our first floor north wing. Captis has created targeted biosensors and bioimaging agents for cancer and other diseases.

We are pleased to have them return to the incubator!


Thank You for Your Continued Support!

OBI is gearing up for some excellent free entrepreneurial programming this year, designed to support startups of all stages of development across the state. We have monthly Lunch & Learns on all kinds of interesting topics geared toward the life science community, regular Happy Hour networking events, and a robust BioMentoring program.

We are so pleased to be able to bring you these valuable programs and events, and we thank you for your support over the past 10 years since our incubator opened. To help support our upcoming educational offerings, each of our programs has sponsorship opportunities available. We also have Platinum, Gold, and Silver corporate sponsorship packages for a year-long impact.

To continue your support of OBI’s programming with a tax-deductible sponsorship, please take a look at our Sponsorship Kit and contact Rene Miller for sponsorship or questions.


Upcoming Events

OBI Accelerate Happy Hour Networking
January 11 | 5:30-7:00 PM
OBI Event Space, Portland
Free but nearly full! Register here

 

OBI Lunch & Learn: Bootstrapping Social
January 17 | 12:00-1:00 PM
Virtual
Free – register here

 

America’s Seed Fund Week
and Virtual Road Tour 2024
January 23 and 24
Virtual
More information here

 

group of people attending a seminarOHSU Innovates Speaker Series:
Securing Non-Dilutive Funding for Innovative Businesses
January 24 | 9:00-10:00 AM
Virtual
Free – learn more and register

 

ITHS Biomedical Innovation Fireside Chat Series
Jan 25, Feb 8 & 22, Mar 7, Apr 4 & 18, May 2 | 2:00-3:00 PM
Virtual
Free – register here

 

Built Oregon Presents PitchBlack 2024
February 7 | 5:30 PM
The Patricia Reser Center for the Arts, Beaverton
Get tickets

OBI & OTRADI December 2023 Newsletter

Cheers to Winter Celebrations

The Oregon Bioscience Incubator & OTRADI team sends you warm holiday greetings and hopes you have fun and festive winter celebrations with your friends and family. Our offices will be closed December 25 through January 1, and we look forward to seeing you in 2024!


Welcome New Board Members

Our newest OTRADI board members are Jennifer Fox and Amanda Oborne.

Jennifer joined OTRADI as Assistant Director in 2008 and was President & Executive Director from 2013 to 2019. She is currently Director of Network & Outcomes at Autodesk Research, and we are delighted for her return to OTRADI as a board member.

We’re also very excited to welcome Ideaship’s Managing Director Amanda Oborne to our board. Prior to Ideaship, Amanda served as Executive Director for Oregon Entrepreneurs Network and VP of Food & Farms at Ecotrust.


Client Company Wins

ESG Brands

  • Recognition for Revitalizing Portland’s Start-up Scene: We’ve gained recognition as a key contributor to the resurgence of the Portland start-up landscape — scaling the world’s next natural fiber to fight climate change, and enable the textile industry to meet climate targets. Check out the feature on us in the Business Journal: Read more.
  • Cover Story and 2-Page Spread: Thrilled to share that our success has been showcased prominently in Portland Business Journal showcasing 2 out of our 5 teammates! We’ve secured a headline cover story and an extensive 2-page spread, amplifying our impact and reach.
  • Successful Completion of First Scale-Up Trial: Celebrating a major milestone, we have completed ESG’s first scale-up trial with a prominent factory group, demonstrating our capability and confidence from within the industry.
  • Innovation Highlight: Potable Water MVP from Process Waste: We are thrilled to announce the successful creation of our first Minimum Viable Product (MVP): potable water derived from process waste. This breakthrough not only showcases our commitment to sustainable innovation but also highlights the circularity capabilities within our process. Additionally, it demonstrates our ability to create potable water from ESG’s natural fiber banana plant feedstock—an achievement not replicated with any other natural fiber.
  • It’s been an incredible month of accomplishments, and we’re eager to build on this momentum. Stay tuned for more updates on our journey of growth and innovation!

Trace Biosciences

  • Trace Biosciences was featured on page 8 of the OHSU Innovates 2023 Impact Report.
  • Read the report here.

EndoSound

  • We’re happy to report at EndoSound that we successfully closed our series A round of funding, raising $5M, which closed in October.
  • We are now pursuing a Series B round with the goal of raising an additional $12M in funding in anticipation (pending regulatory clearance) of first sales in 1st Q 2024.

ProMedix

  • ProMedix was featured on page 13 of the OHSU Innovates 2023 Impact Report.
  • Read the report here.

Hemex Health

  • Gazelle, Hemex Health’s diagnostics platform, was installed in a blood bank of Rotary Blood Bank near Delhi. This is a new application for Gazelle to test donated blood for beta thalassemia.
  • Hemex Health obtained the first government tender for the National Sickle Cell Anemia Elimination Program from the state of Odisha, one of the 17 states under the program. The Elimination Program aims to eliminate sickle cell disease from India by 2047. The initial installation of Gazelle in Odisha was successfully carried out on November 22 at 20 primary healthcare sites, marking the beginning of the installment process for 500 primary healthcare sites.
  • Gazelle made its debut in Vietnam. Our distributor in Vietnam, Biomedical Vietnam, collaborated with Nghia Lo Regional General Hospital for beta thalassemia screening. Biomedical Vietnam conducted screenings with Gazelle for 48 schoolchildren and individuals of marriage age. The debut was an exciting start for the distributor to showcase Gazelle to subject experts ahead of the nationwide rollout.

Absci (alumnus)

  • Absci recently announced a collaboration with AstraZeneca to deliver an AI-designed antibody as a potential new cancer treatment. Read about it in the Portland Business Journal.

Congratulations on your outstanding achievements!


Vivivi Medical Joins the OBI

Vivivi Medical joined the incubator in December 2023. Founded in Houston, Texas, they are looking forward to making Oregon their headquarters. Vivivi Medical is developing a permanent solution that reverses Benign Prostate
Hyperplasia (BPH) through a robotic/laparoscopic procedure. Learn more at their website and say hello when you see them at the OBI!


Upcoming Events

Oregon Entrepreneurs Network
December Pub Talk: Wrap Party
December 13, 2023
5:15-7:30 PM
Fresh Consulting – Portland
Get tickets here

PDXWIT Presents:
Winter Soiree & Awards Ceremony
December 14, 2023
5:30-7:00 PM
Cambia Health Solutions – Portland
Free – register here

 

OBI Accelerate Happy Hour Networking
January 11, 2024
5:30-7:00 PM
OBI Event Space – Portland
Free – register here

 

OBI Lunch & Learn: Bootstrapping Social
January 17, 2024
12:00-1:00 PM
Virtual
Free – register here

OBI & OTRADI November 2023 Newsletter

OBI Client Company Wins

chessboard with black king still standing

Trace Biosciences

Senju Pharmaceutical

  • We welcomed Samantha Munoz to our team!
  • Our manuscript has been accepted but still in press. We found a cysteine protease, calpain, specific cleaved alpha-spectrin in soft and hard drusen from human donors. This suggests calpain=induced proteolysis participates photoreceptors and RPE cell degeneration during aging and AMD.

Rewire AI

  • Rewire AI’s CEO, John Harkness, was invited to speak on the “If I Knew Now” panel about challenges faced as a startup founder at the Oregon Bioscience Association Biotech Summit.
  • John was also interviewed on the Darwoft “Dare” podcast about Rewire’s efforts to innovate in the biomedical AI space.

AirOmatix

  • In September, 2023, AirOmatix was Runner-Up in the Cascadia CleanTech Accelerator Pitch Competition. Their pitch focused on how their oxygen concentrating technology could reduce global greenhouse gas emissions by eliminating the need for transporting metal cylinders of oxygen.
  • AirOmatix received the Judge’s Award in the Early Stage Startup category of the Oregon Bioscience Association’s 2023 Innovation Showcase. Their pitch touted the benefits of AirOmatix’s small, quiet, high-flow oxygen concentrating technology over the larger, louder, and lower-flow products on the market.

Caravel 

  • Caravel Bio was one of 6 startups selected for the Greentown Go Make with Shell 2023 Program. The Caravel team is proud to announce the company was selected from over 100 applicant companies from around the world to work with Greentown Labs and Shell to develop products for CO2 capture and utilization.
  • As a part of the program, Caravel received $15,000 in non-dilutive funding and will work with mentors and subject matter experts from the Greentown Labs community and Shell to advance Caravel’s Catalytic Biotechnology platform.

Madorra

Hemex Health

  • Patti White, CEO of Hemex Health, recently participated in the 18th Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in London. Throughout the conference, Gazelle garnered significant interest from KOLs and field experts due to its capability to facilitate affordable and accessible SCD diagnosis in low-resource areas.
  • Hemex has concluded its participation in the 64th Annual Conference of the Indian Society of Haematology & Blood Transfusion, a prominent event in the field of hematology. We were invited to present Gazelle during the lecture on “Next-Generation Integrated, Affordable Point-of-Care Solution for Haemoglobinopathy.” This provided us with a valuable opportunity to engage with hematologists and demonstrate the capabilities of Gazelle.

Keliomics

  • New Hire:  Shane Sweeney, Lab Technician.
  • New Advisory Board Member:  Andreas Penk, Former President of Pfizer China; Pfizer Oncology EMEA.
  • Capital raised this past month:  $400k in seed round convertible notes.
  • Projects Completed:  McDonnell Lab – Duke, Olzmann Lab – UC Berkeley, Scherer Lab – UT Southwestern.

HTI

  • Due to strong demand for structure-determination services, HTI signed agreement with Kansas University Medical School as the 2nd cryo-EM imaging partner site. The first partner site is U. of Washington cryo-EM center.
  • OSU selected HTI for their M.S. AI Capstone project.
  • Signed agreement with Miller Nash as HTI legal counsel.
  • CryoFast ™ alpha testing at OHSU in its final stage with results to be shared with our industry/pharma partners.

ESG Brands

Aronora (OBI Alumnus)

  • Aronora recently raised a funding round with investment from New York Blood Center’s venture fund to support their anti-coagulant drug development.

Sparrow Pharmaceuticals (OBI Alumnus)

Congratulations to these outstanding innovators!


CHIPS Act Designates Tech Hubs in Oregon

Congratulations to two Oregon CHIPS and Science Act Tech Hub designees! Led by Oregon State University, the Corvallis Microfluidics Tech Hub, and Pacific Northwest Mass Timber Tech Hub were selected as two of the 31 Tech Hubs designated in the U.S.

In addition, Portland State University led a Tech Hubs proposal which received a Strategy Development Grant, so they may continue their plan development in pursuit of a future Tech Hub designation.


OBI is Now on Instagram!

We’re excited to share that we are now on Instagram! Join us on this visual journey where we’ll keep you updated with behind-the-scenes insights into cutting-edge biotechnology, stay up-to-date on engaging events like Lunch & Learns and Accelerate Happy Hour. Find us on Instagram: @OTRADIBio, and discover our state-of-the-art lab facilities, research projects, industry trends, and more.


Equalize: A Pitch Competition to Empower Academic Women Entrepreneurs

Equalize is a comprehensive program designed to take national action around the disparity of women academic inventors forming university startups. Equalize participants receive education, a field-specific mentor, and access to networks that drive new entrepreneurial connections. Equalize candidates can include faculty, postdocs, and grad students in STEM disciplines.

Applications for the 2024 program are now open – more information here.


Upcoming Events

OBI Accelerate Happy Hour – Last One for 2023!
November 9, 2023
5:30-7:00 PM
OBI Event Space – Portland
Free – register now

 

OBI Lunch & Learn: Startup Project Management Basics
November 14, 2023
12:00-1:00 PM
Virtual
Free – register here

PDXWIT & Prosper Portland
November Happy Hour
November 14, 2023
5:30-7:00 PM
Hotel Lucia – Portland
Register here

 

2023 Oregon Entrepreneurship Awards
November 16, 2023
5:00-9:00 PM
Portland Center Stage – The Armory
Get tickets

OBI Lunch & Learn: Unlocking the Power of Inclusive Leadership
December 7, 2023
12:00-1:00 PM
Virtual
Free – registration now open!

OBI & OTRADI October 2023 Newsletter

Adrienne Klein Joins the OBI Team

Adrienne Klein, Programs and Operations Specialist, brings a unique blend of skills and experiences to her role at Oregon Bioscience Incubator/OTRADI, where she joined the team in October 2023.

Adrienne gained invaluable experience in her previous career in the field of accounting working with start-ups in the Portland area. In her previous role, she was instrumental in providing financial guidance and support to emerging businesses, helping them navigate the complex financial landscape of entrepreneurship. Adrienne’s passion for biotechnology runs deep. Her fascination with the potential of biotech to transform healthcare and improve lives led her to complete her Bachelor’s degree in Public Health at Southern New Hampshire University.

As Programs and Operations Specialist, Adrienne is dedicated to creating an environment where innovation can flourish, resources are readily available, and strategic guidance is within reach for biotech start-ups. She manages day-to-day operations, facilitates networking and collaboration among biotech entrepreneurs, and coordinates essential programs and resources to propel innovative biotechnology ventures forward.

Welcome, Adrienne – we are thrilled to have you onboard!


OBI Client Company Wins

AirOmatix

ESG Brands

  • Ideaship has successfully completed a $100,000 patent equity investment in ESG Brands. Ideaship has been instrumental in supporting our intellectual property (IP) applications and will continue to play a pivotal role in shaping our IP strategy, thereby establishing a robust foundation to facilitate our growth backed by venture capital.
  • Secured our first customer within the industrial textiles space.
  • Successfully consolidated the fiber supply chain to afford faster processing times, and expedite the scale-up of our Tempo™ technology.

Rewire AI

  • Rewire AI was awarded a Phase I SBIR from NIH NIGMS to develop Rewire’s patented “AutoML” platform for automated generation of custom AI models.
  • Rewire AI was selected as a finalist to pitch in the Life Science Washington Institute “Startup Showcase” and was selected as an NIH SBIR funded startup to pitch and present in the NIH booth at the 2023 HLTH conference in Las Vegas. Additionally, Rewire AI was invited to pitch at the MedInvest AI conference in Silicon Valley.
  • Rewire AI’s CEO, John Harkness, was invited to speak with Senator Ron Wyden in the TAO AI Town Hall executive session.
  • Rewire AI secured an additional contract to provide AI capabilities to their largest device partner to-date.

Caravel 

  • Caravel hired Arushi Kalia as an Engineering Research Associate. Arushi will be working on strain engineering and bioprocess development.
  • Caravel has joined the SQM Lithium Ventures Accelerator. The Caravel team will be exploring applications of their protein engineering platform in lithium mining, aided by scientists and engineers from SQM. SQM, headquartered in Chile, is a global leader in lithium mining and chemical production.

Hemex Health

  • Patti White, CEO of Hemex Health, received an award from Alliance Indus and Fiona Ma (CA State Treasurer) for the strong partnerships with Indian businesses that brought Gazelle sickle cell test, an innovative decentralized point-of-need testing solution, to the market. The award also recognizes Hemex’s significant contribution to the Make In India initiative.
  • Peter Galen, Chief Innovation Officer of Hemex Health, was honored with an invitation to speak at the American Medical Device Summit. Peter ignited discussions on propelling innovation and prioritizing patient-centricity in the global medical device landscape.
  • In Q3, HemexDx, the subsidiary of Hemex Health in India, conducted demonstrations in states like Tamil and Odisha. These demonstrations, attended by relevant government officials, showcased Gazelle’s performance and bolstered Hemex Health’s progress in pursuing government tenders in India.

Keliomics

Congratulations on these outstanding wins!


OBI Sponsors Saturday Academy Apprenticeships

Saturday Academy offers an Apprenticeship in Science and Engineering (ASE) each year. Acceptance into the program is a competitive process for high-school students, who work with engineers, scientists, and technology professionals full-time for 8 weeks during the summer.

The Oregon Bioscience Incubator is a proud supporter of this program. We just received lovely thank you letters from the 2023 ASE interns we sponsored. These students expressed how much the ASE program meant to them and how much they gained throughout the process and will carry forward to their future endeavors.

Thank you to Saturday Academy for offering this and other career exploration programs to spark curiosity in future scientists and leaders.


Upcoming Events

PDXWIT & IAPP Present: October Happy Hour –
Remaining Human in the time of Big Data, Big Tech and AI

October 17, 2023
5:30-7:00 PM
OBI Event Space, Portland, OR
Register here

 

OBI Lunch & Learn: Streamlining DEI with
Inclusive Hiring and Retention Tools
October 11, 2023
12:00-1:00 PM
Hybrid
Last chance to register!

 

Oregon Bio Biotech Summit 2023
October 25, 2023
1:00-7:30 PM
Twist Bioscience – Wilsonville
Get tickets

 

OBI Accelerate Happy Hour
November 9, 2023
5:30-7:00 PM
OBI Event Space
Save the date!

OBI & OTRADI September 2023 Newsletter

OTRADI Welcomes New Board Members

We are thrilled to welcome Ramsey and Karl to OTRADI’s Board of Directors:

Karl Mundorff, Executive Director of Innovation and Entrepreneurship at Oregon State University

Ramsey Cox, Founder of Ramsey Cox Media Relations and Public Affairs

 


OBI Client Company Wins

Rewire AI

  • Rewire AI’s CSciO, Kristy Lawton, was an invited speaker on OBA’s Bio On The Rocks Artificial Intelligence panel.
  • Rewire AI’s CEO, John Harkness, was an invited speaker on TAO’s Generative AI in Healthcare panel.
  • John Harkness was honored to meeting with Senator Ron Wyden and Business Oregon to discuss Oregon’s role in the international marketplace and how we can support trade from Oregon businesses, like Rewire AI.
  • Rewire launched the next generation of their image analysis platform, called Polygon AI. This milestone marks the addition of new AI capabilities, advanced multiplex analysis, and 3D image processing.

Trace Biosciences

  • Received an investment from the Elevate Innovation Gap Fund.
  • Trace Biosciences is creating imaging agents for surgery that highlights nerves to eliminate surgical nerve damage.

Gamma Diagnostics

  • We are thrilled to announce an exclusive distribution agreement and the SAHPRA approval of GammaCoeur™ CVD Risk ELISA Test System with Afri Grow (Pty) Ltd. For more information, see our press release.
  • We were awarded a Phase I STTR of $277,710 by the NIH to develop antisense oligonucleotides to regulate Gamma Prime Fibrinogen levels.

Hemex Health

  • Our CEO, Patti White, and Gerrit van Roekel, VP of Business Development, traveled to Ghana to show our new, easy-to-use cartridge that will simplify sample preparation for our sickle test to clinical partners at Korle Bu Teaching Hospital in Accra.
  • Pinecrest Healthcare Ltd, our distributor in Nigeria, presented Gazelle at the Nigeria Society for Haematology and Blood Transfusion conference, outlining Gazelle’s role in facilitating Sickle Cell Disease (SCD) testing in the country to subject matter experts.

HTI

  • Successfully presented CryoFast ™ – an AI-based platform for automating cryo-EM image collection at ACA’23 and M&M’23 – two international microscopy conferences. Met with industry partners and received strong product support from the cryo-EM community.
  • Received NSF Phase II supplemental funding to integrate CryoFast ™ with the leading cryo-EM camera vendor’s data collection application.
  • Welcome Leo Crowder and welcome back Ryan Dehart – two great additions to our development team.
  • Looking to fill an opening for a Sr. Development AI/ML Engineer (see job description here).
  • Signed MSA with a major European chemicals company for cryo-EM structure determination services for agricultural crop protection chemicals project.
  • Embarked on a new project using cryo-EM to assess Lipid Nanoparticles with mRNA for a leading non-profit working on scaling Coronavirus vaccine production to developing lower-income countries.

Sparrow Pharmaceuticals (Alumnus)

  • Endocrine Society announced that their Outstanding Innovation Award will recognize Sparrow’s work on a potential new medicine for patients with Cushing’s syndrome, autonomous cortisol secretion, or who rely on long-term glucocorticoid (e.g., prednisone) to control autoimmune diseases and other conditions.
  • Read about the 2024 Laureate Recipients here.

 


Enroll by September 14 for the OCTRI BIP Corp

This 6-week I-Corps short course offers a new approach to accelerate the translation of discoveries from lab to clinical practice. Based on the National Science Foundation’s Innovation Corps (I-CorpsTM) program, BIP Corp is an evidence-based experience that will take you out of your comfort zone to connect with potential customers and provide you with a competitive business case for future funding, partnership and translational science opportunities.

Clinicians, scientists, postdocs, graduate students, engineers and entrepreneurs with an early stage idea. Teams (2+) encouraged.

In this course, you will:

  • Determine the commercial viability of your idea
  • Develop a successful business case to secure funding and attract collaborators
  • Meet with biomedical and business startup experts for advice and feedback
  • Expand your innovation network
  • Further your research idea and gain preliminary data for grant and SBIR/STTR proposals

Wednesdays, September 20-October 25
9:00-11:00 AM
Virtual format
Free for OHSU and non-OHSU participants

Course details and schedule information
Enroll by Sept 14th

 


Upcoming Events

 

Techworks on Tap Up Top
September 14, 2023
2:30-4:30 PM
811 SE Stark St, Unit 300, Portland, OR
Register here

 

OBI Virtual Lunch & Learn: FDA Submissions –
Best Practices for Early Stage Startups
September 20, 2023
12:00-1:00 PM
Virtual
Register now!

 

OBI Virtual Lunch & Learn:
Oregon InC’s SBIR Support Programs
September 27, 2023
12:00-1:00 PM
Virtual
Register now!

 

OBI Accelerate Happy Hour Networking
October 5, 2023
5:30-7:00 PM
OBI Event Space, Portland
Registration now open!

 

OBI Lunch & Learn: Streamlining DEI with
Inclusive Hiring and Retention Tools
October 11, 2023
12:00-1:00 PM
OBI Event Space, Portland
Registration now open!

 

Oregon Bio Biotech Summit 2023
October 25, 2023
1:00-7:30 PM
Twist Bioscience – Wilsonville
Get tickets

OBI & OTRADI August 2023 Newsletter

You’re Invited to Celebrate OTRADI’s 15th Anniversary

Join us for a celebration: 15 years of OTRADI and 10 years of the Oregon Bioscience Incubator!
September 14, 2023 from 5pm – 8pm

You are invited to attend OTRADI’s 15-Year Anniversary and OBI’s 10-Year Anniversary Celebration at the grand opening of OBI’s event space. We’re inviting the entire bio and startup entrepreneurship community, as well as legislators, partners, collaborators and supporters, to attend and celebrate 15 years of bio-research and startup accomplishments for our OTRADI/OBI community.

Come learn about the amazing work our researchers, entrepreneurs and startups have been engaged in for the past 15 years in Oregon. You’ll enjoy sparkling conversation, food, and beverages at the launch of our new event space.

Get tickets!

Premier Sponsors:

  • PhRMA – Building a Better Health Care System
  • HP – Here at HP we are committed to innovating and reinventing your digital life

Ambassador Sponsors:

Food & Beverage Sponsors:

Sponsorship opportunities still available. Inquire here.

 


OBI Client Company Wins

CANX, LLC

  • CANX recently hired Felix Cohen to their staff.
  • They are developing therapeutics to address iron-related health conditions such as iron overload disease and certain forms of cancer which depend on iron for their growth.
  • CANX’s lab is located at OBI.

ESG Brands

  • Selected for German-funded impact accelerator, Global Entrepreneurship Centre (GEC) Summer Cohort. 1 of 15 global start-ups chosen by GEC to accelerate scale and funding in order to unlock global impact.
  • Proud to announce we have secured partnership and funding from GTT Group’s Ideaship Fund focused on accelerating growth through IP strategy and we invite you to contact chase.kahmann@theESGbrands.com to learn more.
  • Successfully online and operating out of OBI Lab space kicking off local Portland IP development at the intersection of farms x chemistry x fashion.

Hemex Health

  • Hemex Health welcomes Stacey Kuo as their new Marketing & Communications Manager.
  • Peter Galen, Chief Innovation Officer, served as a panelist at Davos Worldwide Summer 2023, a conference focused on designing and implementing global impact initiatives. During the panel, Peter discussed the crucial role healthcare companies play in eradicating Sickle Cell Disease.
  • We are thrilled to announce that Josh Cyphers has joined us as the new VP of Finance at Hemex Health. Josh has held senior roles in both large and startup companies, and brings a passion for making a positive social impact.

 


OCTRI Biomedical Innovation Commercialization Readiness Program

This 6-week I-Corps short course offers a new approach to accelerate the translation of discoveries from lab to clinical practice. Based on the National Science Foundation’s Innovation Corps (I-CorpsTM) program, BIP Corp is an evidence-based experience that will take you out of your comfort zone to connect with potential customers and provide you with a competitive business case for future funding, partnership and translational science opportunities.

Clinicians, scientists, postdocs, graduate students, engineers and entrepreneurs with an early stage idea. Teams (2+) encouraged.

In this course, you will:

  • Determine the commercial viability of your idea
  • Develop a successful business case to secure funding and attract collaborators
  • Meet with biomedical and business startup experts for advice and feedback
  • Expand your innovation network
  • Further your research idea and gain preliminary data for grant and SBIR/STTR proposals

Wednesdays, September 20-October 25
9:00-11:00 AM
Virtual format
Free for OHSU and non-OHSU participants

Course details and schedule information
Enroll by Sept 14th

 


Now Open – 2023 BVC Applications

BendVenture conference logo with brown mountain in backgroundAre you a founder who is ready to take your company to the next level? If so, Bend Venture Conference wants to hear from you! For the past 20 years, the Bend Venture Conference (BVC) has been the premier angel conference in the Pacific Northwest, making a difference in Central Oregon and beyond. In addition to funding opportunities, participants make meaningful connections with fellow entrepreneurs, investors, top fund managers, and business leaders. Applications to participate and pitch at BVC 2023 are now open!

This exceptional event offers three categories of competition: Growth Stage, Impact and Early Stage. Applicants can apply from anywhere, but must commit to attending the conference in person on October 19 and 20, 2023.

 


Investor Match is Seeking Founders

A message from InvestorMatch:

InvestorMatch.ai is designed to eliminate the constant noise created when searching, qualifying funders and matching them to your funding needs. Our onboarding processes is comprehensive using machine learning and natural language processing, which translates to less meetings, less time and most importantly, better quality connections that lead to successful engagements.

And …. yes it’s free to founders.

Our database of international funders, private, public and commercial, is one of the largest. We specifically make the introduction to your ideal funder using your criteria. No more wondering ”do they get us” but rather curated introductions to the right people, at the right time, with the right resources.

InvestorMatch.ai is without charge have you join our platform in exchange for your feedback. Finding the right opportunities is all about qualification, with great data, that’s our mission.

Ready to get funded by a firm that understands you, your product or service and is eager to move forward ? Log in to: app.InvestorMatch.ai and let’s find you funding.

 


Upcoming Events

 

PIE Demo Day 2023
August 10, 2023
4:00-6:00 PM
The Redd on Salmon St. – Portland
Virtual option too!
Register here

 

Technology Association of Oregon logo

Founders Investing in Founders Happy Hour
August 16, 2023
4:00-6:00 PM
TrovaTrip – Portland
Register now

 

Oregon Bio Women CONNECT 2023
August 17, 2023
5:00-8:00 PM
Genentech – Portland
Get tickets

 

Careers in Science Communication Webinar
August 23, 2023
2:00-3:00 PM (Pacific)
Virtual
Register – free

 

PDXWIT Presents: Game Night Summer Soiree
August 24, 2023
5:30-7:00 PM
Autodesk – Portland
Free to attend – register here

OBI & OTRADI July 2023 Newsletter

OBI Client Company Wins

HTI:

  • Successfully delivered CryoDiscovery™ presentation at ACA23  ( American Crystallographic Association) on July 9 with over 200 attendees.
  • Signed MSA (master services agreement) for cryo-em nanoparticles analysis with path.org, the non-profit funded by the Gates Foundation in Seattle.
  • Had over 30 partner meetings at BIO 2023 which resulted in few good sales leads.

ESG Brands

  • Awarded acceptance into the Germany supported Global Entrepreneurship Centre (GEC) for scaling start-ups which includes €25,000 in-kind contribution and 10 weeks of supported programming to facilitate growth. The GEC scales innovative companies with sustainable technologies, processes, and business models for impact.
  • Raised $200,000 out of the $500,000 goal for 2nd round funding. Targeting to close before the end of July to support scale-up and further development.
  • Accomplished successful repeatability trial for their accelerated degumming process.
  • Accomplished 90/10 blended sliver: a precursor to yarn spinning, and a key milestone in the development process.

PDX Pharmaceuticals

  • We were granted a new US patent (11,679,082) on nanoparticle co-delivering broad ranges of mitotic kinase inhibitors and immune checkpoint inhibitors.
  • We received the phase I portion ($400K/1 year) of our fast-track SBIR award from the NCI focusing development of a new radiation sensitizer based on our nanoparticle platform.

Hemex Health

  • We were awarded a $3M NIH grant to bring the Gazelle Hb Variant Test for Sickle Cell Disease (SCD) to the U.S. market.
  • The Hb Variant Test, one of the tests supported by the Gazelle diagnostic platform, can detect SCD and beta thalassemia – genetic blood disorders that can result in debilitating pain, disability, severe complications or death.

Oregon Startups – Need Advice?

We have a network of BioMentors who are available to provide short-term pro bono advice and assistance to promising life science and digital health entrepreneurs across the state of Oregon. Our BioMentors have valuable expertise in a wide range of business topics that are integral to the success of early-stage life science companies, including:

ACCOUNTING, BUSINESS PLANS, DIGITAL HEALTH, GOVERNMENT FUNDING, HEALTH IT
LEGAL/IP, LICENSING, MACHINE LEARNING/AI, MANAGEMENT, MANUFACTURING
MARKET ANALYSIS, MARKETING, PRIVATE FUNDING, PRODUCT DEVELOPMENT, REGULATORY/FDA

For more information and assistance, fill out this form and we’ll match you with a BioMentor who can help.

 


Now Open – 2023 BVC Applications

BendVenture conference logo with brown mountain in background

Are you a founder who is ready to take your company to the next level? If so, Bend Venture Conference wants to hear from you! For the past 20 years, the Bend Venture Conference (BVC) has been the premier angel conference in the Pacific Northwest, making a difference in Central Oregon and beyond. In addition to funding opportunities, participants make meaningful connections with fellow entrepreneurs, investors, top fund managers, and business leaders. Applications to participate and pitch at BVC 2023 are now open!

This exceptional event offers three categories of competition: Growth Stage, Impact and Early Stage. Applicants can apply from anywhere, but must commit to attending the conference in person on October 19 and 20, 2023.

 


MedX@Düsseldorf!

November 13th to 16th 2023, the world’s largest trade show for the health industry will take place in Düsseldorf, Germany. MEDICA’s Start-up Park is the global meeting point for digital pioneers and the place where young companies can boost their business.

The office of Economic Development Düsseldorf organizes for the third year in a row the MedX@Düsseldorf competition – an incredible and unique opportunity for startups in the MedTech industry to take their success to new heights.

This is the perfect occasion for Startups to connect with new, international partners, to meet decision makers and to gain visibility on the health market. This could be the first or next big step towards internationalization.

On top of the booth, startups can look forward to a tailored MedTech workshop with insights of the European Market and the local ecosystem.

Further information as well as the application form can be found on the following website: www.duesseldorf.de/medx.

The application deadline is August 4. We look forward to receiving innovative and promising ideas from the MedTech industry.


Upcoming Events

 

Biomedical Entrepreneurship Fireside Chat
July 13, 2023
2:00-3:00 PM
Virtual
Free to attend – register here

 

PDXWIT Presents: July Happy Hour
Data & Algorithmic Justice
July 18, 2023
12:00-1:00 PM
Virtual
Free to attend – register here

 

Scismic Webinar: U.S. Visa and Immigration
Options for International Scientists and Researchers
July 18, 2023
2:00-3:00 PM (Pacific)
Virtual
Free registration

 

Technology Association of Oregon
Party in the Pinot
July 22, 2023
5:00-9:30 PM
Scholls Valley Lodge – Hillsboro
Get tickets

 

Women in Science PDX
Resume Feedback Mixer
July 26, 2023
6:00-8:30 PM
Lucky Lab Beer Hall – Portland
Free to attend – register here

 

Oregon Bio: Bio on Tap
July 27, 2023
5:00-8:00 PM
McMenamins Cornelius Pass Roadhouse – Hillsboro
Get tickets

 

PIE Demo Day 2023
August 10, 2023
4:00-6:00 PM
The Redd on Salmon St. – Portland
Register here

OBI & OTRADI June 2023 Newsletter

It’s OTRADI’s 15th Anniversary!

A message from Executive Director, Heather Ellis:

We are excited to be celebrating 15 years of OTRADI and 10 years of the Oregon Bioscience Incubator (OBI). I would like to thank all the Oregonians who have supported the work that we do at the OBI.  For those who don’t know our background, OTRADI is a non-profit institute primarily funded by the state of Oregon via grants administered by Business Oregon.

OTRADI and the OBI are 100% driven by our mission, which is to fuel the economic development of Oregon’s bio industry by translating innovative research into the next generation of products and companies that benefit health and create high-wage jobs for Oregon.

In a recent economic impact survey of the 18-year period between 2002 and 2020, total bioscience employment in Oregon increased 85% (+5,270 jobs), total wages increased 215% (+$593.4 million), and average annual wages increased 71% (+$31,340). Oregon’s 1,480 life science firms and leading academic and research institutions generated a total economic impact of almost 66,000 jobs and $15.7 billion in output in 2020. (Association, 2022)

Since OTRADI’s inception in 2008, we have done our best to listen to the needs of these startups and we have evolved and responded to these needs by building our facility and developing programs to help build and advance the bio startup community in Oregon.  OTRADI has evolved over the past fifteen years from a research institute, which was what was sorely needed at that time, into—ten years ago—building out and opening the Oregon Bioscience Incubator—the state’s first and only bio-focused startup hub.

In 2013, when we opened the doors of the OBI, we started with six startup companies. In response to overwhelming demand, we have expanded throughout the years, and we are now home to thirty-two startup companies working on innovative new drugs, medical devices, and digital health IT products.

Our goal was simple—do everything in our power to make it easier for scientists to take the plunge and launch and grow their own startup companies here in Oregon.

Bio startups are different than other startups.  Before they can bring their health and wellness products to market, they must overcome the high bar set by the FDA— which requires specialized space, highly trained personnel, a long timeline, and lots of investment. We heard this, and the OBI responded by building our incubator to be a physical home with labs and specialized equipment for startups.

Bio startups also need a robust network of mentors, advisors and investors to succeed. We heard this, and the OBI responded by creating the state’s first BioMentoring network, made up of more than 120 professionals willing to donate their valuable time to help bio-entrepreneurs across the State succeed.

Bio startups also need entrepreneurial support and a community of public and private organizations to help them grow.  We heard this, and the OBI responded by building strong partnerships and collaborations with the state’s research universities and support organizations, including Oregon Health and Science University, Oregon Bioscience Association, Technology Association of Oregon, Oregon Entrepreneur Network, Portland State Business Accelerator, private venture capital funds, angel investment groups, developers, and more. We thank these key partners for their hard work and long-time support of our bio startup community.

Although I am biased, I truly believe that the OBI holds the state’s most innovative and promising startup companies. Every day at the OBI, is about showcasing and advancing our 32 startup companies’ work, so please let me take a moment to brag on their behalf.

In the past 15 years, the state’s investment in the OBI has allowed our startups to raise $685M in federal and private funding, generate $85M in revenue, and create 871 jobs. I am more than proud of our startups’ return on investment for Oregon, and we’re just getting started.

We see incredible promise on the horizon.  The OBI will be here to listen and to respond to the evolving needs of our bio startup community as they catapult Oregon into the international spotlight with their innovative work.

Please let me thank the most important people within our organization.  Thank you to OTRADI’s esteemed board of directors; to our two Entrepreneurs-in-Residence, Bill Newman and Gordon Hoffman; and to OTRADI’s small but mighty staff, including Rene Miller, Susan Thompson, and Sarah Vivian.

Finally, let me thank the immensely talented companies that currently reside at the OBI:

AirOmatix

Buchanan Science

CANX LLC

Circumvent Pharmaceuticals

EndoSound

ESG Brands

Gamma Diagnostics

GenerX

Health Technology Innovations

Hemex Health

Keliomics

Madorra

NeuvaRx

OmnEcoil Instruments

PDX Pharmaceuticals

ProMedix

Qtonics

Refeyn

Rewire Neuro

RxHomeTest

Senju

Sirona Dx

Sonivate Medical

StoneStable

Suturegard Medical

Thaena

Trace Biosciences

Vaginal Biome Science

Veana Therapeutics

Velanidi Technologies

Virogenomics BioDevelopment

VitalFlo

We truly believe that Oregon entrepreneurs will drive the next generation of breakthroughs to improve lives.  Thank you for your collaboration and support over the past fifteen years, and we look forward to your continued support as partners in these exciting days to come.

References:
Oregon Bioscience Association. (2022). Oregon’s Bio Boom 2022 Economic Impact Report. https://www.oregonbio.org/wp-content/uploads/2022/06/2022FinalEIR_Full.pdf

 


Welcome to the OBI
AirOmatix and ESG Brands

AirOmatix is developing the only portable oxygen concentrator for high-flow oxygen patients, freeing them from bulky oxygen cylinders.  Our novel, patent-pending technology will also enable us to develop low-flow oxygen concentrators that are smaller and quieter than existing options.

ESG Brands is a sustainable technology company operating in the materials science space with agricultural waste as feedstock. ESG Brands core technology is a green chemistry based degumming process for the textile industry–clothing and footwear, home textiles, and technical textiles–converting agricultural waste into cotton 10x faster than conventional processes with potable water as a byproduct. In addition, the company is active in sustainable manufacturing and the broader materials science space: food and beverage, and next-gen bio-synthetics. ESG Brands believe that Environmental, Social, and Governance (ESG) is essential for a sustainable future, and are committed to using business to make a positive impact on the planet. The first materials product from ESG will be marketed as BANEX, the world’s next natural fiber, from the daily waste streams at banana plantations.

AirOmatix and ESG Brands join the OBI on June 15, 2023. Let’s give them a warm welcome!

 


OBI Client Company Wins

ProMedix, Inc.:

VitalFlo:

SUTUREGARD Medical:

  • At SUTUREGARD Medical, we released a new product this year called HEMIGARD Interlock, which allows surgical incision closure/support without sutures.  A proprietary hook and loop technology from 3M has been incorporated into our existing HEMIGARD design and allows for considerable tension relief at the incision healing edge.  This protects skin edge blood flow and optimizes healing and scarring outcomes.
  • Our Classic HEMIGARD ASRD (Adhesive Suture Retention Device) is used now in over 230 hospitals in the USA and helps surgeons close high tension or at risk wounds.  We envision HEMIGARD Interlock for gentler support in elective surgeries such as joint replacement, bunion correction, cosmetic surgery and other.
  • Q1 2023 was our first profitable quarter and we hope to build on this momentum and continue to our goal of being self funding through sales revenue.

Trace Biosciences:

Gamma Diagnostics:

  • We published a 103-patient COVID-19 study showing that our diagnostic test for gamma prime fibrinogen (GPF) can differentiate between mild/moderately ill patients, severely ill patients, and non-patients better than six other widely-used diagnostic tests.
  • The paper is at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147444/.

Keliomics:

HTI:

  • Attended BIO23 as a co-sponsor of the Oregon Bioscience Association‘s Oregon Pavilion. BIO2023,  BIO International Convention | BIO, is the premier international conference with over 17K attendees representing biotech, pharma and investment companies. Meetings set with over 30+ partners to advance cryo-em service and software business.
  • Successfully finished early CryoDiscovery ™ testing at OHSU/PNCC.
  • Successfully submitted the Phase2 matching grant final report to Oregon Business.
  • Submitted application, per NSF invitation,  for TCEP, Technology Enhancement for Commercial Partnerships (TECP) supplemental funding,
  • Signed Cryo-EM MSA with BASF
  • Advanced partnership project with ADRx toward full completion into 3D model building stage

StoneStable:

Synergic Medical Technologies (alumnus):

  • Synergic has initiated a clinical trial for the vibrotactile treatment we have developed for people with Parkinson’s. The study is posted on clinicaltrials.gov (NCT05881460) and our partners at OHSU will start enrolling people soon. We expect the data from this study to enable us to submit to FDA for market clearance.

OBI’s BioMentors Offer Free Help for Oregon Startups

We have a network of over 120 BioMentors who are available to provide short-term pro bono advice and assistance to promising life science and digital health entrepreneurs across the state of Oregon. Our BioMentors have valuable expertise in a wide range of business topics that are integral to the success of early-stage life science companies, including:

ACCOUNTING

BUSINESS PLANS

DIGITAL HEALTH

GOVERNMENT FUNDING

HEALTH IT

LEGAL/IP

LICENSING

MACHINE LEARNING/AI

MANAGEMENT

MANUFACTURING

MARKET ANALYSIS

MARKETING

PRIVATE FUNDING

PRODUCT DEVELOPMENT

REGULATORY/FDA

 

 

 

 

 

 

 

 

 

For more information and assistance, fill out this form and we’ll match you with a BioMentor who can help.

 


Office Space for Your Bioscience Startup

If you have a bioscience or health innovation startup and need office space, come talk to us! We operate the only bioscience-focused incubator in Oregon, with private offices, private labs, co-working space, and shared labs for startups in bioscience – including digital health, medical devices, AI/ML, diagnostics, therapeutics, pharmaceuticals, and more! We have brand new office spaces available now.

Submit your facility inquiry here and let’s schedule a time to talk.

 


Upcoming Events

 

Technology Association of Oregon logo

Health Tech Forum:
Care Beyond the Provider’s Office
June 15, 2023
3:00-5:30 PM
Google – Portland
Free to attend – register here

PDXWIT Presents:
Pride Happy Hour

June 20, 2023
5:30-7:30 PM
DAT Freight & Analytics – Portland
Free to attend – register here

 

2023 Invent Oregon Collegiate Challenge Finals
June 22, 2023
1:30-6:00 PM
Redd East – Portland
Free to attend – get tickets

 

Angel Oregon Tech Finale & Innovation Showcase
June 22, 2023
3:00-7:00 PM
Jupiter NEXT – Portland
Get tickets here

 

Oregon Bioscience Incubator
Happy Hour Networking

July 6, 2023
5:30-7:00 PM
River Forum Outdoor Patio – Portland
Free to attend – register here

OBI & OTRADI May 2023 Newsletter

OBI Client Company Wins

Rewire AI:

  • Rewire Neuro is now Rewire AI. This change comes as part of a re-energized effort from Rewire to more fully embrace their position as a premier AI company with technology that has application in more markets than just
    neuroscience.

StoneStable:

PDX Pharmaceuticals:

  • PDX Pharmaceuticals has received a Notice of intent to fund a fast-track SBIR application from the National Cancer Institute, which focuses on development of a drug candidate named PETTRA (PLK1 and EGFR Targeted Therapy and Radiation sensitizer) for lung cancer treatment. The budget is about $2.5M over 3 years.
  • PDX Pharmaceuticals has been selected as one of seven semi-finalists for the 2023 AIM-HI Women’s Venture Competition. The winner will receive up to $1 million investment.

VitalFlo:

Health Technology Innovations (HTI):

  • Health Technology Innovations, Inc. (HTI) is excited to announce industry veteran Dr. J. Brad Pesavento has joined the company as its new VP Strategy & Corporate Development. In this role, Brad will head HTI’s business development for cryo-EM services with pharma/biotech customers, lead its commercial strategy and engage with the investment community.
  • Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Santi Adavani is joining HTI Advisory Board as Senior Advisor. Dr. Adavani brings extensive experience in AI/ML and software product development to HTI.
  • Read full press releases here.

Keliomics:

  • We are a finalist at the 2023 Oregon Technology Awards which will be held on May 16, 2023.
  • We are also a finalist at Angel Oregon Life & Bioscience. Finale will be held on May 17 at Amaterra Winery.
  • We kicked off our OncoScreen pilot study in partnership with Legacy Health and enrolled our first patient. This marks the first time an intact breast tumor has been cultured in breast adipose tissue from the same patient.

Gamma Diagnostics:

  • The TAO awards committee has nominated us as a finalist for the Technology Company of the Year, Emerging category. The 2023 Oregon Technology Awards will be held on May 16, 2023.
  • The results of our clinical trial, which demonstrates that our diagnostic test for gamma prime fibrinogen (GPF) measures COVID-19 respiratory disease severity, have been published in the journal “Blood Cells, Molecules, and Diseases.”

ProMedix, Inc.:

EndoSound:

  • EndoSound Inc., a privately held medical device company developing an endoscopic ultrasound platform to diagnose and treat diseases of the gastrointestinal tract, today announced the initial closing of its Series A round financing.
  • The round is being led by GEO Medtech Venture Fund, a leading healthcare venture capital firm that invests in transformative medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery.
  • The financing will support EndoSound’s ongoing research and development and preparations for commercial launch. The EndoSound Vision System (EVS) is designed to eliminate the financial burden of expanding access to care for patients who require an endoscopic ultrasound (EUS) procedure.  By attaching the EVS Transducer to a standard upper endoscope found in all hospitals and GI surgery centers, this critical technology becomes available and affordable in more areas of care.

Trace Biosciences:

  • Trace Biosciences is a finalist at Angel Oregon Life & Bioscience. Finale will be held on May 17 at Amaterra Winery.
  • We welcomed two new team members:
    • Nathan McMahon, Ph.D. – Clinical Project Manager
    • Bryce Timm, Ph.D. – Staff Scientist

AOBIO Finale & Innovation Showcase

It’s been an exciting three months for eighteen regional startups as they have progressed through the Angel Oregon Life and Bioscience (AOBIO) program presented by Oregon Entrepreneurs Network, OTRADI and Oregon Bioscience Incubator, Oregon Health and Science University, and the Oregon Bioscience Association.

Founders from throughout the state have participated in four educational sessions spanning from funding readiness to creating a diverse team to due diligence and how to create the perfect pitch. They have participated in two pitch sessions with feedback from regional investors and industry experts, and recently the finalists were announced: five companies who will pitch for the angel investment on May 17.

Keliomics

Promedix

StoneStable, Inc

Trace Biosciences

VitalFlo

We invite you to get in on the ground floor of Oregon’s most important emerging sectors, and meet entrepreneurs literally building the future right now at the AOBIO Finale + Innovation Showcase on Wednesday, May 17th starting at 3:00 pm at Amaterra Winery

There we will feature the five companies vying for equity investment, the winner of non-dilutive funding through the Emerge Initiative, and a panel presentation titled What Does Success in Life Science Innovation Look Like?

All this and delicious food and wine too.

CLICK HERE to purchase your tickets today!


OBI’s BioMentor Program Offers Free Help for Oregon Startups

We have a network of over 90 BioMentors who are available to provide short-term pro bono advice and assistance to promising life science and digital health entrepreneurs across the state of Oregon. Our BioMentors have valuable expertise in a wide range of business topics that are integral to the success of early-stage life science companies, including:

ACCOUNTING

BUSINESS PLANS

DIGITAL HEALTH

GOVERNMENT FUNDING

HEALTH IT

LEGAL/IP

LICENSING

MACHINE LEARNING/AI

MANAGEMENT

MANUFACTURING

MARKET ANALYSIS

MARKETING

PRIVATE FUNDING

PRODUCT DEVELOPMENT

REGULATORY/FDA

 

 

 

 

 

 

 

 

 

For assistance, fill out this form and we’ll match you with a BioMentor who can help.


Need Space for Your Bioscience Startup?

If you have a bioscience or health innovation startup and need wet lab or office space, come talk to us! We operate the only bioscience-focused incubator in Oregon, with private offices, private labs, co-working space, and shared labs for startups in bioscience – including digital health, medical devices, AI/ML, diagnostics, therapeutics, pharmaceuticals, and more!

Submit your facility inquiry here and let’s schedule a time to talk.


America’s Seed Fund Week

America’s Seed Fund Week is a series of virtual events representing a collaborative outreach effort that will connect entrepreneurs working on advanced technologies and the organizations that support them to the country’s largest source of early-stage funding.

This is a free and virtual opportunity for small businesses to learn about non-dilutive funding available through America’s Seed Fund that awards $4 billion annually to small businesses for R&D. Come meet with the federal agency representatives, attend roundtables, connect with entrepreneur support organizations, and find other helpful resources.

Find out more information and register here.


TiE Women Applications are Open Through June 15

TiE Women is dedicated to Embrace, Engage and Empower women entrepreneurs across the globe. The program is focused on women entrepreneurs, irrespective of the size of their enterprises, origins, standing or background. The program consists of a series of local and global events and culminates with one women-led business from Oregon competing in a global pitch competition for cash prizes!

CRITERIA:

  • Female founded or co-founded startup
  • A female founder or co-founder that owns at least 30% of the equity in the company
  • Company has been in business for less than seven years (date of company registration no earlier than Jan. 1, 2016) at the time of application
  • The ultimate objective is to help startups in their fundraising efforts hence preference will be given to startups raising funds.

TIMELINE:
Local / Global Events: Ongoing (apply to receive exclusive invitations to attend)
Applications Open: April 24, 2023
Deadline to Apply: June 15, 2023
State Pitch Competition: August TBD, 2023
Global Pitch Competition: Will take place at the TiE Global Summit, November TBD, 2023

Apply here by June 15th.


Upcoming Events

PDXWIT & AWS Present:
How to Prepare for a Technical Interview

May 11, 2023
4:30-7:30 PM
AWS – Portland
Register here

 

Technology Association of Oregon logo

2023 Oregon Technology Awards:
Imagining a New Future

May 16, 2023
4:00-9:00 PM
Oregon Convention Center – Portland
Get tickets here

 

AOBIO Finale & Innovation Showcase
May 17, 2023
3:00-7:00 PM
Amaterra Winery – Portland
Get tickets here

 

Raising Capital: Debt vs. Equity
A Venture Catalyst Event
May 18, 2023
12:00-1:15 PM
Virtual
Register here

 

Bio in the High Desert
May 18, 2023
5:00-8:00 PM
Deschutes Brewery – Bend
Get tickets here

 

Legal Priorities for Startups:
Panel Discussion + Q&A
May 24, 2023
12:00-1:30 PM
Beaverton Building or Virtual
Register here

OBI & OTRADI April 2023 Newsletter

Angel Oregon Life & Bioscience
Fast Pitch Event – Tonight!

Meet the founders who will pitch for a direct angel investment of up to $300K at Angel Oregon Life & Bioscience (AOBIO) with this fast-pitch event hosted by Oregon Bioscience Association, Oregon Entrepreneurs Network (OEN), Oregon Bioscience Incubator  and OHSU. You won’t want to miss the AOBIO Fast Pitch on Tuesday, April 11th online at 5:00 p.m. This is your opportunity to meet the life and bioscience startups vying for angel investment!

During the Fast Pitch session, nine AOBIO entrepreneurs (including five OBI client companies) will have a 3-5 minute pitch introducing their company to local investors. This Fast Pitch event is the next stop on the road to the AOBIO Grand Finale & Showcase, and you can expect to see four of these incredible companies make it to the main stage pitch on May 17th!

The pitch companies include:

REGISTER HERE for the free FastPitch event to receive your virtual link


Welcome New Client Company
Vaginal Biome Science


In April, we welcomed Vaginal Biome Science to the incubator. They are occupying one of our brand new spaces in the Willamette Wharf building. From their website:

Together with our strong alliance of partners, we are broadening and accelerating groundbreaking studies into the vaginal biome, pioneering new understanding of the role of the biome as a determinant of vaginal and overall health, and developing new products, solutions, and protocols – redefining decades-old and tired approaches to women’s health.

We’re happy to have you on board!


Client Company Wins

PDX Pharmaceuticals:

  • PDX Pharma received continued Phase II SBIR funding from the NCI to support a novel lung cancer treatment, ARAC-02. Read more here.

Veana Therapeutics:

  • Veana Therapeutics is pleased to announce publication of a proof-of-concept study demonstrating that its oral drug, a-TEA-LS (aka VIMO) improves the anti-tumor efficacy of immune checkpoint blockade antibody in pre-clinical models of triple negative breast cancer.

Health Technology Innovations (HTI):

  • Dr. Gabriella Kiss joins HTI Advisory Board as Sr. senior advisor. Dr. Kiss brings extensive experience in life science and Business Development to HTI.
  • A leading cryo-EM instrument vendor has provided an LOI for integrating CryoDiscovery™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing, with their product.
  • The Pacific Northwest Computing Center (PNCC) and OHSU have approved for CryoDiscovery ™ field testing.
  • ADRx, a drug discovery vendor, has initiated another project for Cryo-EM analysis.

Gamma Diagnostics:

  • The TAO awards committee has nominated us as a finalist for the Technology Company of the Year, Emerging category.
  • The 2023 Oregon Technology Awards will be held on May 16, 2023.

StoneStable:

  • StoneStable will pitch in the Angel Oregon Life & Bioscience Fast Pitch event on April 11.

Sonivate Medical:

  • Sonivate Medical, Inc. has been invited to SEASON Aesthetic Conference to be held at George Washington University, Washington, DC at the end of April 2023.  This will be a gathering of key opinion leaders in dermatology and plastic surgery to discuss the application of ultrasound for cosmetic procedures e.g., facial fillers.
  • Besides discussions, there will be hands on using a cadaver lab for injections and several stations for the participants to rotate through including Sonivate’s next generation product.  Sonivate is one of a very few companies invited to present at this research oriented, technical symposium.  The presentation is titled SonicEyeâ Finger Probe Ultrasound System – Meeting Customer Needs through Disciplined Research.

VitalFlo:

  • VitalFlo will pitch in the Angel Oregon Life & Bioscience Fast Pitch event on April 11.

ProMedix, Inc.:

  • ProMedix Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Technology Transfer (STTR) grant for $250,000.00 to conduct research and development (R&D) work on improving outcomes from sepsis through active digital monitoring of peripheral blood flow.
  • ProMedix was selected to advance to the final round of Creative Destruction Labs.
  • ProMedix will pitch in the Angel Oregon Life & Bioscience Fast Pitch event on April 11.

EndoSound:

  • EndoSound is hiring an engineering intern. Read the job description here and send your resume to hammer@endosound.com.

Trace Biosciences:

  • Trace Biosciences will pitch in the Angel Oregon Life & Bioscience Fast Pitch event on April 11.

Hemex Health:

  • Hemex won a 3-year $3M NIH grant from the NHLBI to commercialize our Hb Variant test for the US market! Read the press release.
  • Hemex is collaborating with MUJN Diagnostics Inc., to develop a diagnostics system that can be used to support patients being treated with alternative therapies for brain health.

Keliomics:

  • Keliomics will pitch in the Angel Oregon Life & Bioscience Fast Pitch event on April 11.

Need Space for Your Bioscience Startup?

If you have a bioscience or health innovation startup and need wet lab or office space, come talk to us! We operate the only bioscience-focused incubator in Oregon, with private offices, private labs, co-working space, and shared labs for startups in bioscience – including digital health, medical devices, AI/ML, diagnostics, therapeutics, pharmaceuticals, and more!

Submit your facility inquiry here and let’s schedule a time to talk!


Upcoming Events

AOBIO Fast Pitch
April 11, 2023
5:00-7:00 PM
Virtual
Register here

 

April PubTalk: How to Build a Business of Impact
April 12, 2023
5:15-7:30 PM
Fresh Consulting in Portland
Get tickets here

 

PDXWIT Presents:
April Happy Hour:
Pathways into Privacy and Security
April 18, 2023
5:30-7:00 PM
RadarFirst in Portland
Register here

 

OBI Lunch & Learn: OHSU Innovates
April 19, 2023
12:00-1:00 PM
Virtual
Register here

 

Oregon Startup Center Educational Session:
Preparing Financials for Funding
April 26, 2023
11:30 AM-1:00 PM
Beaverton Building
Register here

 

OBI Accelerate Biotech + Digital Health
Happy Hour

May 4, 2023
5:30-7:00 PM
George Fox University Portland Center
Registration now open!

OBI & OTRADI March 2023 Newsletter

Client Company Wins

Health Technology Innovations (HTI):

  • Charles Rice, a local Portland resident, has joined HTI as a Senior Machine Learning Development Engineer.
  • Intel Corp. has asked HTI to benchmark their new Xeon platform with CryoDiscovery ™, HTI’s AI-based automation platform for cryo-EM image acquisition and processing.

VitalFlo:

  • We won PitchOregon’s Life Science & Healthcare category last month!

OmnEcoil Instruments:

  • We received FDA approval at the end of last week to initiate a clinical trial of our device for simultaneous MRI imaging and biopsying of the prostate.
  • We have also subsequently received IRB approval from OHSU for this trial.
  • We expect to initiate patient recruitment in the near future.

Hemex Health

  • Patti White, CEO and co-founder of Hemex Health, was asked to speak at the IFC (International Finance Corporation) Global Private Health Conference in Cape Town, South Africa, about the innovation that small companies can bring to global health problems and the huge potential market opportunities.
  • Hemex Health is featured on Business Oregon’s Innovation landing page, under “Oregon Business Solves Challenging Global Disease Testing Issue.

OBI Mentor of the Month:
Matt Hollingsworth

Matt Hollingsworth is the CEO and Co-founder of Carta Healthcare. Matt’s experience focuses on AI/Data Science and HeathTech. He started his career as high energy physicist, worked at CERN, and was part of the team there that discovered the Higgs Boson. Matt co-founded his first startup as technical co-founder with a colleague, and then went to Stanford’s business school to specialize in healthcare operations. There, he joined the data-driven healthcare operations group, SURF. Matt started Carta based upon tech built while at Stanford. He has an MBA from Stanford Graduate School of Business, and a BA/MS in Physics from the University of Tennessee.

When asked what his colleagues appreciate about him, Matt says, “I have a fairly deep understanding of technological capabilities (spent most of my career in technical roles) and I am very good at marrying that with product and sales strategy. I’m the person in the room that reminds the engineers that cool technology cannot always be sold and the sales people that everything that can be sold should not or cannot necessarily be built. I can help people find product/market fit faster, especially in complex industries where the whole ‘lean startup’ methodology breaks down.”

Matt joined the OBI Mentoring Program this year and has hit the ground running with his mentees. Thank you, Matt, for all you do to help our startup community!


AOBIO Seeks Investors

Get all the details about investing in the Angel Oregon Life & Bioscience investment pool.

Pacific Northwest accredited investors are invited to come learn about investing with Oregon Entrepreneurs Network‘s Angel Oregon Life & Bioscience (AOBIO). The program is designed for angel investors interested in life and bioscience innovation emerging in Oregon and Southwest Washington. New and experienced angel investors are welcome!

AOBIO Investor Information Session
Thursday, March 16th
9:00 AM – 10:15 AM
Zoom – REGISTER HERE

At this session we’ll cover:

  • Investment goals and objectives
  • How the investment program works, including details of the due diligence process
  • Investment team leadership
  • Key dates, fees and program details
  • Educational track content and speakers
  • Q&A

Need Space for Your Bioscience Startup?

If you have a bioscience or health innovation startup and need wet lab or office space, come talk to us! We operate the only bioscience-focused incubator in Oregon, with private offices, private labs, co-working space, and shared labs for startups in bioscience – including digital health, medical devices, AI/ML, diagnostics, therapeutics, pharmaceuticals, and more! We currently have limited space availability, with some new spaces opening up very soon.

Submit your facility inquiry here and let’s schedule a time to talk!


OHSU is Hiring

 

OHSU is currently hiring two positions to share with our OBI community. Please feel free to spread the word!

  • IT Specialist
    • This position will support work done at the OHSU Casey Reading Center related to ongoing ophthalmic clinical trials and studies. This will involve programming and maintaining code for clinical trial systems, software, data processing and quality control, as well as bioinformatics reporting. Apply here.
  • Research Data Analyst 2 (Quality Assurance Manager)
    • This position will support work done at the Casey Reading Center (CRC) related to their ongoing clinical trials and studies. Requires a detail-oriented candidate who will gain experience in clinical trial FDA and international regulations. More information here.

Upcoming Events

 

OregonBio: Bio on the Rocks
March 14, 2023
5:00-8:00 PM
Ironlight in Lake Oswego
Get tickets here

 

March PubTalk: The Founder Journey
March 15, 2023
5:15-7:30 PM
Fresh Consulting in Portland
Get tickets here

 

AOBIO Investor Information Session
First time angel investors welcome!
March 16, 2023
9:00-10:15 AM
RSVP here

 

PDXWIT Presents:
March Happy Hour

March 21, 2023
5:30-7:30 PM
Viewpoint in Portland
Register here

-and-

PDXWIT Presents:
LGBTQ+ in Tech – Paths to Leadership
March 29, 2023
12:00-1:00 PM
Virtual
Register in advance

 

OBI Accelerate Biotech + Digital Health
Happy Hour

April 6, 2023
5:30-7:00 PM
Casa Colima Mexican Restaurant & Cantina in Portland
Registration now open!

OBI & OTRADI February 2023 Newsletter

AOBIO is Back!

Angel Oregon Life & Bioscience is back for its 2nd year! What is AOBIO? It’s a four-week investment-readiness education series for life and bioscience startups at any stage of development. But wait, there’s more! It’s also an angel investment program. At the end of the education program, those companies that are indeed investment-ready can apply to go through due diligence for up to a $300,000 equity angel investment, to be presented at the AOBIO Finale + Innovation Showcase in May.

Education series starts February 22, 2023. Learn more here! Inquire with Rene Miller or Heather Ellis for a discount coupon code for this series.

Founders: there’s a free Entrepreneur Information Session on Wednesday, February 15 from 8:30-9:15 a.m. on Zoom. RSVP here.

For accredited angel investors (including first timers!), attend a free Investor Information Session on Wednesday, February 15 from 4:00-5:15 p.m. on Zoom. RSVP here.

Angel Oregon Bio is presented by OEN in partnership with Oregon Bioscience Incubator, OHSU, and OregonBio.


Client Company Wins

EndoSound

  • EndoSound receives investment from AGA’s GI Opportunity Fund. Read Business Wire press release here.

Hemex Health

  • Our team at HemexDx had a fantastic time at the 25th MTAR Labcon 2023 in Alibaug! We were thrilled to interact with delegates from the Raigad region and learn about their perspectives on Gazelle.

Aronora (alumnus)

  • Erik Tucker, PhD, founder and CEO of Aronora received a National Academy of Inventors Fellow award last night at the National Academy of Inventors Annual Winter Warmer: Celebrating Innovation Excellence in Oregon.

New Mentoring Cohort Begins

OBI Mentees

 

OBI Mentors

OBI’s Winter-Spring 2023 mentoring cohort is off and running. Each mentor-mentee pairing meets for about 2 hours a month for 6 months. For more information on how to join the next cohort, please see our Mentoring page.


PSU Center for Entrepreneurship is Hiring an Assistant Director

If you’re looking for a fulfilling opportunity working with students, entrepreneurs, and the local community, Portland State University Center for Entrepreneurship has an Assistant Director position that may be perfect for you!

Learn more and apply.


Women in Science PDX Mentor/Mentee Mixer

Mentor-mentee relationships can have an incredible impact on the lives and careers of mentees and mentors alike. At this event, we aim to provide the opportunity for mentees and mentors to engage with one another to discuss their goals and career paths, and to potentially develop mentor-mentee relationships that will last beyond the scope of this event.

This all-ages mixer will take place on March 1st at Lucky Labrador Beer Hall in NW Portland and will provide an opportunity for mentees to meet with several different mentors, in addition to plenty of open networking time.

For more information and registration, click here.


I-Corps Teams Forming

two men and women at table in business meeting

The I-Corps@NCATS lead institution, University of Alabama Birmingham, is hosting a virtual all-consortium I-Corps course and is currently registering teams. The orientation is on 2/24 and it runs through 3/31, see this link for a detailed schedule and registration for the “All CTSA Site” cohort. Attached is the flyer, this course is open to all early-stage life sciences technologies (idea through SBIR stages).


Upcoming Events

AOBIO Entrepreneur Information Session
February 15, 2023
8:30-9:15 AM
RSVP here

&

AOBIO Investor Information Session
February 15, 2023
4:00-5:15 PM
RSVP here

 

PDXWIT Presents:
Black History Month Happy Hour

February 21, 2023
5:30-7:30 PM
Virtual
Register here

 

Business Oregon logo

OBI Virtual Lunch & Learn:
Business Oregon’s Commercialization Gap Fund
and SBIR Overview
February 28, 2023
12:00-1:00 PM
Virtual
Register here

 

OBI Accelerate Biotech + Digital Health
Happy Hour

March 2, 2023
5:30-7:00 PM
Marriott Courtyard City Center
Registration now open!

 

Tie Oregon’s Westside Pitch Competition
March 9, 2023
4:00-7:00 PM
Walters Cultural Arts Center, Hillsboro
Register here

OBI & OTRADI End-of-Year 2022 Newsletter

Ringing in the New Year!

Welcome 2023! But before we leave 2022 behind, this end-of-year newsletter features a big OBI project that wrapped up in 2022, plus a recap of some of the outstanding and innovative projects that our client companies are working on. We hope you enjoy sharing in their success stories as much as we do.

This special edition of the OBI & OTRADI newsletter also includes some helpful information for our readers, including updates, opportunities, and some really great upcoming events. Please feel free to share. We hope you have a peaceful and prosperous 2023.


Our HIOP Space is Completed:
Thank you to Business Oregon! 

In 2021, OBI/OTRADI was granted High Impact Opportunity Project (HIOP) implementation funding from Business Oregon to build out new space to support growth of the bioscience sector in Oregon. We got right to work, transforming our prior administrative offices in the Willamette Wharf building into new labs and offices. Due to supply chain issues during a global pandemic, progress was not always speedy, but this project is now fully complete. Thank you, Business Oregon!

Business Oregon logo

The OBI used the HIOP dollars to fund the build-out of 3,300 square feet into six labs and six offices to expand incubator space for startup bio companies. This new space funded via HIOP dollars has allowed us to bring in seven new companies from our waiting list into the OBI facility. One additional lab is still unleased and available to one of OBI’s current companies or a new company upon completion of our selection committee process. For life science startups seeking space, inquire here.

The seven companies in the new space include CANX, GenerX, Keliomics, PDX Pharmaceuticals, Qtonics, Trace Biosciences (formerly Inherent Targeting), and VitalFlo; they support 17 jobs with one company actively hiring an additional position. These companies have raised over $7,527,000 in funding, which was mainly secured via SBIR grants and seed funding.


Client Company Wins in 2022

Aronora (alumnus)

CANX

  • CANX, LLC joined the OBI in October 2022
  • CANX is developing therapeutics to address iron-related health conditions such as iron overload disease and certain forms of cancer which depend on iron for their growth.
  • Founder Kerry Masterson successfully completed the OHSU I-Corp 5-week BIP Corps program.

Caregiven (alumnus)

  • In our latest product update we launched our affiliate program with 4 amazing companies who support caregivers: Grief Coach, SilverBillseFuneral, and Pinventory. While Caregiven does not advertise to our users, we do offer referral links to our affiliate partners who offer users a discount and provide Caregiven with lead generation revenue.
  • Alaska’s Dementia Action Collaborative profiled Caregiven as a valuable resource to its stakeholder community in their recent newsletter.
  • Caregiven was selected to participate in the APIS Health Angel program.
  • Caregiven was 1 of 4 finalists from the Australian round of the Zurich Innovation Championship. Selected from an applicant pool of over 90 insuretech solutions, Caregiven presented to Zurich’s Australian executive team including the global head of their LifeWell initiative.
  • We also surpassed 1,000 sign-ups in mid-February – that’s over one thousand families going through a caregiving event globally who are benefitting from our product.
  • Founder and CEO Candice Smith was a featured panelist at OBI’s February Lunch & Learn on How Accelerators Can Help Boost Your Startup.
  • Caregiven was acquired by Delta Dental of Iowa and its subsidiary Veratrus Health. Candice Smith, Caregiven’s founder and CEO, has joined the Delta Dental team! Read the press release here.

CytoImage

Endosound

  • EndoSound is pleased to announce two new full-time employees. We are thrilled to have these two join our growing team.
    • Peter Hoffman has joined as Senior Product Development Engineer.  He will help to bring new and innovative ultrasound products to market. His 10+ years engineering experience ranges from robotics to medical devices with much of his time at Olympus developing novel biopsy tools for the lungs. He has authored 6 patent applications. Peter holds a BS in Mechanical Engineering and a minor in Business and Entrepreneurship from Oregon State University.
    • Patrick Hurley has joined as the Vice President of Marketing. Patrick comes with 13 years in product and market management in medical device, as well as several years as a life sciences consultant. Patrick has documented successes in each role as he continued to grow with responsibilities. He has helped build brand identity and established strong relationships with KOLs in the GI community. He holds a Ph.D. in biology, specializing in neuroscience from Wesleyan University.
  • Winner of AGA Shark Tank and Innovation of the year. We had the opportunity to compete in the American Gastroenterology Association (AGA) Shark Tank for innovative technologies in early April and won!!
  • We’ll be competing again with our innovative Endoscopic Ultrasound device at the end of May at the largest Gastroenterology professional conference in the world called Digestive Disease Week (DDW).
  • We have also been honored with the Innovation of the Year from the American Society for Gastrointestinal Endoscopy (ASGE). This distinction is granted to companies with products that show promise for advancing the field of GI endoscopy.
  • Together, these awards demonstrate to the broader GI community that our mission to democratize EUS is taking shape. There could not be a better time to follow the EndoSound journey. View our LinkedIn page.
  • We recently announced Scott Fraser as a new addition to our board.  Scott comes with a world of knowledge in startups, the Gastroenterology (GI) space, and the Ambulatory Surgical Center (ASC) market.
  • In late May, we had our first ever booth at Digestive Disease Week (DDW).  This conference is the premier conference for the GI space, attracting doctors, industry professionals, and investors from all over the world.  We had tremendous response at the booth and as a result of several meetings with physicians and strategic partners.
  • Some of the Endosound team, in partnership with physicians in Ecuador, showcased the Endosound Vision System (EVS) on Endoscopy on Air (EOA) on June 3rd.  The Global Annual Live Streaming Event on EOA had physicians from around the world educate and demonstrate their techniques in various endoscopic procedures to the 11,000 virtual attendees.  We were honored to sponsor a session with partner Dr. Carlos Robles Medranda at the Ecuadorian Institute of Digestive Disease.

Gamma Diagnostics

  • Our podcast with Expert Dojo was released online.
  • MedRxiv published our study of gamma prime fibrinogen in COVID-19 patients.
  • David Farrell, Founder and CSO participated as a featured panelist at OBI’s February Lunch & Learn on How Accelerators Can Help Boost Your Startup.
  • Gamma Diagnostics recently participated in the Expert Dojo international accelerator program.
  • We are thrilled to announce the promotion of Jamie Noll, Pharm.D., B.S. Nutrition to Chief Scientific Officer for Gamma Diagnostics Inc., effective immediately. Jamie joined the Gamma Dx team late last year as a scientific and clinical advisor and in a very short time has helped establish key KOL relationships in the medical and clinical research community. She has had various roles and extensive experience in the pharmaceutical industry last of which was as a Medical Science Liaison for Puma Biotechnology.
  • “I have known Jamie for over 14 years and our professional and personal relationship has been forged through challenging projects and arduous decisions. Not only is she extremely talented in her field but she represents the highest standard in ethics and integrity. I feel honored and privileged she has decided to join us in the CSO capacity.” Ajay Nair, CEO Gamma Diagnostics Inc.
  • “Dr. Noll is a fabulous addition to the Gamma Diagnostics team! Her industry experience and scientific expertise are critical assets that will help propel Gamma Diagnostics forward.” Dr. David Farrell, Founder, Scientific Advisor, Gamma Diagnostics Inc.
  • Gamma Diagnostics presented at the Expert Dojo Investor Festival on April 7 in Los Angeles. Our new CSO, Dr. Jamie Noll, and Founder Dr. David Farrell presented. See event details here.
  • We filed a new provisional patent: Provisional Patent Application in United States No. 63/268,605 ‘Use of γ’ fibrinogen as a Biomarker in the Detection of Covid-19 and Prognosis of Severe Disease’
  • We filed an Emergency Use Authorization to the FDA entitled: “Gamma-prime fibrinogen ELISA”
  • Gamma Diagnostics Inc. and OHSU have signed a licensing agreement that seeks to further develop and commercially promote the use of Gamma Prime Fibrinogen (GPF) as an inflammatory and clotting risk biomarker.
  • High GPF levels have previously shown positive correlation with peripheral artery disease, heart failure and CVD deaths in the ARIC study. Dr. David Farrell (Founder and CSO) published an abstract at AHA 2021 showing COVID-19 patients can develop extraordinarily high levels of GPF.
  • Gamma Diagnostics Inc. will now continue to invest in further clinical studies, regulatory submission, and commercialization activities to bring GPF as a biomarker to market.
  • Gamma Diagnostics Inc. is proud to announce that Mr. Ajay Nair, currently President and CEO, will serve as Chairman of the Executive Board and transition the Chief Executive Officer role to Mr. Chris Venter, currently CFO of the Company, effective November 18th, 2022.

GenerX

  • GenerX moved its headquarters from Santa Clara, CA into one of the brand news labs in the OBI in Portland on December 1, 2022.
  • GenerX is a pharmaceutical development company, has moved its headquarters from California to the OBI. GenerX is engaged in the development, manufacturing, acquisition, licensing, and partnership of sterile injectable generic drug products for the U.S. and overseas markets. Their mission is to provide affordable generic medicines to patients through innovative solutions by leveraging our expertise and partnerships with world class FDA approved manufacturing.

Hemex Health

  • Hemex Health pitched to Inflect Health in January 2022.
  • Whitney Wilhardt has joined Hemex as PR and Marketing Specialist.
  • We sent our first Gazelles to Riyadh in Saudi Arabia.
  • We’re scheduled to ship commercially to Bahrein, Oman, Kuwait and Algeria, and we are already selling to Lebanon and UAE (Dubai and Abu Dhabi).
  • We’ve partnered with distributors in Savona, Italy, our first European location.
  • Umut Gurkan, our Chief Scientist for Sickle Cell Disease, based at Case Western in Ohio, was elected into the American Institute for Medical and Biological Engineering’s College of Fellows for his continuing achievements in medical and biological engineering.
  • Patti White, Co-founder and CEO, recently participated as a presenter in an Angel Oregon Bio educational seminar and was be a featured panelist in two of OBI’s Lunch & Learns on Women in Leadership. View the March event here and the June event here.
  • We received the 2022 West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) grant award for catalyzing pediatric innovation (CPI), which supports the development of pediatric innovation from ideation through commercialization. We plan to use this grant to help apply for US FDA clearance to bring our affordable POC sickle cell test to the US.
  • We have two abstracts that were accepted for the 4th Global Congress on Sickle Cell Disease (June 16-18) in Paris.
    • “Point-of-care diagnostic for quantification of fetal haemoglobin (Hb F) levels in monitoring hydroxyurea therapy for children with Sickle Cell Disease (SCD) in Ghana” has been accepted for a poster presentation.
    • “Evaluation of first microchip-based point-of-care device for diagnosis of Beta-Thalassemia in India” has been accepted for a poster presentation.
  • Hemex Health announced a significant enhancement to their Gazelle™ Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The increased accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings. Hemex will provide “over the air” updates with the Hb F enhancement that can be downloaded directly to existing Gazelle Readers. The improvement will ship with new systems.
  • We are proud to announce the official launch of the Gazelle™ PathoCatch™ COVID-19 FIA test, a diagnostic solution for point-of-care testing, made in collaboration with @MylabSolutions. Read the full press release.
  • We received National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for continuing to support Hemex Health and Case School of Engineering at Case Western Reserve University with a $1.7M Phase II STTR follow up award for our “portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C (diabetes) testing.”
  • We launched our COVID-19 point-of-care diagnostic, Gazelle PathoCatch, in India on July 7 and plan to launch to our other distributors worldwide later this summer.
  • CEO and Co-Founder Patti White was interviewed by International Finance Corporation (IFC).
  • We received Portland Business Journal’s Global Impact Award as part of their Health Care of the Future Program. Patti White, CEO and co-founder, accepted the award during their ceremony held on August 18.
  • Gazelle received Indian Council of Medical Research (ICMR) recommendation for sickle cell testing in India. Gazelle was one of three diagnostic platforms selected for this highly competitive and rigorous nod of approval.
  • We are proud to announce during this Sickle Cell Awareness Month (September 2022) that Hemex has shipped 210,000 SCD tests to 25 countries.
  • Hemex presented two posters at the Tropical Medicine Show (ASTMH) in Seattle.
    • The first discussed research on Gazelle’s ability to detect and differentiate P. knowlesi (a malaria species indigenous to SE Asia) from other malaria species.
    • The seconds was a study conducted in Ghana on Gazelle’s ability to measure fetal hemoglobin, which has possible applications for monitoring treatment for sickle cell disease.
  • NIH Seed sponsored Hemex at the Redefining Early-Stage Investments (RESI) Conference, January 10, 2023, which connects startups with early-stage investors.
  • The Zambian Network for Sickle Cell Disease in conjunction with the Zambian Ministry of Health launched Gazelle SCD testing devices in several district hospitals.
  • Hemex presented a poster on our beta thalassemia test at the American Society of Hematology (ASH) in New Orleans in December 2022.

HTI

  • Health Technology Innovations, Inc. was awarded a $1 million SBIR Phase II grant from the National Science Foundation to commercialize CryoDiscovery ™, a Cryo-EM Automation and Intelligence Platform for Drug Discovery.
  • HTI is hiring AI/ML software development engineers, interns & post docs.
  • Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Doug Kawahara is joining HTI as Senior Advisor for AI/ML in Drug Discovery. Dr. Kawahara brings extensive experience in drug discovery and development to HTI. He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Read full press release.
  • HTI attended the 17th Annual Drug Discovery Chemistry event in San Diego on April 18-22, presenting a Poster session on CryoDiscovery™ its machine learning platform for cryo-EM image processing, and providing information on its cryo-EM Services offerings for drug discovery.
  • HTI CTO,  Narasimha Kumar, presented a poster session virtually at The Astbury Conversation 2022, on April 25-26 on CryoDiscovery™: Public Data-based AI/ML model enhancements for Cryo-EM Image Analysis. The Astbury is one of Europe’s premier conferences on macromolecular research, including a keynote by cryo-EM Nobel Laureate Richard Henderson.
  • HTI has signed master service agreements with IDEAYA Biosciences and ADRx for cryo-EM structure determination services to support their drug discovery efforts. IDEAYA is a synthetic lethality-focused precision medicine oncology company and ADRx is a biotechnology company with a unique approach to halting diseases of protein aggregation.
  • Received Phase II matching grant award from Business Oregon.
  • In collaboration with Oregon BIO, HTI attended the Bio International 2022 with great success.
  • HTI presented CryoDiscovery™ and CryoFast™ at the Microscopy & Microanalysis 2022 and American Crystallographic Association 2022 conferences on July 29 – Aug  4 in Portland, Oregon
  • HTI signed a service agreement with ADRx Pharma for Cryo-EM sample optimization and image analysis.
  • Signed Master Service Agreement with ADRx and a Top Tier International Pharmaceutical company for Cryo-EM services.
  • HTI is now offering its Cryo-EM services via Scientist.com, a leading “science as a service” e-commerce site for Life Sciences. This adds a second e-commerce sales channel beyond ScienceExchange.com, the world’s first online R&D marketplace to accelerate scientific discovery, of which HTI became a member last year.
  • Set up collaboration with Salk Institute for Cryo-EM data sets sharing.
  • Filed patent of CryoFAST™ architecture (CRYOGENIC ELECTRON MICROSCOPY FULLY AUTOMATED ACQUISITION FOR SINGLE PARTICLE TOMOGRAPHY).
  • Signed Master Service Agreement with AstraZeneca for Cryo-EM single particle analysis.
  • Delivered Cryo-EM 3D structure model with encouraging results for ADRx.

Izon

  • Jared Lynch has been made Sales Director for the United States region as of October 2022.
  • Anthony McNeil is now the West Coast Sales and Applications Scientist.
  • Izon will complete our Gen 2 qEV column releases with all sized columns available after January 17, 2023. This includes qEV singles, originals, 1s, 2s, 10s, and 100s.
  • Izon is quite pleased with the adoption of our version 2 of the Automatic Fraction Collector which was released in February 2022.
  • We have several new product releases planned for 2023.
  • We are excited for ISEV2023 in Seattle in May, where Izon will be a sponsor.

Keliomics

  • Joined the OBI in October 2022. They moved into two of OBI’s new offices and one of the brand-new labs.
  • Keliomics offers pharmacophenotyping for patients with solid tumors including breast, prostate, and certain types of metastatic cancer.
  • Keliomics was one of the five winners of the Beaverton Startup Challenge 2023, winning $25,000.

Madorra

NeuvaRx

  • NeuvaRx joined the OBI in March 2022. NeuvaRx is preclinical-stage biopharmaceutical company dedicated to the development of therapies and diagnostic tools for neurovascular disorders, including, but not limited to ischemic and hemorrhagic stroke and vascular dementia.
  • NeuvaRx received an NIH phase I STTR award that started July 1.
  • We also received a matching grant award from Oregon Business Development for the STTR award.

OmnEcoil Instruments

  • OmnEcoil was mentioned in a May 2022 report entitled: “Global Biopsy Devices Pipeline Market Landscape Report 2021: Stage of Development, Segment, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trial – ResearchAndMarkets.com.” You can read the press release here.

PDX Pharmaceuticals

  • PDX Pharmaceuticals joined the OBI in February 2022. PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company bringing complementary biological pathways together to achieve synergistic clinical benefits. Their patented mesoporous silica-based nanoparticle platform (Pdx-NP) has been optimized to co-deliver multiple classes of therapeutics (e.g., siRNA, small molecule drugs, antibodies, immunostimulants) to ensure that they reach the target cells at the same time to fully realize their synergy. It can deliver cargos to both cancer and immune cells. Their current focus is to generate effective anti-tumor immune response through profound CD8+ anti-tumor T cell production.
  • We have a new publication in Nature Communications.
  • Also we won a matching grant for phase II small business innovative research (SBIR) from Business Oregon this year. The award (USD 100,000) will be used for our IP protection, financing a new facility, and fundraising activities.
  • PDX Pharma was recognized by Portland Business Journal and received two philanthropic awards on October 27.
    • 2022 Innovation in Philanthropy award (PDX Pharmaceuticals in partnership with OHSU).
    • Top 10 philanthropic small companies (below $10M in revenue).
  • These awards recognized our commitment, through donation and volunteer work, to support education and training in cancer research and nanotechnology.
  • PDX Pharmaceuticals expanded within the OBI to an additional lab, one of the brand-new labs recently opened in Suite 270.
  • PDX Pharma’s ARAC-02 drug candidate has been selected into the Nanotechnology Characterization Lab (NCL)’s collaboration and characterization program. ARAC-02 targets PD-L1, PLK1, and TLR9 for the treatment of lung cancer. More information here.

ProMedix

Qtonics

  • Qtonics moved within the OBI from a co-working desk space to one of our newly built offices.

Refeyn

  • Launched a new product line specifically designed for gene therapy applications, called the SamuxMP. The Refeyn SamuxMP is a mass photometer optimized for adeno-associated virus (AAV) characterization and is an essential analytical tool for laboratories working with AAVs. The SamuxMP precisely measures the empty/full capsid ratio for AAVs of any serotype. SamuxMP mass photometry measurements are rapid and require very little sample.
  • Brenda Watt has been promoted to Customer Success Manager in the Portland office, and Ritu is a new member of the Portland team.
  • Refeyn closed Series B funding round, led by Northpond Ventures! Read their press release here.

Rewire Neuro

  • Received a Business Oregon grant award to develop a marketing strategy and hire additional staff for their AI-as-a-service platform in diagnostics and analysis.
  • Rewire Neuro was a finalist in Pitch Oregon by TiE Oregon, in the Life Science category.
  • John Harkness, President and CEO, was a presenter in an Angel Oregon Bio educational seminar.
  • Rewire attended BIO International as part of the Oregon Pavilion and pitched at the Startup Stadium as a finalist, gaining recognition, feedback, and interest from a large group of investors and potential partners from around the world.
  • Rewire Neuro, Inc., makers of Pipsqueak Pro – the revolutionary AI image analysis platform for biological researchers, announces their partner platform integration with eLabNext, part of Eppendorf Group, and premier Electronic Lab Notebook (ELN) platform provider.
  • Rewire will be integrating our image analysis software into eLabNext’s electronic lab notebook, which will enable users to seamlessly move between conducting their image analysis and their collaborative data organizational environment, providing deeper analysis and insights for the entire lab.
  • Pipsqueak Pro was born from the lab–developed by scientists to rapidly speed up manual image analysis, cellular quantification, and multi-channel (colocalization) analysis for both image and video media. The platform uses a patented machine learning system to improve your ROI predictions with minimal user input. Our AutoML™ process will customize the AI’s detection capabilities to your needs and improve your lab’s analysis workflow.
  • Rewire Neuro and Neurescence are partnering to enhance fluorescence calcium imaging of the nervous system with cutting edge neuronal segmentation and analysis capability.
    • Neurescence Inc. (Toronto, Canada), the manufacturer of the MultiscopesTM, and Rewire Neuro, Inc. (Portland, Oregon), a provider of artificial intelligence software development services (“AI-a-a-S”) announced their strategic development partnership today. With the aim to optimize the automated analysis workflow for neuroscientists, this technology integration utilizes deep learning to rapidly improve detection and quantification of neuronal activity while reducing the processing time of data-dense brain recordings. Videos that would previously take 2 weeks to be processed now result in neuronal detection in 30 minutes with double the accuracy compared to the existing automated neuronal segmentation methods in the market.

RxHomeTest

  • RxHomeTest pitched to Inflect Health in January, 2022.

Senju Pharmaceuticals

  • Dr. Thomas R. Shearer discovered that the thinning of the retinal ganglion cell layer (GCL) occurs in patients with branch retinal artery occlusion (BRAO) as well as in central retinal artery occlusion (CRAO), recently published in PLosOne.
  • We welcomed Takatoshi Uchida from Japan in 2022.

Sirona Dx

  • In March 2022, Sirona Dx announced a co-marketing agreement with Ultivue for multiplexed tissue biomarker solutions.
  • Sirona Dx announced a partnership with Scailyte for AI driven end-point specific single cell analysis in July 2022.

 

Sonivate Medical

  • Sonivate Medical, Inc. has received funding as part of an SBIR Program from the US Air Force for a Phase I ($74,886).  It is a 90-day Phase I to be completed by January 27, 2023.  This Phase I is to develop the requirements for an Ultra-High Frequency Linear Probe for clinical applications in MSK, ophthalmology and clinical ultrasound views < 3 cm.
  • In addition, Sonivate will secure an Air Force clinician to be PI for the clinical research in the Phase II application.

Sparrow Pharmaceuticals (alumnus)

  • Sparrow Pharmaceuticals received ethics committee and regulatory authority go-ahead for three Phase 2 clinical trials, in patients with Cushing syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.
  • Dr. David Katz was selected to give oral presentations on new clinical pharmacology and non-clinical study results at three prestigious conferences in May-June: European Congress of Endocrinology in Milan, European League Against Rheumatism in Copenhagen, and Endocrine Society in Atlanta.
  • Sparrow has dosed the 1st patient in a phase 2 clinical trial of SPI-62 with prednisolone for polymyalgia rheumatica. Read press release here.
  • Congratulations to Sparrow CSO and Founder, David Katz, for the honor of being a PharmaVoice 100! David was recognized for his entrepreneurial spirit and pursuit of finding a treatment for disorders due to steroid excess using scientific prowess and an artist’s vision. Read Dr. Katz’ interview.

StoneStable

  • CSO and Founder Ken Stedman was interviewed by a local KATU reporter about the new SARS CoV-2 subvariant, which was then picked up and shown on Good Morning America.
  • StoneStable, Inc. moved in to their new lab space in Suite 130A at the OBI.
  • StoneStable, Inc. was one of the finalists for the Angel Oregon Life & Bio (AOBIO) investment. See press release.
  • Ken Stedman and Dan Snyder from StoneStable were at the BIO meeting in San Diego and made a number of connections with international pharmaceutical companies, large and small.
  • We are proud to announce that StoneStable, Inc. has been accepted into the Creative Destruction Lab program in the International Advanced Therapies Track.

SUTUREGARD Medical

  • SUTUREGARD Medical, Inc. received the honor of being chosen by MedTech Innovator for the MedTech Innovator Road Show.  In their words, ”MedTech Innovator is the largest and highest performing accelerator of medical technology in the world and the medtech industry’s premiere showcase and competition for innovative medical device, digital health and diagnostic companies.”
  • We will be pitching April 14 and hope to leverage our participation into favorable business development pathways.
  • We received a lot of attention at trade shows including the American College of Foot and Ankle Surgeons in Austin Texas where we presented our 3rd study showing ~80% reduction in postoperative wound complications after repair of ankle fractures.
  • We have enjoyed record sales in Q1 2022.
  • Dr Alton Johnson of University of Michigan Podiatry presented at the Society for Advanced Wound Care (SAWC) last month in Phoenix on HEMIGARD closure of Stage 4 (bone involved) heel wounds.  He won first place in the Practice Innovation category for this work.  HEMIGARD is allowing surgeons to close wounds that have not been able to be closed with normal suture materials.  Normal suture does not work well on soft heel skin which does not resist tearing when under tension.  HEMIGARD corrects this problem.
  • The most recent episode (Season 4 – Episode 3 entitled “A Smell from Hell”) of “My Feet are Killing Me” featured HEMIGARD being used by “Dr. Brad” to close a very tough plantar wound.  It does have graphic content including live surgery footage.  The patient in question can hardly walk due to masses of callus on the ball of her foot – the surgical excision leaves a large wound that is difficult to close, and Dr. Brad uses HEMIGARD to help close the defect.  The patient has an excellent result and is ecstatic! “My Feet Are Killing Me” A Smell from Hell (TV Episode 2022) – IMDb.
  • Our biggest recent win had almost nothing to do with us.  A general surgeon at Kaiser Permanente in Oakland got a hold of our wound closure device HEMIGARD, loved it, got it approved locally and then nationally and now we have received orders from multiple Kaiser clinical facilities. This surgeon is not an advisor or consultant to us, and just liked what HEMIGARD was doing for her wound closure results.
  • We were one of 28 medical device startup companies selected from over 1000 worldwide applicants for the MedTech Innovator Accelerator 2022 program.  This is wrapping up soon at AdvaMed in Boston at the end of the month and there are several competitions in play.
  • One is the one minute video competition.  Please enjoy (and “like” on LinkedIn) our story of how Dr. Brad used HEMIGARD to stop Shantell’s feet from killing her!
  • SUTUREGARD wins American Diabetes Association 2022 Showcase Innovation Award.  We were recently (November 4, 2022) honored to receive this award, having successfully competed with 160 other companies from the USA and beyond.  Above we are receiving the award presented by Dr. Robert Gabbay, the Chief Medical Officer of the ADA (2nd from L).  The ADA heard our message about how our HEMIGARD product has dramatically improved surgical outcomes for diabetic amputation patients.
  • As you may know, many initial amputations do not heal on these patients who almost always have vascular disease and neuropathy, and often require more morbid above or below knee amputations with high risk of systemic complications including mortality.  HEMIGARD reduced need for further amputation by 89% by preventing healing complications with the initial amputation.  This study of 80 patients is valid real-world evidence that resonated with the ADA judges.
  • We look forward to bringing HEMIGARD to all those who do provide surgical care for diabetics with the goal of improving their surgical outcomes!

Synergic Medical Technologies

  • Synergic was a finalist in the 2022 Oregon Technology Awards in the Pre-Revenue category.
  • Synergic is proud to announce that we have received breakthrough device designation from the FDA! This is a big day for us in our mission of bringing solutions to the Parkinson’s community. We appreciate this special recognition and support of the FDA in our on-going development of the VT Touch.

Thaena

  • Thaena held its annual 2022 Thaena Microbiome Symposium in a virtual format. It focused on the rise of probiotics: the roles they play in various organ systems, our health, and clinical applications.
  • View recordings from the symposium here.

Trace Biosciences

  • Trace Biosciences (formerly Inherent Targeting) was selected as a finalist for the Angel Oregon Life & Bio (AOBIO) investment competition through OEN, competing for a ~$300k investment, with the winner announced at the Finale event on May 26th at Amaterra Winery in Portland. See press release.
  • We were awarded an SBIR matching grant from Business Oregon for ~$50k to complete in vitro testing and regulatory planning of our lead contrast agent towards clinical translation.
  • We were selected to participate in the Creative Destruction Lab Biomedical Engineering track taking place out of Vancouver WA.
  • We received an SBIR matching grant from Business Oregon to complete some additional in vitro toxicology testing and regulatory work for our Phase I NSF STTR project.
  • We received a phase I SBIR award from the NINDS at the NIH to develop our imaging agents for the application of intraoperative nerve damage assessment to improve nerve repair surgery.
  • This fall, Trace Biosciences moved within the OBI to one of the new offices and a brand-new lab.

Veana Therapeutics

  • Received a Business Oregon grant to help provide funding toward commercialization for its VT-101 oral medication for oncology patients.
  • Founder and CEO Emmanuel Akporiaye, PhD, recently presented at an Angel Oregon Bio educational seminar.
  • Their ongoing clinical trial for the study of Alpha-TEA and trastuzumab for the treatment of refractory HER2+ metastatic breast cancer continues at the University of Washington/Fred Hutchinson Cancer Center.
  • Participated in the Research in Your Back Yard panel at the OBI in May.
  • Recently enrolled a third patient in their clinical trial at Fred Hutchinson Cancer Center in Seattle and will soon be opening a second trial site at Providence Cancer Center, Portland.

VIR Biotechnology

  • VIR Biotechnology graduated from the OBI February 28, 2022, after joining the incubator in 2015 as TomegaVax, an OHSU spinoff that is pursuing an HIV vaccine. VIR Biotechnology has had many successes throughout their time at the Oregon Bioscience Incubator, including initiating their Phase 1 clinical trial of VIR-1111, an investigational human immunodeficiency virus (HIV) T cell vaccine.
  • Upon graduation, VIR Biotechnology has relocated their lab and office from OTRADI’s incubator in the Willamette Wharf building on Portland’s South Waterfront, to the Riverside Centre business park just down the street from the incubator.

Virogenomics BioDevelopment

  • VBD was awarded its third year of funding on our SBIR Phase 2B grant focused on manufacture and toxicology of DRQ, our therapeutic for multiple sclerosis.
  • After 20 years with Virogenomics and then with VBD, Jeff King has decided to step-down as CEO of VBD.  He remains part of VBD’s Board of Directors. Renee Shirley will become CEO of VBD starting in 2023.

VitalFlo

  • VitalFlo officially joined the OBI in October 2022, moving into one of the newly built offices.
  • VitalFlo helps leading clinicians and researchers improve patient outcomes and advance lung health by providing comprehensive respiratory data, analysis and care.
  • VitalFlo Announces Public Investment Campaign to Help Doctors Measure, Monitor, and Predict Patient’s Lung Health
    • “Do you think asthma and COPD should be treated preventatively instead of with trips to the ER? So does VitalFlo,” says Luke Marshall, PhD, VitalFlo Founder and CEO.
    • The team at VitalFlo has built a spirometry platform to help patients and their primary care doctors proactively manage their asthma, COPD, and other respiratory concerns.
  • VitalFlo has officially launched its Wefunder campaign. With Wefunder, everyone, regardless of background, connections, or income, will finally be able to invest in VitalFlo and be a critical part of their future success. Read More.
  • VitalFlo was one of the finalists in the Impact category at Bend Venture Conference.

Congratulations to all of you on your hard work and successful endeavors! You’re doing great things for healthcare.


Business Oregon SBMA Grant

Business Oregon logo

Do you have or know of a small business affected by COVID-19? Small businesses may be eligible for one of Oregon’s Small Business and Microenterprise Grant Assistance awards. This program is funded by CARES Act funding for businesses who meet eligibility requirements.

For more information, see Business Oregon’s SBMA Program page.

Note: Applications open on January 23 at 8 a.m. and are due at 5 p.m. on January 27, 2023.


Save the Date for OTRADI’s 15th Anniversary Celebration

Mark your calendars to come out and help us celebrate our 15th anniversary! More information to come, so stay tuned.


Thank You for Your Continued Support of our Programs

OBI is gearing up for some excellent free entrepreneurial programming this year. We have monthly Lunch & Learns on all kinds of interesting topics geared toward the life science community, monthly Happy Hour networking, a robust mentoring & advising program, and more. Each of these programs has sponsorship opportunities available.

To help support our programming with a tax-deductible sponsorship, please take a look at our Program Sponsorship Kit and contact Rene Miller for sponsorship or questions.


Upcoming OBI Events

Image by DCStudio on Freepik

OBI Virtual Lunch & Learn:
Diversity in Clinical Trials
January 18, 2023
12:00-1:00 PM
Register here

 

Accelerate Biotech + Digital Health Happy Hour
February 2, 2023
5:30-7:00 PM
Oregon Bioscience Incubator, Portland
Tickets are limited – get yours now!

 

Business Oregon logo

OBI Virtual Lunch & Learn:
Business Oregon’s Commercialization Gap Fund
and SBIR Overview
February 28, 2023
12:00-1:00 PM
Save the date!

 

Other Community Events

PDX Women in Tech Presents:
January Happy Hour & Town Hall
January 17, 2023
5:30-7:30 PM
Virtual
Register here

 

UW WE-REACH Biomedical Entrepreneurship
Fireside Chat Series
January 19, 26, February 2, and 9, 2023
2:00-3:00 PM
Virtual
Register here

 

Lunch & Learn: What Every MedTech Startup Leader
Needs to Know About Attempting a Commercial Launch
January 25, 2023
12:00-1:30 PM
Virtual
Register here

 

Image by Mikhail Nilov on Pexels

Built Oregon Presents
PitchBlack 2023

February 7, 2023
6:30 PM
The Patricia Reser Center for the Arts, Beaverton
Tickets on sale now

OBI & OTRADI December 2022 Newsletter

Happy Holidays from Oregon Bioscience Incubator!

OBI Team

To observe the holidays and spend time with our families, OBI/OTRADI will be closed December 23-January 2. We wish you all a joyful holiday season and a happy start to 2023!


Rene Miller Promoted to OBI Associate Director

Following the departure of Hazel Valdez, Rene Miller has been promoted to the Associate Director position. Rene first joined the Oregon Bioscience Incubator/OTRADI in January 2020. As Associate Director, Rene recruits and helps select new client companies to join the incubator, implements and markets community and client programs and events, leads DEI initiatives, and manages communications and social media outreach.

Rene holds Bachelor of Science degrees in Business from Portland State University and Clinical Laboratory Science from Oregon Health & Science University/Oregon Institute of Technology, as well as a Master of Science in Nutrition from University of Western States. Her background includes clinical laboratory experience and small business ownership. As a longtime Chamber of Commerce participant, she also brought her interest in supporting and encouraging business growth and development to the OBI.


Welcome GenerX to the OBI

GenerX, a pharmaceutical development company, has moved its headquarters from California to the OBI. GenerX is engaged in the development, manufacturing, acquisition, licensing, and partnership of sterile injectable generic drug products for the U.S. and overseas markets. Their mission is to provide affordable generic medicines to patients through innovative solutions by leveraging our expertise and partnerships with world class FDA approved manufacturing facilities.

GenerX moved into one of our brand new labs on December 1, and we are thrilled to have them join us!


Client Company Wins

Keliomics

Synergic Medical Technologies

  • Synergic is proud to announce that we have received breakthrough device designation from the FDA! This is a big day for us in our mission of bringing solutions to the Parkinson’s community. We appreciate this special recognition and support of the FDA in our on-going development of the VT Touch.

Gamma Diagnostics

  • Gamma Diagnostics Inc. is proud to announce that Mr. Ajay Nair, currently President and CEO, will serve as Chairman of the Executive Board and transition the Chief Executive Officer role to Mr. Chris Venter, currently CFO of the Company, effective November 18th, 2022.

Suturegard Medical

  • SUTUREGARD wins American Diabetes Association 2022 Showcase Innovation Award.  We were recently (November 4, 2022) honored to receive this award, having successfully competed with 160 other companies from the USA and beyond.  Above we are receiving the award presented by Dr. Robert Gabbay, the Chief Medical Officer of the ADA (2nd from L).  The ADA heard our message about how our HEMIGARD product has dramatically improved surgical outcomes for diabetic amputation patients.
  • As you may know, many initial amputations do not heal on these patients who almost always have vascular disease and neuropathy, and often require more morbid above or below knee amputations with high risk of systemic complications including mortality.  HEMIGARD reduced need for further amputation by 89% by preventing healing complications with the initial amputation.  This study of 80 patients is valid real world evidence that resonated with the ADA judges.
  • We look forward to bringing HEMIGARD to all those who do provide surgical care for diabetics with the goal of improving their surgical outcomes!

GenerX

  • GenerX moved its headquarters from Santa Clara, CA into the OBI in Portland on December 1.

StoneStable

  • StoneStable is hiring a part-time technician. See their job description here.

Congratulations on all of your achievements!


VertueLab’s Federal Funding News

gray and orange vertue lab logo on white background

VertueLab’s December newsletter is chock full of federal funding opportunities and resources, such as:

  • Department of Energy (DOE)
  • National Science Foundation (NSF)
  • National Oceanographic and Atmospheric Administration (NOAA)
  • Department of Homeland Security (DHS)
  • Department of Defense (DoD)

As one of Oregon’s signature research centers (alongside OTRADI and ONAMI), VertueLab is always there to help Oregon entrepreneurs with helpful information and free advice.


Partner Spotlight: Northwest Tenant Group

Stanford Scriven is the founder and principal of Northwest Tenant Group, Portland’s only independent, conflict-free real estate firm. His approach is that of a “Chief Real Estate Officer” for Northwest companies who need to utilize real estate without the headache. He has proudly managed real estate projects for over 100 companies ranging from startups to the Fortune 150. Learn more about Northwest Tenant Group’s services at www.nwtenantgroup.com.


Upcoming Events

OBI events

Accelerate Biotech + Digital Health Happy Hour
January 5, 2023
5:30-7:00 PM
Marriott Courtyard City Center
Register here – tickets are going fast!

 

Other community partner events

OEN Pub Talk: Exit Strategies Realized… Now What?
December 14, 2022
5:15-7:30 PM
Holcene
Get tickets here

 

PDX Women in Tech Winter Soiree & Awards Ceremony
December 15, 2022
5:00-7:00 PM
In-person or virtual
Register here

OBI & OTRADI November 2022 Newsletter

OBI client company wins

PDX Pharmaceuticals

  • PDX Pharma was recognized by Portland Business Journal and received two philanthropic awards on October 27.
    • 2022 Innovation in Philanthropy award (PDX Pharmaceuticals in partnership with OHSU)
    • Top 10 philanthropic small companies (below $10M in revenue)
  • These awards recognized our commitment, through donation and volunteer work, to support education and training in cancer research and nanotechnology.

VitalFlo

  • VitalFlo Announces Public Investment Campaign to Help Doctors Measure, Monitor, and Predict Patient’s Lung Health
    • “Do you think asthma and COPD should be treated preventatively instead of with trips to the ER? So does VitalFlo,” says Luke Marshall, PhD, VitalFlo Founder and CEO.
    • The team at VitalFlo has built a spirometry platform to help patients and their primary care doctors proactively manage their asthma, COPD, and other respiratory concerns.
  • VitalFlo has officially launched its Wefunder campaign. With Wefunder, everyone, regardless of background, connections, or income, will finally be able to invest in VitalFlo and be a critical part of their future success. Read More
  • VitalFlo was one of the finalists in the Impact category at Bend Venture Conference.

Trace Biosciences

  • We were selected to participate in the Creative Destruction Lab Biomedical Engineering track taking place out of Vancouver WA.
  • We received an SBIR matching grant from Business Oregon to complete some additional in vitro toxicology testing and regulatory work for our Phase I NSF STTR project.
  • We received a phase I SBIR award from the NINDS at the NIH to develop our imaging agents for the application of intraoperative nerve damage assessment to improve nerve repair surgery.

ProMedix

  • ProMedix currently has an open round for funding and would love to discuss further with any interested parties at OBI or beyond. Please email Scott Filer, CEO: scott_filer@promedixinc.com
  • ProMedix was recently selected from a competitive group of startups for the Creative Destruction Lab‘s healthcare cohort. This will help to solidify a go-to-market strategy for our technology as well as expand to a large network of healthcare innovators.
  • ProMedix has been announced as a finalist for the Seattle Angel Conference. In addition it is being highlighted as stage presenting startup company at the large Octane MedTech Innovation Forum in Southern California.
  • We also brought onboard Robert Jenks, MBA as our Acting CFO. Bob is a former Managing Director for GE Equity.
  • ProMedix was featured in the OHSU Innovates 2022 Impact Report.

Sonivate Medical

  • Sonivate Medical, Inc. has received funding as part of an SBIR Program from the US Air Force for a Phase I ($74,886).  It is a 90-day Phase I to be completed by January 27, 2023.  This Phase I is to develop the requirements for an Ultra-High Frequency Linear Probe for clinical applications in MSK, ophthalmology and clinical ultrasound views < 3 cm.
  • In addition, Sonivate will secure an Air Force clinician to be PI for the clinical research in the Phase II application.

CANX

Hemex Health

  • Hemex presented two posters at the Tropical Medicine Show (ASTMH) in Seattle.
    • The first discussed research on Gazelle’s ability to detect and differentiate P. knowlesi (a malaria species indigenous to SE Asia) from other malaria species.
    • The seconds was a study conducted in Ghana on Gazelle’s ability to measure fetal hemoglobin, which has possible applications for monitoring treatment for sickle cell disease.

Rewire Neuro

  • Rewire Neuro and Neurescence are partnering to enhance fluorescence calcium imaging of the nervous system with cutting edge neuronal segmentation and analysis capability.
    • Neurescence Inc. (Toronto, Canada), the manufacturer of the MultiscopesTM, and Rewire Neuro, Inc. (Portland, Oregon), a provider of artificial intelligence software development services (“AI-a-a-S”) announced their strategic development partnership today. With the aim to optimize the automated analysis workflow for neuroscientists, this technology integration utilizes deep learning to rapidly improve detection and quantification of neuronal activity while reducing the processing time of data-dense brain recordings. Videos that would previously take 2 weeks to be processed now result in neuronal detection in 30 minutes with double the accuracy compared to the existing automated neuronal segmentation methods in the market.

CytoImage

Caregiven (alumnus)

Congratulations on all of your achievements!


Wishing Hazel Valdez the best in her new role

OBI’s Associate Director, Hazel Valdez, has accepted a position as Executive Director for PDXWIT and will be leaving OBI on November 18, 2022.

While at OBI, Hazel has worked to formalize OBI’s selection process, injected Diversity, Equity, and Inclusion work into daily operations, built a job board, completed a digital health project initiative, and led the organization’s diversify funding efforts. Hazel has always communicated that she wanted to become an Executive Director herself, so we are ecstatic to see her achieve this goal.

While we are saddened to see her go, we are grateful for all the work she has done and the friendships we have formed. We wish her congratulations on this achievement and look forward to working with her as a partner in this great community.


CBRE report: Life science market normalizes in Q3 after record-setting 2021

Executive Summary

  • U.S. life sciences employment increased by 5.4% year-over-year in Q3 2022. While year-over-year growth in the Biotech R&D sector remained high at 11%, it began to plateau in Q3 with little change between July and August.
  • Life sciences venture capital funding decreased by 29% quarter-over-quarter to $4.1 billion in Q3, in line with pre-pandemic levels.
  • The overall lab vacancy rate increased by 30 basis points (bps) quarter-over-quarter to 5.3% in Q3, largely due to new supply totaling 2.1 million sq. ft. outpacing absorption of 363,047 sq. ft.
  • The average lab asking rent of the top 12 U.S. markets increased by 6.8% quarter-over-quarter to $60.28 per sq. ft. NNN.
  • Under-construction lab space increased by 4.9 million sq. ft. quarter-over-quarter to 37.4 million sq. ft., 88% of which was being built on a speculative basis and 26.3% preleased.
  • Download the report PDF here.

For more information, contact Ajay Malhotra, Ajay.Malhotra@cbre.com or Kristin Hammond, Kristin.Hammond@cbre.com at CBRE Portland.


Pitch Oregon applications due Nov. 15

PITCH OREGON is entering another year, showcasing the talent and innovation of Pacific Northwest founders. Each year, Pitch Oregon brings together entrepreneurs, investors, and mentors from the region, creating a collaborative and dynamic environment for launching startups on their growth journeys.

Winners of the growth categories for Pitch Oregon 2023 will receive investment through a special purpose vehicle (SPV). A cash prize will be awarded to the Early-Stage winner.

Last year, $875K was invested in six companies and we’re expecting approximately the same again in 2023!

WHO CAN APPLY:  Pitch Oregon will have 3 Growth categories and one Early-Stage category. Applicants will self-select which category to apply for. To be eligible for one of the Growth categories, startups must have raised more than $250,000 in total investment or have more than $250,000 in revenue. Pitch Oregon categories include:

  • Cleantech / Sustainability (growth)
  • Life science (growth)
  • Software / Technology (growth)
  • Early Stage (industry agnostic)

Deadline to apply is November 15.
More information here.


OHSU Innovates 2022 Impact Report

The OHSU Innovates 2022 Impact Report provides a snapshot of the successes that come from innovative science, academic-industry collaborations and an infrastructure that stewards ideas to impact. You’ll find numbers that show the impact of funding great ideas, and you’ll see profiles of some of the OHSU innovators and start-ups that demonstrate the change that innovation can bring.  The report also shares OHSU services and resources that aim to help build a vibrant entrepreneurial ecosystem.

A special shoutout to OBI client companies ProMedix, who is featured on pages 8 and 14; and CytoImage, whose profile appears on page 13 of the report.


UC Davis is hosting NIH course

group of people attending a seminar

NIH Course in Neurotherapeutics Discovery and Development for Academic Scientists

Applications are now being accepted for the 2023 session of the Training in Neurotherapeutics Discovery and Development for Academic Scientists Course, taking place March 14 -17, 2023 at UC Davis in Davis, CA. The deadline to apply is December 5, 2022.

This NIH-sponsored short course focuses on fundamentals of drug discovery and development of novel neurotherapeutics. It offers a mix of didactic lectures, workshops, round robins, and one-on-one academic/pharma mentorship, with time for networking and in-person collaboration. Led by Course Directors Michael Rogawski, MD, PhD, and Barbara Slusher, PhD, MAS, the course is taught by a faculty of leading Pharma industry and academic drug discovery professionals. Participants will have ongoing access to senior faculty who will assist them to achieve success in their individual drug development projects.

The 2023 session will be held in person at UC Davis in Davis, CA. There is no cost to apply, and for successful applicants, tuition, travel, and lodging are fully coveredApply here by December 5.


Upcoming events

OBI events

Hybrid Lunch & Learn: Financial Success
Through Accounting Best Practices
November 16, 2022
12:00-1:00 PM
OBI or Virtual Option
Register here

 

Hybrid Lunch & Learn:
Commercial
Real Estate Q&A
December 7, 2022
12:00-1:00 PM
OBI or Virtual Option
SAVE THE DATE – registration coming soon

 

Other community partner events

Voices of Equity: Backlash & Social Movements
November 11, 2022
9:00-9:30 AM
Register here

 

Biotech Summit 2022 + Bio on the Vine
November 15, 2022
2:00-8:00 PM
Knight Cancer Research Building – Portland
Purchase tickets here

-and-

Bio in the Valley 2022
December 1, 2022
5:00-8:00 PM
Phil and Penny Knight Campus for
Accelerating Scientific Impact – Eugene
Purchase tickets here

 

Inclusion That Moves You
December 7, 2022
12:00-1:15 PM
Register here

OBI & OTRADI October 2022 Newsletter

Welcoming Another New Client Company to OBI!

CANX LLC is developing therapeutics to address iron-related health conditions such as iron overload disease and certain forms of cancer which depend on iron for their growth.

Welcome to the Willamette Wharf building and our OBI client company community!


OBI Client Company Wins

stacked rocks

Rewire Neuro

  • Rewire Neuro, Inc., makers of Pipsqueak Pro – the revolutionary AI image analysis platform for biological researchers, announces their partner platform integration with eLabNext, part of Eppendorf Group, and premier Electronic Lab Notebook (ELN) platform provider.
  • Rewire will be integrating our image analysis software into eLabNext’s electronic lab notebook, which will enable users to seamlessly move between conducting their image analysis and their collaborative data organizational environment, providing deeper analysis and insights for the entire lab.
  • Pipsqueak Pro was born from the lab–developed by scientists to rapidly speed up manual image analysis, cellular quantification, and multi-channel (colocalization) analysis for both image and video media. The platform uses a patented machine learning system to improve your ROI predictions with minimal user input. Our AutoML™ process will customize the AI’s detection capabilities to your needs and improve your lab’s analysis workflow.

VitalFlo

PDX Pharmaceuticals

StoneStable

HTI

  • Signed Master Service Agreement with ADRx and a Top Tier International Pharmaceutical company for Cryo-EM services.
  • HTI is now offering its Cryo-EM services via Scientist.com, a leading “science as a service” e-commerce site for Life Sciences. This adds a second e-commerce sales channel beyond ScienceExchange.com, the world’s first online R&D marketplace to accelerate scientific discovery, of which HTI became a member last year.
  • Set up collaboration with Salk Institute for Cryo-EM data sets sharing.
  • Filed patent of CryoFAST™ architecture (CRYOGENIC ELECTRON MICROSCOPY FULLY AUTOMATED ACQUISITION FOR SINGLE PARTICLE TOMOGRAPHY).

Hemex Health

  • We are proud to announce during this Sickle Cell Awareness Month (September 2022) that Hemex has shipped 210,000 SCD tests to 25 countries.

SUTUREGARD Medical

  • We were one of 28 medical device startup companies selected from over 1000 worldwide applicants for the MedTech Innovator Accelerator 2022 program.  This is wrapping up soon at AdvaMed in Boston at the end of the month and there are several competitions in play.
  • One is the one minute video competition.  Please enjoy (and “like” on LinkedIn) our story of how Dr. Brad used HEMIGARD to stop Shantell’s feet from killing her!

Promedix


OBI’s Mentoring Program:
Applications Now Open

Now is your opportunity to join the Winter-Spring 2023 OBI mentoring cohort. If you have been thinking about becoming a mentor or mentee in the OBI Mentoring Program, your wait is over – applications are now open.

Applications will be open until October 31.

Read more about the OBI Mentoring Program and our year-round Advising Program here.


Mentor of the Month:
Satish Viswanatham

Satish Viswanatham is a new mentor in our OBI Mentoring Program. He brings a master’s degree in computer science, 15+ years working in startups, and previous mentoring experience to his relationship with his mentee. Satish is most experienced in cloud engineering, IT, and security. Over the years, he has mentored dozens of engineering leaders to be successful in their careers and startups.

Thank you, Satish, for your commitment to our startup community!


2022 Bend Venture Conference:
Attend • Present • Invest

BendVenture conference logo with brown mountain in background

The Bend Venture Conference (BVC), held on October 20 & 21, 2022 in Bend, Oregon, is the signature event for entrepreneurial activity in the Pacific Northwest. The major objectives of this event are to provide exposure and investment opportunities for entrepreneurs and build an engaged community of investors in Central Oregon.

The event attracts over 600 attendees, many of whom come from beyond Central Oregon (50% of attendees come from outside the region). Investments, awards, and prizes have totaled over $10 million in the last five years, making BVC the largest angel conference in the West.

There are three tracks for the competition: Early Stage, Growth Stage, and Impact (including VitalFlo, an OBI client company finalist in the Impact category). Don’t miss it! Get your tickets HERE.

*****

And you won’t want to miss this:
OBI is holding a free networking lunch at OSU-Cascades Innovation Co-Lab in Bend on October 20 before the BVC seminars begin.
Details and registration here!


SBIR/STTR Program: From the Sources’ Mouth

BBCetc’s SBIR/STTR Assistance Program invites everyone to join their monthly “From the Sources’ Mouth” series featuring SBIR/STTR program managers telling you what you need to know to have success with their agencies. These monthly events feature a 1-hour virtual training session conducted by a federal program manager and cover their specific agency’s mission and tips for creating a successful proposal, all sessions include time for Q&A with the agency presenter. They also host a large event every fall, featuring presenters across several agencies. This series is for technology-based entrepreneurs, startups and small businesses familiar with the SBIR/STTR programs who want to learn more about proposal submission.

September’s 7th-annual event featured 3-day SBIR/STTR training with federal program managers across all 11 agencies, with presentations from program managers, panel discussions and live Q&A. If you missed it, you can watch recordings here.


Upcoming Events

OBI Events

Accelerate Biotech + Digital Health
Networking Lunch in Bend
October 20, 2022
12:00-1:30 PM
OSU-Cascades Innovation Co-Lab – Bend
Register here

 

Accelerate Biotech + Digital Health Happy Hour
November 3, 2022
5:30-7:00 PM
George Fox University Portland Center
Register here

 

Hybrid Lunch & Learn: Financial Success
Through Accounting Best Practices
November 16, 2022
12:00-1:00 PM
OBI or Virtual Option
Register here

 

Other Community Partner Events

AvaMed MedTech conference logo dark blue with white lettering and a globe symbol

The MedTech Conference
October 24-26, 2022
Boston, Massachusetts
Information here

 

OEN Entrepreneurship Awards 2022:
EXPONENTIAL: THE POWER OF US
November 17, 2022
5:30-9:00 PM
Portland Art Museum
Purchase tickets here

 

Biotech Summit 2022 + Bio on the Vine
November 15, 2022
2:00-8:00 PM
Knight Cancer Research Building – Portland
Purchase tickets here

-and-

Bio in the Valley 2022
December 1, 2022
5:00-8:00 PM
Phil and Penny Knight Campus for
Accelerating Scientific Impact – Eugene
Purchase tickets here

OBI & OTRADI September 2022 Newsletter

Welcome New Client Companies to the OBI!

VitalFlo helps leading clinicians and researchers improve patient outcomes and advance lung health by providing comprehensive respiratory data, analysis and care.

Keliomics offers pharmacophenotyping for patients with solid tumors including breast, prostate, and certain types of metastatic cancer.


OBI Client Company Wins

Madorra

Hemex Health

  • We received Portland Business Journal’s Global Impact Award as part of their Health Care of the Future Program. Patti White, CEO and co-founder, accepted the award during their ceremony held on August 18.
  • Gazelle received Indian Council of Medical Research (ICMR) recommendation for sickle cell testing in India. Gazelle was one of three diagnostic platforms selected for this highly competitive and rigorous nod of approval.

SUTUREGARD Medical

  • Our biggest recent win had almost nothing to do with us.  A general surgeon at Kaiser Permanente in Oakland got a hold of our wound closure device HEMIGARD, loved it, got it approved locally and then nationally and now we have received orders from multiple Kaiser clinical facilities.
  • This surgeon is not an advisor or consultant to us, and just liked what HEMIGARD was doing for her wound closure results.

Promedix

Sparrow Pharmaceuticals (OBI alumus)

  • Sparrow has dosed the 1st patient in a phase 2 clinical trial of SPI-62 with prednisolone for polymyalgia rheumatica. Read press release here.
  • Congratulations to Sparrow CSO and Founder, David Katz, for the honor of being a PharmaVoice 100! David was recognized for his entrepreneurial spirit and pursuit of finding a treatment for disorders due to steroid excess using scientific prowess and an artist’s vision. Read Dr. Katz’ interview.

Business Oregon Announces Two Grant Opportunities

Business Oregon logo

Business Oregon announces the opening of matching grant applications. Applicants who have received recent Phase I or Phase II SBIR or STTR grants may be eligible for an Oregon matching grant of $50,000 or $100,000. Applications are due by October 7. Read the details and find the application here.

Business Oregon has also opened a Request for Grant Applications for High Impact Opportunity Projects (HIOP). Grant applications must be received by 8:00 am on October 10, 2022. More information on the eligibility for the grant program and the application materials are available on the Business Oregon HIOP website.


Mentor of the Month:
Claire Celeste Carnes

Claire Celeste Carnes (CC) is a Curriculum Designer and Adjunct Instructor at the New York University Wagner School. She has a strong 20+ year career in marketing and communications, especially in technology and health. Her educational background includes an MBA from Northwestern University with a marketing focus. As a PDX-WIT mentor for multiple years, a prior OBI Biomentor, and member and board member for Women’s Leadership Council in Portland, CC shows her dedication to helping others. She brings a passion and enthusiasm for her work, plus a structured, analytical approach combined with metrics.

Thank you, CC, for your commitment to our startup community!


OBI’s Mentoring Program:
Applications open October 1

And just like that, Fall is here. With it comes preparations to select the Winter-Spring 2023 OBI mentoring cohort. If you have been thinking about joining the OBI’s Mentoring Program, save the date – applications open on October 1 and remain open until October 31.

Read more about the OBI Mentoring Program and our year-round Advising Program here.


Biomedical Innovation: Commercialization Readiness Program

Have an idea for an innovative technology but don’t know where to start? BIP Corp is a 5-week experiential course designed to help you and your team assess and validate your biomedical technology. Gain the knowledge and tools to initiate innovation and commercialization of your technology, and develop a competitive business case to secure funding, partnerships, and further research opportunities.

Sept 21 – Oct 26, 2022 entirely virtual.

View full course schedule and details.
ENROLL here.
Offered at no-cost by OHSU’s Oregon Clinical and Translational Research Institute (OCTRI) and I-Corps@NCATS.

This course is appropriate for faculty, researchers, students, and industry scientists with an early-stage idea or team with an idea. Non-OHSU participants welcome. BIP Corp instructors are experts from across the bioscience industry and academia with experience bringing healthcare technologies and therapeutics to market.

Contact Melissa Mudd, muddm@ohsu.edu, with questions.


2022 Bend Venture Conference:
Attend • Present • Invest

BendVenture conference logo with brown mountain in background

The Bend Venture Conference (BVC), held on October 20 & 21, 2022 in Bend, Oregon, is the signature event for entrepreneurial activity in the Pacific Northwest. The major objectives of this event are to provide exposure and investment opportunities for entrepreneurs and build an engaged community of investors in Central Oregon.

The event attracts over 600 attendees, many of whom come from beyond Central Oregon (50% of attendees come from outside the region). Investments, awards, and prizes have totaled over $10 million in the last five years, making BVC the largest angel conference in the West.

There are three tracks for the competition: Early Stage, Growth Stage, and Impact. Don’t miss it! Get your tickets HERE.


2023 Beaverton Startup Challenge

The Oregon Technology Business Center (OTBC) recently changed our name to the Oregon Startup Center. We want to help serve all entrepreneurs and the various sectors they represent with our 8th Beaverton Startup Challenge.

2023 Beaverton Startup Challenge Funding Competition FAQ

  • On-line application will run August 24 – October 5, 2022
    Go to oregonstartupcenter.org for the application link
  • 10-12 semi finalists will be chosen in late October. Semi finalists
    will then pitch to our angel investors.
  • Five finalists will be selected by late November.
  • Checks given and celebration will be held in early December.
  • How much funding do I receive from OSC if I am one of the five
    finalists?
    • $25,000 in cash and services to each winning company
    • $4,800 charged for mentoring, advising, business contacts,
      connections and other community partner introductions AND office
      space.
    • $20,200 net cash paid to each finalist.
    • The winning companies sign a 2-year convertible note at 8% annual
      interest payable to Westside Startup Fund 8.
  • The Beaverton Challenge started in 2016. For the 2022 Challenge
    $50K from the City of Beaverton was matched with $102,863 from
    18 angel investors for a total fund size of $152,863.
  • Of the 35 Challenge winners so far, 26 of them (75%) are still in
    business.
  • Cumulatively, the Challenge companies have gone on to raise over
    $95 million in additional funding!

Upcoming Events

OBI Events

Lunch & Learn: Public Relations &
Thought Leadership for Life Science Startups

September 22, 2022
12:00-1:00 PM
Oregon Bioscience Incubator & virtual option
Register here

 

Accelerate Biotech + Digital Health Happy Hour
October 13, 2022
5:30-7:00 PM
Field Office Courtyard & Living Room
Register here

 

Other Community Partner Events

Women in Science PDX:
Finding and Using Your Voice
September 14, 2022
12:00-1:00 PM
Virtual
Register here

 

TiE Oregon Westside Pub Talk:
Equity Financing at all Stages

September 20, 2022
5:15-7:00 PM
Golden Valley Brewery – Bethany
Register here

 

Zapproved & TechTown PDX Lunch & Learn:
Accountability in Action
September 21, 2022
12:00-1:00 PM
Virtual
Register here

 

Pitch Latinx 2022
October 5, 2022
5:30-8:00 PM
The Redd East – Portland
Get tickets here

 

Oregon Bioengineering Symposium
October 6, 2022
LaSells Stewart Center at Oregon State University
Details here

 

AvaMed MedTech conference logo dark blue with white lettering and a globe symbol

The MedTech Conference
October 24-26, 2022
Boston, Massachusetts
Information here

 

Bio in the Valley 2022
December 1, 2022
5:00-8:00 PM
Phil and Penny Knight Campus for
Accelerating Scientific Impact – Eugene
Purchase tickets here

OBI & OTRADI August 2022 Newsletter

OBI Client Company Wins

 

Hemex Health

  • We received National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for continuing to support Hemex Health and Case School of Engineering at Case Western Reserve University with a $1.7M Phase II STTR follow up award for our “portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C (diabetes) testing.”
  • We launched our COVID-19 point-of-care diagnostic, Gazelle PathoCatch, in India on July 7 and plan to launch to our other distributors worldwide later this summer.
  • CEO and Co-Founder Patti White was interviewed by International Finance Corporation (IFC).

ProMedix

NeuvaRx

  • NeuvaRx received an NIH phase I STTR award that started July 1.
  • We also received a matching grant award from Oregon Business Development for the STTR award.

Gamma Diagnostics

  • Gamma Diagnostics Inc. and OHSU have signed a licensing agreement that seeks to further develop and commercially promote the use of Gamma Prime Fibrinogen (GPF) as an inflammatory and clotting risk biomarker.
  • High GPF levels have previously shown positive correlation with peripheral artery disease, heart failure and CVD deaths in the ARIC study. Dr. David Farrell (Founder and CSO) published an abstract at AHA 2021 showing COVID-19 patients can develop extraordinarily high levels of GPF.
  • Gamma Diagnostics Inc. will now continue to invest in further clinical studies, regulatory submission, and commercialization activities to bring GPF as a biomarker to market.

Inherent Targeting

  • We were awarded an SBIR matching grant from Business Oregon for ~$50k to complete in vitro testing and regulatory planning of our lead contrast agent towards clinical translation.

Outstanding wins!


Wanted: Digital Health Feedback

OBI is looking for feedback from the community about accelerating the growth of digital health. Digital health is a fast-growing segment in Oregon’s healthcare ecosystem. We’re looking for community feedback about your views on digital health and the resources that companies need to grow. Click here to take the 12-question survey.

Thank you for your participation!


Mentor of the Month:
Mary Phillips

Mary Phillips joined the OBI Mentoring Program as a Mentor after going through the program as a Mentee in her role as Chief Strategic Officer for Thaena, Inc.

With a B.Sc. Chemistry from Durham University, a Ph.D. in Physical Chemistry from Imperial College in London, and her background as a USPTO Registered Patent Agent – combined with many years of experience in startups and university tech transfer, Mary brings a wealth of knowledge to her role as an OBI Mentor.

Mary says, “My passion is solving puzzles – and all the pieces of how startups come together are great puzzles! The most complicated puzzle pieces of startups are the founders. Working with the founder to overcome the hurdles and obstacles and confidently lead using their style to achieve their goals is, for me, very fulfilling work. And then there is the joy of seeing a founder take an idea and turn it into an innovation that people will buy – knowing that I helped in some way in making that possible.” Mary is a connector, coach, mentor, and strategist for STEMMbridge in Corvallis, Oregon.

Thank you, Mary, for all you do for our Oregon startups!


Think BIG: Bend Innovation Group

Introducing Bend Innovation Group (BIG), founded in beautiful Bend, Oregon:

“A common conception among members of the Bend Innovation Group (BIG) is that the enormous beauty of our region inspires dreamers and innovators. This is evidenced by the successful and expansive growth in Bend and throughout the Central Oregon region over the past two decades. Our members also share the vision that Bend is well positioned to prosper in our future growth if supported by a historically successful, highly experienced, and knowledgeable team of professionals, public and industry partners, and a channel of entrepreneurs who are ready to establish their footprint and lay their stake in our wonderful town.

It’s on this premise that BIG has been conceived and is taking form to foster conscientious, generational development in our region leveraging the strengths of our founding members’ decades of success in the health sciences. We’re a group of med-tech innovators and entrepreneurs, practicing physicians, professors and researchers, and successful financial professionals who have come together to pool our life experiences, share our knowledge, our time, and our passion with like minded entrepreneurs.

In addition to contributing to regional growth and development our goal is to improve the lives of others, both locally and well beyond.

By supporting healthcare innovation with our mentoring, private and public partnerships, and funding resources we’re able to foster early phase, pre-revenue startups from concept, through launch, and onto seed funding stages of growth.”

For more information about BIG, visit their website and check out their team, portfolio companies, and fellowship program.


Oregon’s Bio Boom:
2022 Economic Impact Report

Our friends at Oregon Bioscience Association recently released a comprehensive 2022 economic impact report, measuring the economic, fiscal, and demographic impacts of Oregon’s Bioscience industry. This report also includes Clark County, Washington. Our industry is doing great things in Oregon and SW Washington.

You can download the full report or the summary in PDF format here. Read it and celebrate Oregon’s Bio Boom!


2022 Bend Venture Conference:
Attend • Present • Invest

BendVenture conference logo with brown mountain in background

The Bend Venture Conference (BVC), held on October 20 & 21, 2022 in Bend, Oregon, is the signature event for entrepreneurial activity in the Pacific Northwest. The major objectives of this event are to provide exposure and investment opportunities for entrepreneurs and build an engaged community of investors in Central Oregon.

The event attracts over 600 attendees, many of whom come from beyond Central Oregon (50% of attendees come from outside the region). Investments, awards, and prizes have totaled over $10 million in the last five years, making BVC the largest angel conference in the West.

There are three tracks for the competition: Early Stage, Growth Stage, and Impact. Applications are due by August 16, 2022. For more information and application, click here.


Hiring or Job Searching?


OBI has launched a free Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


Upcoming Events

OBI Events

Lunch & Learn: Creating Equity Every Day
August 25, 2022
12:00-1:00 PM
Oregon Bioscience Incubator & virtual option
Register here

 

Accelerate Biotech + Digital Health Happy Hour
September 1, 2022
5:30-7:00 PM
Oregon Bioscience Incubator
Register here

 

Other Community Partner Events

Women in Science PDX:
Women in Biotech Panel
August 17, 2022
12:00-1:00 PM
Virtual
Register here

 

Partners in Diversity: Say Hey!
August 17, 2022
5:30-8:00 PM
World Trade Center Building Two Plaza
Register here

 

2023 Beaverton Challenge Information Session
August 24, 2022
4:00-6:00 PM
OTBC Office – Beaverton
Register here

 

Bio in the Valley 2022
December 1, 2022
5:00-8:00 PM
Phil and Penny Knight Campus for
Accelerating Scientific Impact – Eugene
Purchase tickets here

OBI & OTRADI July 2022 Newsletter

Business Oregon Awards Matching
Grants to Five OBI Client Companies

Business Oregon logo

Just announced! Business Oregon and Oregon InC have awarded Phase I matching grants of up to $50,000 to OBI client companies Inherent Targeting, NeuvaRx, and OmnEcoil Instruments.

  • Inherent Targeting will use their award for analysis of a lead compound and in preparation for FDA approval of their fluorescent compound used in surgeries to prevent nerve damage.
  • NeuvaRX will use their grant for IP protection and product testing in their compound to improve treatment of hemorrhagic stroke.
  • OmnEcoil’s award will provide regulatory support services for their prostate cancer diagnostics.

Business Oregon and Oregon InC have also awarded Phase II matching grants of up to $100,000 to OBI client companies Health Technology Innovation (HTI) and PDX Pharmaceuticals.

  • HTI’s grant award will help commercialize and accelerate its CryoDiscovery™ product launch.
  • PDX Pharmaceuticals will utilize their grant for IP protection, in financing a new facility, and for fundraising support.

Congratulations to these five companies and the 14 others who received these Phase I and Phase II matching grants to to enhance their federal SBIR and STTR grant awards. Read the full press release for more details.


More OBI Client Company Wins

Endosound

  • We recently announced Scott Fraser as a new addition to our board.  Scott comes with a world of knowledge in startups, the Gastroenterology (GI) space, and the Ambulatory Surgical Center (ASC) market.
  • In late May, we had our first ever booth at Digestive Disease Week (DDW).  This conference is the premier conference for the GI space, attracting doctors, industry professionals, and investors from all over the world.  We had tremendous response at the booth and as a result of several meetings with physicians and strategic partners.
  • Some of the Endosound team, in partnership with physicians in Ecuador, showcased the Endosound Vision System (EVS) on Endoscopy on Air (EOA) on June 3rd.  The Global Annual Live Streaming Event on EOA had physicians from around the world educate and demonstrate their techniques in various endoscopic procedures to the 11,000 virtual attendees.  We were honored to sponsor a session with partner Dr. Carlos Robles Medranda at the Ecuadorian Institute of Digestive Disease.

HTI

  • Received Phase II matching grant award from Business Oregon (see above)!
  • In collaboration with Oregon BIO, HTI attended the Bio International 2022 with great success.
  • HTI will present CryoDiscovery™ and CryoFast™ at the Microscopy & Microanalysis 2022 and American Crystallographic Association 2022 conferences on July 29 – Aug  4 in Portland, Oregon
  • HTI signed a service agreement with ADRx Pharma for Cryo-EM sample optimization and image analysis.

Hemex Health

  • We are proud to announce the official launch of the Gazelle™ PathoCatch™ COVID-19 FIA test, a diagnostic solution for point-of-care testing, made in collaboration with @MylabSolutions. Read the full press release.

Rewire Neuro

  • Rewire attended BIO International as part of the Oregon Pavilion and pitched at the Startup Stadium as a finalist, gaining recognition, feedback, and interest from a large group of investors and potential partners from around the world.

StoneStable, Inc.

  • Ken Stedman and Dan Snyder from StoneStable were at the BIO meeting in San Diego and made a number of connections with international pharmaceutical companies, large and small.

Wanted: Digital Health Feedback

OBI is looking for feedback from the community about accelerating the growth of digital health. Digital health is a fast-growing segment in Oregon’s healthcare ecosystem. We’re looking for community feedback about your views on digital health and the resources that companies need to grow. Click here to take the 12-question survey.

Thank you for your participation!


Summer-Fall Mentoring Cohort Begins

We are thrilled to welcome 13 mentees and 16 mentors to our Summer-Fall 2022 mentoring cohort. They began working together on July 1 for the 6-month program which runs through the end of the year.

 

Mentees (L to R for each row): Eduardo Ceballos, Kim Hutchison, Reva Barewal, Alexander Honkala, Jeremy Hammer, Sandhiprakash Bhide, Alison Carrigg, Cory Szybala, Elie Traer, Sydney Quinton-Cox Forbes, Melissa Belli, Jason Scott, and Jean Summerton.

 

Mentors (L to R for each row): Josh Ellison, Satish Viswanatham, Mary Phillips, Katie Rubino, Jacquie Murray, Shannon Heizenrader, Philbert Lee, Michael Phillips, Aaron Daugherty, Alex Reed, Claire Celeste Carnes, Kabir Bhatia, Shelly Sweeney, Mel Ellis, Lynn Sheehan, and Daren Connor.

To learn more about OBI’s mentoring program, please see our Mentoring page. Applications will open in October for the next cohort.


Hiring or Seeking?
Post it on OBI’s Job Board!


OBI has launched a FREE Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


Join us in Bend in July!

If you are attending Oregon Bioscience Association’s Bio in the High Desert on July 19, let’s continue the fun the next day at noon with OBI/OTRADI and OSU-Cascades Innovation Co-Lab’s Lunch & Learn!

Join us on July 20 at OSU-Cascades Graduate Research Center in Bend for a panel discussion on strategies to fund your biotech company, focusing on where to find funding and how to unlock these opportunities. We will discuss funding for startups, growth-stage companies, and mature businesses.

Or if you prefer, you can join us on Zoom for the livestream. Link will be provided upon registration.

Moderator: Adam Krynicki, Executive Director, OSU-Cascades Innovation Co-Lab

Adam Krynicki, J.D., Esq. is the Executive Director of the OSU-Cascades Innovation Co-Lab. With over 15 years of experience in startup acceleration, funding, and intellectual property, Adam is an expert at building initiatives that support innovators, entrepreneurs, and their communities.

Register here


Brand New Office & Lab Space Available

Looking for office and/or wet lab space for your bioscience, medical device, or health innovation startup? Would you like to become a part of the OBI startup community? We are nearing completion on brand new office and lab space in our Willamette Wharf building. Learn more here by filling out a facilities request form, and let’s talk.


Upcoming Events

Oregon Bioscience Association:
OBW CONNECT Live
July 7, 2022
5:00-8:00 PM
Ironlight in Lake Oswego
Purchase tickets here

OBI Accelerate Biotech + Digital Health
July Happy Hour

July 14, 2022
5:30-7:00 PM
Canvas at Press Blocks Penthouse & Rooftop
Portland, Oregon
Free to attend – register here!

Biomedical Entrepreneurship Fireside Chat
July 14 & 21, 2022
2:00-3:00 PM
Virtual program
Register here

Bio in the High Desert: What’s Brewing
July 19, 2022
5:00-7:30 PM
OSU-Cascades Campus
Bend, Oregon
Purchase tickets here

OBI Hybrid Lunch & Learn:
Biotech Funding Strategies
July 20, 2022
12:00-1:00 PM
OSU-Cascades Graduate Research Center
Bend, Oregon
Free to attend – register here

Technology Association of Oregon logo

TAO: Party in the Pinot
July 23, 2022
5:00-10:00 PM
Scholls Valley Lodge
Hillsboro, OR
Purchase tickets here

OBI & OTRADI June 2022 Newsletter

Welcome NeuvaRx to the OBI!

NeuvaRx is preclinical-stage biopharmaceutical company dedicated to the development of therapies and diagnostic tools for neurovascular disorders, including, but not limited to ischemic and hemorrhagic stroke and vascular dementia.

We are happy to have you onboard!


OBI Client Company Wins

Veana Therapeutics

StoneStable, Inc.

Gamma Diagnostics, Inc.

  • We filed a Provisional Patent Application in United States No. 63/268,605: “Use of γ’ fibrinogen as a Biomarker in the Detection of Covid-19 and Prognosis of Severe Disease.”
  • And we filed a pre-Emergency Use Authorization to the FDA entitled: “Gamma-prime fibrinogen ELISA.”

Hemex Health

  • Hemex Health announced a significant enhancement to their Gazelle™ Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The increased accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings. Hemex will provide “over the air” updates with the Hb F enhancement that can be downloaded directly to existing Gazelle Readers. The improvement will ship with new systems. Read press release here.

SUTUREGARD

  • The most recent episode (Season 4 – Episode 3 entitled “A Smell from Hell”) of “My Feet are Killing Me” featured HEMIGARD being used by “Dr. Brad” to close a very tough plantar wound.  It does have graphic content including live surgery footage.  The patient in question can hardly walk due to masses of callus on the ball of her foot – the surgical excision leaves a large wound that is difficult to close, and Dr. Brad uses HEMIGARD to help close the defect.  The patient has an excellent result and is ecstatic! View it on Amazon Prime or other streaming platforms.

Inherent Targeting

Sparrow Pharmaceuticals (an OBI alumnus)

  • Sparrow Pharmaceuticals received ethics committee and regulatory authority go-ahead for three Phase 2 clinical trials, in patients with Cushing syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.
  • Dr. David Katz was selected to give oral presentations on new clinical pharmacology and non-clinical study results at three prestigious conferences in May-June: European Congress of Endocrinology in Milan, European League Against Rheumatism in Copenhagen, and Endocrine Society in Atlanta. Read press release here.

AOBIO Congratulations!

A fabulous afternoon at the inaugural Angel Oregon Life & Bioscience (AOBIO) Grand Finale & Innovation Showcase, an in-person celebration on May 26th, 2022, 3-7 p.m. at Amaterra Winery in Portland.

OBI & OTRADI Executive Director Heather Ellis (pictured below, left) and Amanda Oborne from OEN (right) presented the Big Check to Ray Browning, co-founder of Biomotum, winner of the ~$300,000 AOBIO Investors’ angel investment!

Congratulations to all of the 2022 AOBIO finalists: Inherent Targeting, Savorease Therapeutic Foods, and StoneStable!

Also big congratulations to High Peak Medical Systems, who won the EMERGE award, sponsored by Black Founders Matter Fund.

AOBIO is a collaborative effort by Oregon Entrepreneurs Network, OHSU, Oregon Bioscience Association, and OBI/OTRADI. Thanks to everyone who participated in making this program a success!


OBI Mentor of the Month:
Shelly Sweeney

Shelly Sweeney is the Founder and Solopreneur Business Coach of Beeline Coaching. She joined the OBI Mentoring Program in January, 2022 and receives high praise from her mentee each month. Her past experience with startups include working with entrepreneurs and startups, as well as surgical device startups.

Shelly says, “I have always been a leader out-performing goals wherever I have worked and someone managers described as someone they wish ‘they had nine more of.’  My coworkers describe me as someone who they can call to listen to them, share ideas and be a positive influence.” We agree! Thank you, Shelly, for all you do for the OBI community!


Hiring or Seeking?
Post it on OBI’s Job Board!

 

OBI has launched a Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


OBI’s New Shared Lab
Sponsored by PhRMA

On May 20, to celebrate International Clinical Trials Day, we held a Research in Your Back Yard panel discussion program, followed by a ribbon cutting for our newest shared equipment lab for OBI client companies. Thanks to a generous donation by PhRMA, we outfitted our new shared lab with a biosafety cabinet, CO2 incubators, centrifuge, rocker platform, and vortex mixer.

Thank you to PhRMA for your support!


OBI Clients Earn Share of NIH Grants in Oregon

OBI & OTRADI current and graduated client companies made up eight of the 44 largest NIH grant recipients in Oregon for fiscal year 2021! Published in the Portland Business Journal in April, 2022, we were well-represented with the following rankings:

PDX Pharmaceuticals #9, Aronora #11, Hemex Health #14, Virogenomics BioDevelopment #18, Rewire Neuro #20, Madorra #23, Veana Therapeutics #29, and Inherent Targeting #39.

Rankings were determined by NIH grant dollar amounts in FY 2021; data was provided by the Department of Health & Human Services. Congratulations! We can’t wait to see what 2022 brings!


Brand New Office & Lab Space Available

Looking for office and/or wet lab space for your bioscience, medical device, or health innovation startup? Would you like to become a part of the OBI startup community? We are nearing completion on brand new office and lab space in our Willamette Wharf building. Learn more here by filling out a facilities request form, and let’s talk.


Upcoming Events

Zapproved & Cinder:
Voices of Equity
Gender Identity & Pronouns
One Non-Binary Story
June 10, 2022
9:00-9:30 AM
Register here

 

TiE Women Open Mic Night
June 14, 2022
5:30-8:30 PM
Register here

 

OBI Hybrid Lunch & Learn
Women in Leadership Part 2:
Continuing the Conversation
June 22, 2022
12:00-1:00 PM
Register here

 

Oregon Bioscience Association:
OBW CONNECT Live
with Emily Leproust of Twist Bioscience
July 7, 2022
5:00-8:00 PM
Tickets here

 

Save the Date!
OBI Accelerate Biotech + Digital Health
July Happy Hour

July 14, 2022
5:30-7:00 PM
Canvas Rooftop
Save the Date

OBI & OTRADI May 2022 Newsletter

OBI Client Company Wins

Inherent Targeting

StoneStable, Inc.

EndoSound

  • EndoSound is pleased to announce two new full-time employees. We are thrilled to have these two join our growing team.
    • Peter Hoffman has joined as Senior Product Development Engineer.  He will help to bring new and innovative ultrasound products to market. His 10+ years engineering experience ranges from robotics to medical devices with much of his time at Olympus developing novel biopsy tools for the lungs. He has authored 6 patent applications. Peter holds a BS in Mechanical Engineering and a minor in Business and Entrepreneurship from Oregon State University.
    • Patrick Hurley has joined as the Vice President of Marketing. Patrick comes with 13 years in product and market management in medical device, as well as several years as a life sciences consultant. Patrick has documented successes in each role as he continued to grow with responsibilities. He has helped build brand identity and established strong relationships with KOLs in the GI community. He holds a Ph.D. in biology, specializing in neuroscience from Wesleyan University.
  • Winner of AGA Shark Tank and Innovation of the year. We had the opportunity to compete in the American Gastroenterology Association (AGA) Shark Tank for innovative technologies in early April and won!!
  • We’ll be competing again with our innovative Endoscopic Ultrasound device at the end of May at the largest Gastroenterology professional conference in the world called Digestive Disease Week (DDW).
  • We have also been honored with the Innovation of the Year from the American Society for Gastrointestinal Endoscopy (ASGE). This distinction is granted to companies with products that show promise for advancing the field of GI endoscopy.
  • Together, these awards demonstrate to the broader GI community that our mission to democratize EUS is taking shape. There could not be a better time to follow the EndoSound journey. View our LinkedIn page.

Gamma Diagnostics, Inc.

  • Gamma Diagnostics presented at the Expert Dojo Investor Festival on April 7 in Los Angeles. Our new CSO, Dr. Jamie Noll, and Founder Dr. David Farrell presented. See event details here.

HTI

  • HTI has signed master service agreements with IDEAYA Biosciences and ADRx for cryo-EM structure determination services to support their drug discovery efforts. IDEAYA is a synthetic lethality-focused precision medicine oncology company and ADRx is a biotechnology company with a unique approach to halting diseases of protein aggregation.
  • HTI presented poster sessions on CryoDiscovery, its AI platform for cryo-EM image processing, at the 17th Annual Drug Discovery Chemistry conference in San Diego and at the 2022 Astbury Conversation, a leading macromolecular conference held at the University of Leeds in the UK. HTI has also been selected for a session presentation at Microscopy and Microanalysis 2022, the microscopy industry’s premier conference to be held in Portland, Oregon from July 31st to August 4th.

Hemex Health

  • We have two abstracts that were accepted for the 4th Global Congress on Sickle Cell Disease (June 16-18) in Paris.
    • “Point-of-care diagnostic for quantification of fetal haemoglobin (Hb F) levels in monitoring hydroxyurea therapy for children with Sickle Cell Disease (SCD) in Ghana” has been accepted for a poster presentation.
    • “Evaluation of first microchip-based point-of-care device for diagnosis of Beta-Thalassemia in India” has been accepted for a poster presentation.

SUTUREGARD

  • Dr Alton Johnson of University of Michigan Podiatry presented at the Society for Advanced Wound Care (SAWC) last month in Phoenix on HEMIGARD closure of Stage 4 (bone involved) heel wounds.  He won first place in the Practice Innovation category for this work.  HEMIGARD is allowing surgeons to close wounds that have not been able to be closed with normal suture materials.  Normal suture does not work well on soft heel skin which does not resist tearing when under tension.  HEMIGARD corrects this problem.

Synergic Medical Technologies

Madorra

Refeyn


Research in Your Back Yard
May 20 at 10 a.m.

Celebrate International Clinical Trials Day on May 20, by streaming an OBI/OTRADI panel titled, “Research in Our Backyard: Developing Cures, Creating Jobs in Oregon,” in partnership with the Oregon Alliance of Clinical Researchers.

In our panel discussion, we’ll be bringing together the perspectives of an Oregon Bioscience Incubator researcher, clinical researcher, patient, and the biopharmaceutical industry to explain everything that goes into developing treatments and cures for local patients and the important work happening here in our state.

Panelists: Emmanuel Akporiaye, Veana Therapeutics, an OBI resident company; Searcy Craighead, Oregon patient and member of Kaleidoscope Fighting Lupus; Curt A. Heiting, B.B.A., President of Cyn3rgy Research and Development and member of the Oregon Alliance of Clinical Researchers; and Reid Porter, Senior Director of State Public Affairs at the Pharmaceutical Researchers and Manufacturers of America (PhRMA).

Register here!


Hiring or Seeking?
Post it on OBI’s Job Board 


OBI has launched a Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


Don’t Miss the AOBIO Finale!

Join us for the inaugural Angel Oregon Life & Bioscience (AOBIO) Grand Finale & Innovation Showcase, an in-person celebration on May 26th, 2022, 3-7pm at Amaterra Winery in Portland.

You won’t want to miss the Big Check Moment, sponsored by OBI/OTRADI, when AOBIO Investors announce which of the four finalists have earned the angel investment, up to $300,000!

Finalists for AOBIO 2022 are:

All this and Amaterra wine and views! Join us for this special celebration of entrepreneurship in Oregon.

Purchase Tickets Here


Final Call to Complete
Bioscience Ecosystem Inventory Survey

The Oregon Bioscience Incubator (OBI) is the state’s first and only bioscience-focused incubator. The multi-client company bioscience complex provides startups and scientists access to entrepreneurial mentoring, state-of-the-art bioscience facilities, meeting space, and shared equipment. While OBI currently provides free resources to the full community, we understand there are still some unmet needs and would like to learn more about how OBI can help fill resource gaps.

If you haven’t already, please take 15 minutes to fill out this survey to help assess the needs of the community by identifying additional resources needed. The survey will close at the end of May. Thank you!


Act Now for MedX @Düsseldorf!

Compete now for a free both at MEDICA’s Start-up Park! You target the global market, you believe in the success of your product and you are ready for the next big step towards internationalization. Your focus is now on networking and gaining visibility, and you are looking for the best way to connect with important partners. The Office of Economic Development Düsseldorf can offer you that unique opportunity with a booth at MEDICA’s Start-Up Park.

Applications accepted if your startup…

  • offers an innovative product/ service in digital health
  • is not registered in Germany
  • has 1–20 employees
  • was launched after 2017
  • has an annual turnover of 0–3 M Euro

Apply at MedX @Düsseldorf until 30th June 2022 to get selected for a pitch competition in order to compete for a spot at the global meeting point for digital pioneers – the Start-up Park. We will inform you by 8th July 2022 if you were chosen for a digital pitch competition in front of a jury. See this link for more details!


Upcoming Events

Zapproved Event:
The Myth of the Model Minority,
featuring OBI’s Associate Director Hazel Valdez
May 13, 2022
9:00-10:00 AM
Register here

Research in Your Back Yard
Panel Discussion
May 20, 2022
10:00-11:00 AM
Register here

 

AOBIO 2022 Grand Finale &
Innovation Showcase
May 26, 2022
3:00-7:00 PM
Amaterra Winery
Get tickets here

OBI & OTRADI April 2022 Newsletter

Business Oregon has
Matching Grants Available

Business Oregon logo

Business Oregon has just announced a Request for Grant Applications. Applicants who have recently received federal Phase I SBIR/STTR awards, or Phase II awards, may be eligible for a state matching grant.

More information is available at the Business Oregon website. Applications are due by May 8, 2022.


OBI Client Company Wins

 

Gamma Diagnostics, Inc.

  • We are thrilled to announce the promotion of Jamie Noll, Pharm.D., B.S. Nutrition to Chief Scientific Officer for Gamma Diagnostics Inc., effective immediately. Jamie joined the Gamma Dx team late last year as a scientific and clinical advisor and in a very short time has helped establish key KOL relationships in the medical and clinical research community. She has had various roles and extensive experience in the pharmaceutical industry last of which was as a Medical Science Liaison for Puma Biotechnology.
  • “I have known Jamie for over 14 years and our professional and personal relationship has been forged through challenging projects and arduous decisions. Not only is she extremely talented in her field but she represents the highest standard in ethics and integrity. I feel honored and privileged she has decided to join us in the CSO capacity.” Ajay Nair, CEO Gamma Diagnostics Inc.
  • “Dr. Noll is a fabulous addition to the Gamma Diagnostics team! Her industry experience and scientific expertise are critical assets that will help propel Gamma Diagnostics forward.” Dr. David Farrell, Founder, Scientific Advisor, Gamma Diagnostics Inc.

HTI

  • Health Technology Innovations, Inc. (HTI) is excited to announce that Dr. Doug Kawahara is joining HTI as Senior Advisor for AI/ML in Drug Discovery. Dr. Kawahara brings extensive experience in drug discovery and development to HTI. He is currently President & CEO of Elex Biotech (Portland, OR), a company developing novel drugs for the treatment of arrhythmia and heart failure. Read full press release.
  • HTI will be attending the 17th Annual Drug Discovery Chemistry event in San Diego on April 18-22, presenting a Poster session on CryoDiscovery™ its machine learning platform for cryo-EM image processing, and providing information on its cryo-EM Services offerings for drug discovery. If you would like to connect with us at the event, please reach out to Kennedy Brown, VP Business Development, via email kennedy@hti.ai or on LinkedIn https://www.linkedin.com/in/kennedy-brown/
  • HTI CTO,  Narasimha Kumar, will be presenting a poster session virtually at The Astbury Conversation 2022, on April 25-26 on CryoDiscovery™: Public Data-based AI/ML model enhancements for Cryo-EM Image Analysis. The Astbury is one of Europe’s premier conferences on macromolecular research, including a keynote by cryo-EM Nobel Laureate Richard Henderson. If you would like to connect with Kumar to learn more about CryoDiscovery and his presentation please contact him via email at kumar@hti.ai.

Hemex Health

  • We received the 2022 West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) grant award for catalyzing pediatric innovation (CPI), which supports the development of pediatric innovation from ideation through commercialization. We plan to use this grant to help apply for US FDA clearance to bring our affordable POC sickle cell test to the US.

SUTUREGARD

  • SUTUREGARD Medical, Inc. received the honor of being chosen by MedTech Innovator for the MedTech Innovator Road Show.  In their words,”MedTech Innovator is the largest and highest performing accelerator of medical technology in the world and the medtech industry’s premiere showcase and competition for innovative medical device, digital health and diagnostic companies.”
  • We will be pitching April 14 and hope to leverage our participation into favorable business development pathways.
  • We received a lot of attention at trade shows including the American College of Foot and Ankle Surgeons in Austin Texas where we presented our 3rd study showing ~80% reduction in postoperative wound complications after repair of ankle fractures.
  • We have enjoyed record sales in Q1 2022.

Synergic Medical Technologies

Congratulations on your successes. Keep up the good work!


Applications Now Open for
OBI Mentoring Program

Mentor and mentee applications opened on April 1 or this structured, 6-month mentoring program, so now is your opportunity to get involved!

Would You Like to be a Mentor?
If you have experience working with startups in health innovations/life science, consider applying to become a mentor. Benefits of mentoring include:

  • Free mentor training
  • Exclusive access to handpicked startups
  • Exclusive network of mentors
  • Give back to your community
  • OBI highlights its mentors in the monthly newsletter

Growing Your Business? Become a Mentee!
We are looking for entrepreneurs who are already in business but would like guidance, accountability, and support from a mentor to help set and reach business goals. Benefits and time commitments for mentees include:

  • Mentoring helps you grow your business! A recent survey from Kabbage found that 92% of businesses who have a mentor say mentoring has directly impacted their business growth and survival
  • Mentee meets with mentor 2 hours a month for 6 months
  • Mentee checks in with OBI once per month and completes a survey at the end of the program

Applications will be accepted from April 1-30.
For more important dates, details, and a link to the applications, visit www.otradi.org/mentoring.


Mentor of the Month: Michael Phillips

Michael Phillips, JD has been an OBI Mentor for many years. He has been advising startups for 39 years on all aspects of business – formation, capital raising, employment, governance and is always available to lend a hand to entrepreneurs. Michael is a partner at Davis, Wright, Tremaine, LLP. He listens well and offers practical strategic advice, and not just to his OBI mentees – he also currently acts as general counsel on a pro bono bias for the OBA, The Conservations Alliance and 1% for the Planet. He has served as a director for Portland Social ventures, Soul River, Susan B Komen, Portland Center for the Performing arts, the Software Association of Oregon.

Thank you Michael, for your tireless work for our community!


2022 Oregon Technology Awards

Technology Association of Oregon logo

Don’t miss the 38th annual Oregon Technology Awards, Tuesday, May 3 at the Oregon Convention Center.

Celebrate 2022 Lifetime Achievement award recipient Craig Reinhart, Managing Director of Occupier Services at JLL; 2022 Sam Blackman award winner Henry Schuck, CEO & Chairman of Zoominfo; and 2022 Tech Champion award winner, The Lemelson Foundation.

In addition, there will be 2022 Company Awards in 10 categories, including our own Synergic Medical Technologies as a finalist in the Pre-Revenue category. Regional tech and tech-enabled companies are recognized for their accomplishments, leadership, and commitment to the industry and community.

OBI & OTRADI is pleased to be a sponsor for this event. Tickets are on sale now – don’t miss it!


Please Complete OBI’s
Bioscience Ecosystem Inventory Survey

The Oregon Bioscience Incubator (OBI) is the state’s first and only bioscience-focused incubator. The multi-client company bioscience complex provides startups and scientists access to entrepreneurial mentoring, state-of-the-art bioscience facilities, meeting space, and shared equipment. While OBI currently provides free resources to the full community, we understand there are still some unmet needs and would like to learn more about how OBI can help fill resource gaps.

If you haven’t already, please take 15 minutes to fill out this survey to help assess the needs of the community by identifying additional resources needed. Thank you!


Act Now for MedX @Düsseldorf!

Compete now for a free both at MEDICA’s Start-up Park! You target the global market, you believe in the success of your product and you are ready for the next big step towards internationalization. Your focus is now on networking and gaining visibility, and you are looking for the best way to connect with important partners. The Office of Economic Development Düsseldorf can offer you that unique opportunity with a booth at MEDICA’s Start-Up Park.

Applications accepted if your startup…

  • offers an innovative product/ service in digital health
  • is not registered in Germany
  • has 1–20 employees
  • was launched after 2017
  • has an annual turnover of 0–3 M Euro

Apply at MedX @Düsseldorf until 30th June 2022 to get selected for a pitch competition in order to compete for a spot at the global meeting point for digital pioneers – the Start-up Park. We will inform you by 8th July 2022 if you were chosen for a digital pitch competition in front of a jury. See this link for more details!


OHSU Research Week
May 2-5

OHSU Research Week is an annual university-wide event that celebrates research performed by students, faculty, postdocs, and staff across all schools, centers, institutes and education programs.

Don’t miss keynote speakers, career development and negotiation workshops, poster presentations, and Innovation Day!

It’s all virtual this year. Learn more at the OHSU Research Week website.


Join OSU Iterate

Do you have a business idea but need some help? OSU Advantage Accelerator offers Iterate, a free virtual class for researchers, entrepreneurs and prospective entrepreneurs who have a business idea or technology that could become a sellable product or service but aren’t sure what to do next. Come learn how to create a value proposition, find and understand your market, and more.

Iterate consists of four workshops on Wednesdays that build on each other: May 4, 11, 18, & 25 all from 3:00 p.m. to 4:30 p.m. Open to OSU and non-OSU members. Apply today!


Events

Join Us For These Upcoming OBI Events

Hybrid Lunch & Learn:
Demystifying Commercial Real Estate Leasing
April 26, 2022
12:00-1:00 PM
Limited attendees in-person at CBRE
Also livestreamed on Zoom
Register now!

 

Accelerate Biotech + Digital Health Happy Hour
May 5, 2022
5:30-7:00 PM
In-person! Location TBA
Save the date

 

Other Great Community Events

TAO Pride Community Kick-Off
April 14, 2022
4:00-6:00 PM
Mississippi Studios
Register here

 

OregonBio Zoomcast:
Inherent Targeting – Seeing the Nerve for What it is

April 20, 2022
9:00-9:30 AM
Register here

Zapproved Lunch & Learn:
Create Your Personal Racial Equity Roadmap

April 28, 2022
12:00-1:00 PM
Register here

OBI & OTRADI March 2022 Newsletter

Congratulations to VIR Biotechnology on their Graduation from OBI!

VIR Biotechnology graduated from the OBI February 28, 2022, after joining the incubator in 2015 as TomegaVax, an OHSU spinoff that is pursuing an HIV vaccine. VIR Biotechnology has had many successes throughout their time at the Oregon Bioscience Incubator, including initiating their Phase 1 clinical trial of VIR-1111, an investigational human immunodeficiency virus (HIV) T cell vaccine.

Upon graduation, VIR Biotechnology has relocated their lab and office from OTRADI’s incubator in the Willamette Wharf building on Portland’s South Waterfront, to the Riverside Centre business park just down the street from the incubator.


OTRADI Board of Directors Welcomes Carl Anderson

Carl Anderson was recently elected to OBI/OTRADI’s Board of Directors. Carl has retired from a more than three-decades long career as an Occupational Medicine physician, most recently at Northwest Permanente.

Carl brings a decade of private equity investing experience with minority owned Midwest manufacturer, TAG-Holding LLC. He is also a Venture Partner with Oregon Venture Fund.  In addition, he sits on the OHSU-PSU Philanthropic Advisory Board as well as the Alumni Council of National Medical Fellowships; a nonprofit dedicated to increasing the number of minority healthcare professionals.

The Oregon Translational Research and Development Institute’s (OTRADI) mission is dedicated to transforming scientific research developed in the state of Oregon’s research laboratories into commercial ventures.


Major Win for HTI!

Health Technology Innovations, Inc. was awarded a $1M SBIR Phase II grant from the National Science Foundation to commercialize CryoDiscovery ™, a Cryo-EM Automation and Intelligence Platform for Drug Discovery.

HTI has made great progress developing a prototype during Phase I and will be using this Phase II award, along with revenue from its growing cryo-EM services business, to fund its next stage of growth. HTI is hiring AI/ML software development engineers, interns & postdocs. For more information on these job openings, please inquire with VP Research & Development kumar@hti.ai.


More OBI Client Company Wins

Hemex Health

  • We sent our first Gazelles to Riyadh in Saudi Arabia.
  • This month we’re scheduled to ship commercially to Bahrein, Oman, Kuwait and Algeria, and we are already selling to Lebanon and UAE (Dubai and Abu Dhabi).
  • We’ve partnered with distributors in Savona, Italy, our first European location.
  • Umut Gurkan, our Chief Scientist for Sickle Cell Disease, based at Case Western in Ohio, was elected into the American Institute for Medical and Biological Engineering’s College of Fellows for his continuing achievements in medical and biological engineering.
  • Patti White, Co-founder and CEO, recently participated as a presenter in an Angel Oregon Bio educational seminar and will be a featured panelist at OBI’s upcoming Lunch & Learn on Women in Leadership.

Veana Therapeutics, Inc.

  • Founder and CEO Emmanuel Akporiaye, PhD, recently presented at an Angel Oregon Bio educational seminar.
  • Their ongoing clinical trial for the study of Alpha-TEA and trastuzumab for the treatment of refractory HER2+ metastatic breast cancer continues at the University of Washington/Fred Hutchinson Cancer Center.

Madorra

Caregiven

  • Caregiven was 1 of 4 finalists from the Australian round of the Zurich Innovation Championship. Selected from an applicant pool of over 90 insuretech solutions, Caregiven presented to Zurich’s Australian executive team including the global head of their LifeWell initiative.
    • The Zurich Innovation Championship is a worldwide challenge sponsored by the Zurich Insurance Group, one of the top insurance companies in the world, focused on identifying new and innovative solutions that meet the changing needs of their customers and help the industry face the future in an efficient and sustainable way. Selection of Caregiven as a country finalist was further recognition of the importance of recognizing the caregiver market and serving the unique needs of those needing care and those providing it.
  • We also surpassed 1,000 sign-ups in mid-February – that’s over one thousand families going through a caregiving event globally who are benefitting from our product.
  • Founder and CEO Candice Smith was a featured panelist at OBI’s February Lunch & Learn on How Accelerators Can Help Boost Your Startup.

Rewire Neuro

Gamma Diagnostics, Inc.


PDX Pharmaceuticals has Joined OBI

Please give a warm welcome to OBI’s newest residential company, PDX Pharmaceuticals.

PDX Pharmaceuticals is an IND-enabling stage biopharmaceutical company bringing complementary biological pathways together to achieve synergistic clinical benefits. Their patented mesoporous silica-based nanoparticle platform (Pdx-NP) has been optimized to co-deliver multiple classes of therapeutics (e.g., siRNA, small molecule drugs, antibodies, immunostimulants) to ensure that they reach the target cells at the same time to fully realize their synergy. It can deliver cargos to both cancer and immune cells. Their current focus is to generate effective anti-tumor immune response through profound CD8+ anti-tumor T cell production.

We are delighted to have you onboard!


Gearing up for Summer-Fall 2022
Mentoring Program

Mentor and mentee applications will open on April 1 for this structured, 6-month mentoring program, so save the date for your opportunity to get involved!

Would You Like to be a Mentor?
If you have experience working with startups in the bioscience or digital health industry, consider applying to become a mentor. Benefits of mentoring include:

  • Free mentor training
  • Exclusive access to handpicked startups
  • Exclusive network of mentors
  • Give back to your community
  • OBI highlights its mentors in the monthly newsletter

Growing Your Business? Become a Mentee!
We are looking for entrepreneurs who are already in business but would like guidance, accountability, and support from a mentor to help set and reach business goals. Benefits and time commitments for mentees include:

  • Mentoring helps you grow your business! A recent survey from Kabbage found that 92% of businesses who have a mentor say mentoring has directly impacted their business growth and survival
  • Mentee meets with mentor 2 hours a month for 6 months
  • Mentee checks in with OBI once per month and completes a survey at the end of the program

Applications will be accepted from April 1-30.
For more important dates, details, and a link to the applications, visit www.otradi.org/mentoring.


Angel Investors Participate in AOBIO

Calling all angel investors and the investor-curious! Angel Oregon Life & Bioscience (AOBIO) is an education and investment program designed to grow investment in local bio startups while helping new investors learn the sector. Units in a pooled investment fund start at $5K/each, and include the opportunity to join the startup education series, participate in due diligence, learn the ropes from experienced bioscience angel investors, get exposed to cutting edge innovation, and get networked in the bioscience entrepreneurial community. Investor commit date is March 18. More information here.


Your Input Needed on OBI’s
Bioscience Ecosystem Inventory Survey

The Oregon Bioscience Incubator (OBI) is the state’s first and only bioscience-focused incubator. The multi-client company bioscience complex provides startups and scientists access to entrepreneurial mentoring, state-of-the-art bioscience facilities, meeting space, and shared equipment. While OBI currently provides free resources to the full community, we understand there are still some unmet needs and would like to learn more about how OBI can help fill resource gaps.

If you haven’t already, please take 15 minutes to fill out this survey to help assess the needs of the community by identifying additional resources needed. Thank you!


Applications Accepted for MedX @Düsseldorf

Compete now for a free both at MEDICA’s Start-up Park! You target the global market, you believe in the success of your product and you are ready for the next big step towards internationalization. Your focus is now on networking and gaining visibility, and you are looking for the best way to connect with important partners. The Office of Economic Development Düsseldorf can offer you that unique opportunity with a booth at MEDICA’s Start-Up Park.

Applications accepted if your startup…

  • offers an innovative product/ service in digital health
  • is not registered in Germany
  • has 1–20 employees
  • has been launched after 2017
  • has an annual turnover of 0–3 M Euro

Apply at MedX @Düsseldorf until 30th June 2022 to get selected for a pitch competition in order to compete for a spot at the global meeting point for digital pioneers – the Start-up Park. We will inform you by 8th July 2022 if you were chosen for a digital pitch competition in front of a jury. See this link for more details!


Life Science Innovation Northwest 2022

Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This one-and-a-half day event held April 20-21 at the Washington State Convention Center will bring together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life science breakthroughs of our time.

Apply to present at the Life Science Innovation Northwest 2022. Fast pitch, poster presentations, and, new this year, device showcase opportunities. Deadline to apply is March 15. More information here.


Breakout Ventures

Breakout Ventures is a new venture fund in San Francisco that is funding seed and Series A stage bioscience startups. Read about them here.

Would you like to introduce your company to Breakout Ventures? They are taking direct submissions here.


Events

Join Us For These Upcoming OBI Events

Virtual Lunch & Learn Panel
Women in Leadership: Mind the Gap

March 15, 2022
12:00-1:00 PM
Register now!

 

Other Great Community Events

TiE Westside Pitch Competition 2022
March 10, 2022
4:00-7:00 PM
Hillsboro Cultural Arts Center
527 E Main St., Hillsboro
Ticket information

 

Science Talk ’22
March 23-25, 2022
Starts 9:00 AM
Tiffany Center and online
Get tickets here

 

Technology Association of Oregon logo

TECHLANDIA Smart + Connected Series
Starts March 28, 2022
12:30-2:00 PM
Register here

OBI & OTRADI February 2022 Newsletter

Big News for Veana Therapeutics and Rewire Neuro!

OBI client companies Veana Therapeutics and Rewire Neuro each received one of 11 state grants from Business Oregon, designed to leverage their federal SBIR and STTR grant awards.

Veana Therapeutics‘ grant helps provide funding toward commercialization for its VT-101 oral medication for oncology patients.

Rewire Neuro received a grant award to develop a marketing strategy and hire additional staff for their AI-as-a-service platform in diagnostics and analysis.

See Business Oregon’s press release for more information.


More Exciting OBI Client Company Wins

Caregiven

  • As of today we have 865 users signed on to our platform!  We have decreased our customer acquisition costs and churn significantly in recent months.
  • In our latest product update we launched our affiliate program with 4 amazing companies who support caregivers:  Grief Coach, SilverBills, eFuneral, and Pinventory.  While Caregiven does not advertise to our users, we do offer referral links to our affiliate partners who offer users a discount and provide Caregiven with lead generation revenue.
  • Alaska’s Dementia Action Collaborative profiled Caregiven as a valuable resource to its stakeholder community in their recent newsletter.
  • Caregiven was selected to participate in the APIS Health Angel program.

Gamma Diagnostics, Inc.

Hemex Health

  • Whitney Wilhardt has joined Hemex as PR and Marketing Specialist.

HTI

  • Health Technology Innovations, Inc. was awarded an SBIR Phase II grant from the National Science Foundation to commercialize CryoDiscovery ™, a Cryo-EM Automation and Intelligence Platform for Drug Discovery.
  • HTI is hiring AI/ML software development engineers, interns & post doc. Inquire to kumar@hti.ai.

Refeyn

  • Launched a new product line specifically designed for gene therapy applications, called the SamuxMP. The Refeyn SamuxMP is a mass photometer optimized for adeno-associated virus (AAV) characterization and is an essential analytical tool for laboratories working with AAVs. The SamuxMP precisely measures the empty/full capsid ratio for AAVs of any serotype. SamuxMP mass photometry measurements are rapid and require very little sample.
  • Brenda Watt has been promoted to Customer Success Manager in the Portland office, and Ritu is a new member of the Portland team.

Rewire Neuro

  • Rewire Neuro is a finalist in the upcoming Pitch Oregon by TiE Oregon, in the Life Science category.
  • Pitch Oregon will take place February 11, 2022.

StoneStable

  • CSO and Founder Ken Stedman was interviewed by a local KATU reporter about the new SARS CoV-2 subvariant, which was then picked up and shown on Good Morning America.

Congratulations on all of your achievements!


OBI’s Mentor of the Month:
Mel Ellis

 

Mel Ellis joined the  OBI Mentoring Program in 2021 and quickly became a valuable member of our mentoring team. He has a BA from Stanford and an MBA from Harvard. His background includes ten years in professional venture capital in NYC and Boston. Mel was also the owner/operator of a small manufacturing business for 23 years, which he sold in 2014. He brings this valuable experience plus his positive, make-it-happen attitude to his role as a mentor, working with multiple mentees at a time. Thank you, Mel, for all you do!


NEW! Introducing AOBIO

Registration is now open for Angel Oregon Life & Bioscience (AOBIO). Open to bio startups at any stage of development, this program offers a four-week education series focused on investment-readiness led by successful local founders, and includes the opportunity to be considered for an angel investment of up to $300,000 at the end of the program. Presented by OEN in partnership with OHSU, Oregon Bioscience Incubator, and Oregon Bioscience Association, we highly recommend this program for the education and networking opportunities! Series kicks off February 23 at 8:30 a.m. Learn more and register here by February 22.

Calling all angel investors and the investor-curious! Angel Oregon Life & Bioscience (AOBIO) is an education and investment program designed to grow investment in local bio startups while helping new investors learn the sector. Units in a pooled investment fund start at $5K/each, and include the opportunity to join the startup education series, participate in due diligence, learn the ropes from experienced bioscience angel investors, get exposed to cutting edge innovation, and get networked in the bioscience entrepreneurial community. Investor info session to be held February 17th, 4:00 p.m., via Zoom. Sign up for more info here.


University Lab Partners Presents 4-Part SBIR Series

 

February 10 – Introduction to the NIH SBIR program
Learn about the SBIR program background, eligibility requirements, advantages of SBIR, programmatic structure, deciding whether to apply, challenges for first time applicants, and funding trends.

February 17 – How to Create a Competitive NIH SBIR Grant Application Part 1
Review prerequisites, high level planning, the importance of writing style, aligning an application with division priorities, engaging reviewers, application structure, the importance of advisory committees and academic collaborators, and a detailed approach to creating the Summary and Specific Aims sections, with examples.

February 24 – How to Create a Competitive NIH SBIR Application Part 2
Review the Research Strategy sections: Significance, Innovation and Approach. Budgeting will be discussed in detail. We will also review the importance of advisory committees, academic collaborators and the value of Preliminary Data. We will wrap up with the structure and requirements for the Commercialization section.

March 3 – Understanding the SBIR Review Process
Understanding the review process will enable you to: better understand your target audience, inform your grant creation process and interpret and respond to Summary Statements. We will also discuss what reviewers especially look for in your grant application.

More information and registration for these virtual programs here.


OSU Advantage Accelerator Iterate Program

Do you have a business idea but need some help? OSU Advantage Accelerator offers Iterate, a free virtual class for researchers, entrepreneurs and prospective entrepreneurs who have a business idea or technology that could become a sellable product or service but aren’t sure what to do next. Come learn how to create a value proposition, find and understand your market, and more. Iterate consists of four workshops on THURSDAYS that build on each other: Feb. 24, March. 3, 10, & 17, all from 3:00 p.m. to 4:30 p.m. Open to OSU and non-OSU members.
Apply here for the Winter 2022 Workshop Series.

FDA’s New Approvals Offer Greater Treatment Options for Patients

The U.S. Food and Drug Administration (FDA) approved a total of 60 new drugs in 2021. A new report from the FDA catalogs 50 new approvals by the Center for Drug Evaluation and Research (CDER). These novel medicines offer to transform many debilitating diseases, resulting in improved survival, better health outcomes, enhanced quality of life for patients with lupus nephritis, lung cancer, endometrial cancer, migraines and HIV.

Key takeaways from the report here.


Pitch Oregon

“In its 6th year, Pitch Oregon is TiE Oregon’s marquee event, attracting hundreds of entrepreneurs, mentors and investors each year. New this year, we are welcoming companies from around the Pacific Northwest to apply and applicants will compete for an equitable investment!

Applicants in the following categories will have the opportunity to receive an equitable investment. These applicants generate TTM of at least $250,000 or have raised external capital of at least $250,000:

Software / Tech Enabled:  Companies with services or products related to electronics, software, hardware, artificial intelligence, cloud services, etc.
Life Science:  Companies with services or products related to pharmaceuticals, biotechnology, medical devices, biomedical, telehealth, etc. OBI client company Rewire Neuro is a finalist in the Life Science category.
Clean Technology:  Companies that aim to improve environmental sustainability with products or services related to renewable energy, recycling, green transportation, sustainable manufacturing, etc.”

Additionally, Pitch Oregon has an Early-Stage category. OBI mentee Tonsil Tech is a finalist in this category.

You won’t want to miss these fun events – pitches take place on February 11, 2022 from 1:00-4:00, and the winners will be announced at the TiE Oregon Annual Awards Dinner that evening.

More information and registration at TiE Oregon.


Events

Join Us For These Upcoming OBI Events

Virtual Lunch & Learn: How Accelerators Can Help
Boost Your Startup – Founders’ Perspectives

February 16, 2022
12:00-1:00 PM
Register now

 

AOBIO Investment-Readiness Virtual
4-Week Education Series Begins
February 23, 2022
8:30-10 AM
Registration open through February 22

 

Accelerate Biotech + Digital Health
Virtual Happy Hour

March 3, 2022
5:00-6:30 PM
Register here

 

Virtual Lunch & Learn Panel:
Women in Leadership – Mind the Gap

March 15, 2022
12:00-1:00 PM
Save the date

 

Other Great Community Events

Technology Association of Oregon logo

TAO Leadership Exchange:
A Conversation with Women Leaders in Tech
February 24, 2022
9:00-10:30 AM
Register here

 

OTBC Social Media Marketing
Virtual Workshop with Allison Tivnon
February 24, 2022
11:00 AM – 12:00 PM
Register here

 

TiE Westside Pitch Competition 2022
March 10, 2022
4:00-7:00 PM
Hillsboro Cultural Arts Center
527 E Main St., Hillsboro
Ticket information

OBI & OTRADI 2021 End of Year Newsletter

Happy New Year!

Thank you for your support of OBI & OTRADI over the past year.
We wish you an abundance of health, happiness, and success in 2022.


2021 OBI Client Company Recap

  • OBI & OTRADI alumnus Absci was listed at #8 by the Portland Business Journal ofthe largest bioscience and health tech companies in Oregon and SW Washington.
  • Announced completion of $125 million crossover financing to advance AI-powered synthetic biology drug creation platform. Read press release. 
  • Absci made its debut on the NASDAQ (ticker symbol ABSI) on Thursday, July 22, and founder Sean McClain and his team rang the closing bell. 
  • Announced new and expanded collaboration with Merck, with payments and fees of up to $610 million.

 

  • OBI & OTRADI alumnus Aronora was listed #31 by the Portland Business Journal on their list of the top 37 largest bioscience and health technology companies in Oregon and SW Washington.
  • In March upon graduation from the OBI, Aronora relocated their lab and office from OTRADI’s incubator in the Willamette Wharf building, to a brand-new high rise downtown where they have double the office space, a private wet lab, and conference room
  • Aronora reports positive topline data from their phase 2 clinical trial of recombinant antibody therapeutic AB023 in hemodialysis patients. This data was presented at the XXIX Congress of the International Society on Thrombosis and Haemostasias in July. See Aronora’s press release here.

 

  • Buchanan Science joined the OBI as a client company in 2021.
  • Buchanan Science is now in the process of testing approximately 100 blinded serum samples from persons who received vaccination against COVID-19. The sera were previously tested with a CLIA-approved instrumented assay from ProMega that quantitatively measured the antibody levels to SARS-CoV-2 spike.
  • The Buchanan Science BeSure Double Check Rapid test is designed to enable home users to check their antibody levels to RBD, the portion of the viral spike that attaches to human ace2 receptors as an initial step in infection. Persons with high antibody levels to RBD are able to avoid infection due to SARS-CoV-2, or if infected have only minimal symptoms and avoid hospitalization or death.
  • Preliminary indications are that the rapid test is correlating well with protective antibody levels to RBD, and they are currently seeking increased numbers of sera from non-vaccinated individuals who have also not had COVID-19 infections to quantitate test specificity.

 

  • Caregiven participated in Australian CareFactor Pitch Day 2021 on March 22, part of the Information Technology Across Care virtual summit.
  • First public release launched in app stores April 15th.
  • Closed pre-seed with a total of $700K raised from Rogue Venture Partners.
  • Was a 2021 Oregon Technology Awards finalist.
  • Semi-finalist for Aging 2.0’s Global Innovation Search.
  • Candice Smith was interviewed by the HITLab for their Women’s Health Tech Wednesday forum.
  • Highlighted in an article titled “Looking to the Future of Insurance.”
  • Presented “Shark Tank” style to attendees at the ISCPA conference.
  • Finalist in Aging 2.0’s Global Innovation Search.
  • Finalist in the ACORD InsurTech Innovation Challenge.
  • Selected to participate in the American Heart Association of OR/SW Washington’s EmPOWERED to Serve program.
  • Awarded the TAO Start-Up of the Year award in the pre-revenue category.
  • Candice Smith was a guest on the Aging in Portland podcast.
  • Chief Revenue Officer, Anthony Mitchell and Candice had the opportunity to present at the ACORD InsurTech Innovation Challenge NY.
  • Anthony also co-hosted a webinar on The Future of Value Adds in Insurance with an insurance luminary, Jason Gross.
  • Presented at CareTech presented by the Louisville Healthcare CEO’s Council and Aging 2.0, a global search for innovations that improve the patient or member experience.
  • Awarded the second place grant from the American Heart Association’s EmPOWERED to Serve program ($30K), sponsored by the American Heart Association of Oregon & SW Washington.
  • Kicked off the first phase of their first pilot with a national palliative care provider. They will be using Caregiven to expedite the health outcomes their nurses already accomplish, and are including Caregiven as a differentiator for their company in proposals to major health systems nationally.
  • Had over a dozen calls with insurance carriers about Q1 pilots and are under NDA and working on LOIs with several.
  • Attended InsureTech Connect in Las Vegas, sponsored by the Global Insurance Accelerator, and had many wonderful calls with customers and investors alike. Notable conversations occurred with Unum, Northwestern Mutual, MS&AD, Ethos Life, Assurity, and more.  
  • Networking at the event resulted in Candice Smith being asked to speak at the Society of Actuaries ElderTech Summit in December and to be interviewed for an upcoming book focused on the future of insurance.  Additionally, 2 podcasts featuring Caregiven were recently released:  Woman to Woman Podcast and The Heart of Hospice.
  • Successfully completed Session #1 of the Creative Destruction Lab – an invite only program with the goal of helping start-ups “build something massive.”  Of the 20 initial companies, Caregiven was 1 of 14 asked to return for Session #2 in December. Again were successful in Round #2 of the Creative Destruction Lab and have been invited to participate again in February.  Their lead mentor this round comes from Healthy Minds Innovations.  Candice said is amazing to be selected to collaborate with a team that has a direct connection with the Dalai Lama and is committed to using digital tools and modern neuroscience to improve the human experience.
  • Successfully launched their first co-branded experience with Spivey Insurance.

  • Circumvent Pharmaceuticals are co-Principle Investigators on a NIH SBIR grant for the study of “Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating infantile neuronal ceroid lipofuscinosis (INCL).” INCL is a form of Batten Disease.

  • CytoImage founder Tania Vu presented at the international Innovation Stage at BIO Digital 2021.
  • Pitched at an Oregon Venture Fund pitch event at the OBI in October.

 

  • Gamma Therapeutics is now Gamma Diagnostics, Inc.
  • David Eastman retired as CEO, they hired Ajay Nair from Perth, Australia as their new CEO, and he hired Chris Venter, also from Perth, as their Chief Finance Officer.
  • Discovered that their GammaCoeur diagnostic blood test for cardiovascular disease is extremely elevated in COVID-19 patients and predicts the need for hospitalized patients to need extracorporeal membrane oxygenation (ECMO) in order not to suffocate, and it predicts death from COVID-19. They now have a provisional patent on this I.P. that also protects the use of the test as a companion diagnostic for the administration of dexamethasone in COVID-19 patients.
  • Accepted into California’s Expert Dojo accelerator cohort. For companies accepted into the program, Expert Dojo invests $100,000, provides an 8-week training program that trains the members of the company in all aspects of business, and introduces them to investors and mentors.
  • The Department of Defense’s Peer Reviewed Medical Research Program has a Technology/Therapeutic Development Award, and invited Gamma Diagnostics to submit a full proposal to develop GammaCoeur as a companion diagnostic to track COVID-19 disease severity. They submitted the grant on Sept. 2.
  • One of 8 semi-finalists for the Bend Venture Conference in the Impact category.
  • What is Gamma Prime Fibrinogen (GFP)? Dr. David Farrell, Professor of Surgery at OHSU and founder and CSO at Gamma Diagnostics, shared his poster and abstract at the American Heart Association meeting. The results show that their ELISA for GFP shows significantly higher levels in COVID-19 patients who died or required extracorporeal membrane oxygenation (ECMO), which has several important clinical implications relative to administration of anticoagulants and steroids. Read more here in the American Heart Association Circulation.

 

  • Hemex Health’s Gazelle device was highlighted in a 360Dx article.
  • Hemex reports: “On Saturday, Feb 27, Ruaraka Neema hospital in Nairobi held a public screening event for families to bring their kids in for sickle cell screening using Gazelle. The team was able to run most of the samples they collected on one day, the rest on the following Monday morning. Running almost 50 samples in one day is what Gazelle was designed to do, and we’re so proud to see this helping the kids who need it most now.”
  • The Portland Business Journal listed the largest bioscience and health tech companies in Oregon and SW Washington. Hemex Health was listed at #19.
  • In a recent clinical study conducted in Brazil and published in the Malaria Journal, Gazelle was shown to outperform current RDTs (Rapid Diagnostic Tests) in detection of P. vivax malaria. P. vivax, the most widely dispersed species of malaria, tends to be more difficult to detect with RDTs due to typically low levels of parasitemia. They are excited to share the results of the study with you in their press release.
  • Won a Phase I grant to add multispectral imaging to its Hb Variant test to lower the limit of detection and allow the test to screen newborns for sickle cell and other hemoglobin variants.
  • Excited to announce a new partnership with Cureleads for distribution of Gazelle in the Middle East, Turkey and North Africa.
  • CEO Patti White, was a keynote speaker in the OHSU Invent-a-thon Post-Hack.
  • Released our newborn screening capacity for sickle cell anemia in May.
  • Selected as a 2021 TiE50 winner as part of the TiECon program for their Gazelle reader diagnostic device. Press release here.
  • Officially launched their newborn release! Gazelle is now able to diagnose newborns for sickle cell disease before they even leave the hospital. Check out the press release.
  • With their product design and engineering partner Tata Elxsi, the Gazelle Reader won the Social Impact Solution of the Year award at the 2021 NASSCOM Engineering & Innovation Excellence Awards in India!
  • In a recent P. vivax clinical study, Gazelle demonstrated higher sensitivity than the only FDA-approved malaria rapid diagnostic test. Press release here.
  • Featured in the Oregon Lottery spotlight.
  • Patti White was on the speaker panel of the Oregon Pediatric Innovation Event, Powered by CTIP, on September 1.
  • Featured in the September issue of the Elevate Capital newsletter.
  • Gazelle was featured in an NIH article: Future of medicine: Lab-on-a-chip devices starting to make an impact.
  • Pitched at an Oregon Venture Fund pitch event at the OBI in October.
  • A clinical study featuring Gazelle’s sickle cell disease test was featured in Frontiers in Medicine. The researchers found that Gazelle’s speed, accuracy and ease-of-use made it ideal for use in low-resource settings with a high prevalence of the disease.
  • In November, Hemex introduced an enhancement to its Hb Variant test that enables testing for beta thalassemia in addition to sickle cell disease. Gazelle is now the only point-of-care test for beta thalassemia on the market. Additionally, they were able to update our installed base automatically over the Cloud. Here is the link to the press release that explains more.
  • Hemex Health has been invited to pitch to Inflect Health in January, 2022.

 

  • HTI has announced that Dr. Jeff King has joined their team as Senior Advisor.
  • Dr. Craig Yoshioka joined HTI as Senior Advisor for cryo-EM. Read their press release for background information on Dr. Yoshioka and HTI’s innovative cryo-EM technology.
  • HTI’s CryoDiscovery™: A Machine Learning Platform for Automated Cryo-EM Class Selection poster was selected by One World Cryo-EM conference on March 10-11.
  • CryoDiscovery™: A Machine Learning Platform for Automated Cryo-EM Class Selection for Single Particle Analysis in Structural Biology paper has been accepted by the Microscopy and Microanalysis 2021 conference (M&M), to be presented in August 2021.
  • HTI has also been accepted as a Premier Member into the NVIDIA Inception Program for AI and data science startups.
  • CryoDiscovery (TM): A Machine Learning Platform for Automated Cryo-electron Microscopy 2D Class Selection paper was presented at the ACA (American Crystallographic Association) conference in Aug 2021.
  • Became a member of the Nvidia Inception and Intel AI Builder program.
  • Pfizer is beta testing HTI’s CryoDiscovery ™ – A Cryo-EM Automation & Intelligence Platform for Drug Discovery.
  • Nimbus Wadget, Inc signed another service agreement to start a cryo-EM 3-D structure determination project.
  • Signed MSAs (master service agreement) with Agios, Flare Therapeutics, Atavistik, and IDEAYA Biosciences for cryo-EM services.
  • CryoDiscovery ™ was presented at the 4th Annual CryoNET Symposium, October 18-19th 2021.
  • Pitched at an Oregon Venture Fund pitch event at the OBI in October.

 

  • Inherent Targeting was awarded a fast-track SBIR grant from the NCI at the NIH worth a total of $2.25M to complete lead selection and preclinical testing for investigational new drug approval of their nerve-specific fluorescence guided surgery contrast agents.
  • Awarded a SBIR matching grant from Business Oregon worth $82k to cover IP and business development expenses.
  • Presented at the Angel Capital Association Summit Innovation Showcase, sponsored by the Oregon Bioscience Association.
  • CEO Connor Barth was awarded OHSU’s Early Career Innovator Award. The Early Career Innovator Award is presented to an OHSU employee such as a student, post-doctoral fellow, medical resident or someone else early in their professional career who possesses a passion for innovation and developing technologies to solve real-world problems. They work closely with the innovation ecosystems within and outside of OHSU to prepare their innovations for commercial success.
  • Connor Barth presented at BIO Digital 2021 Innovation Stage.
  • Recently awarded an SBIR Phase 1 grant from the NSF.
  • Represented OHSU startups and present at the Pacific Northwest Startup Showcase on Oct 12.

 

  • Izon has recently released two new consumables products to the market. These kits will further establish Izon as an industry leader in extracellular vesicle analysis. Please see product pages: qEV RNA Extraction Kit, qEV Concentration Kit
  • Henry Scheffer joined as our new Research Associate, Brennan Van Deren joined as a part time Quality Assurance Intern, and Anthony McNeil came onboard as Applications Scientist.
  • Izon Science is excited to announce the release of its Gen 2 qEV SEC columns as well as its new column size, the qEV1. Izon is confident these columns will perform better in nearly all performance metrics important to the extracellular vesicle community including higher total EV yields, lower levels of contaminating proteins, and higher EV purity as measured by # of EVs/ug of protein when compared to their legacy columns.

 

 

  • OmnEcoil Instruments‘s Dr. Fergus Coakley, inventor of the OmnEcoil instrument, was an author of a November 2021 research article in the American Journal of Roentgenology, entitled, “ In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting.“

 

  • OBI & OTRADI alumnus Oncol Drug Discovery Service made substantial progress in developing optimized SOP for generating CART against targeted cancer. Generated two targeted CART lines of high potency and purity (93-96% purity).

 

  • ProMedix, Inc. had abstracts from their clinical trials selected from a national pool of applications for presentation at both the Society of Academic Emergency Medicine and Pediatric Academic Society national meetings in spring 2021.
  • Awarded a $30K grant from OHSU Technology Transfer.
  • ProMedix has a new publication on “Point-of-Care Capillary Refill Technology Improves Accuracy of Peripheral Perfusion Assessment,” in Frontiers in Medicine.
  • Competitively selected for the mHUB MedTech Incubator in Chicago. Read mHub’s press release.
  • ProMedix is developing HydraSense to provide a rapid, accurate, and noninvasive assessment at the clinical bedside or remote care setting to help diagnose sepsis and monitor patient decline and response to treatment.

 

  • Qtonics joined the OBI as a client company in 2021.
  • Will be moving into a private office within the OBI in February, 2022.

 

  • Learn about mass photometry as a revolutionary new way to analyze molecules in a series of videos on Refeyn’s YouTube channel.

  • Rewire Neuro‘s Pipsqueak AI version 5.5.0 has been released. It features new detection models, smoother model customization, and better co-localization analysis.
  • Won a Cougar Cage grant from WSU (it is their version of Shark Tank).
  • Won Angel Oregon Tech 2021 and received a $125,000 equity investment from AOTech investors. Out of 90 companies who went through the program, nine were selected to pitch at the final AOTech at TechFestNW event on May 21, and Rewire Neuro was the judges’ top pick.
  • Received funding from Elevate Capital’s Oregon Gap Fund.
  • Pitched at an Oregon Venture Fund pitch event at the OBI in October.
  • Awarded a Phase II SBIR from the NIH. This two-year grant will help them develop additional cell detection capabilities and integrate their AI platform into partnering diagnostics devices and applications.
  • Rewire Neuro is a finalist in the upcoming Pitch Oregon by TiE Oregon, in the Life Science category. Pitch Oregon will take place February 11, 2022.
  • RxHomeTest has been invited to pitch to Inflect Health in January, 2022.
  • Senju Pharmaceutical has announced marketing approval for the ophthalmic VEGF inhibitor “Ranibizumab BS Intravitreal Injection Kit 10 mg/mL.
  • In December 2021, announced the launch of a new treatment for Ranibizumab. See press release.

 

  • Sirona Dx launched a rapid saliva-based PCR COVID-19 testing service utilizing advanced microfluidics.
  • Dr. Nasry Yassa, CEO, and Andrew Brown, Chief Commercial Officer, presented at Fluidigm Virtual Mass Cytometry Investor Day. Listen to the webcast here.

 

 

  • OBI & OTRADI alumnus Sparrow Pharmaceuticals‘ novel approach to the treatment of Cushing’s syndrome was featured by the Endocrine Society in their membership newsletter Endocrine News.
  • Sparrow received a May Proceed letter from FDA for a Phase 2 clinical trial in patients with ACTH-dependent Cushing’s syndrome, which will open to patients in January. Press release here.

 

  • StoneStable, Inc. had patents issued in Canada and India.
  • Successfully demonstrated that silica-treated adenovirus is significantly more resistant to freeze-thaw cycles, which can be a big improvement over current vaccines.
  • Currently looking to raise its seed round.

 

  • SUTUREGARD shipped the most HEMIGARD ever before in Q1 2021.
  • Teamed with one of the leading foot and ankle surgeons in the world, Dr Mark Myerson. He has now enrolled 8 colleagues across the country and is initiating a clinical trial of HEMIGARD in ankle replacement/fusion surgery.
  • Attended the Chicago Lower Extremity Surgery Symposium in April as invited speakers, and we had the HEMIGARD successfully demo’d on live video by the Symposium Chairman, Dr. Edgardo Rodriguez-Collazo.
  • Named a Top 10 Innovation by Podiatry Today, a leading trade journal. This is unsolicited, unlike some trade publication lists which are paid for. SUTUREGARD is featured at the end of the article; they saved the best for last!
  • The Veteran’s Administration is now ordering HEMIGARD. The U.S. Veteran population has a high incidence of wound problems and they will be making a big impact in reducing wound complications and improving limb salvage efforts. The HEMIGARD is a great tool to not only speed the surgical closure, reduce the need for additional deep sutures, but also to support the healing through the difficult postoperative period when the foot may swell and the wound may open (dehisce).
  • Continuing to gain traction with Q2 2021 sales highest ever, and 50% growth in revenue from Q2 to Q3, with a record month to start Q4.
  • SUTUREGARD and HEMIGARD products were placed on the MEDLINE catalog and have now been ordered by multiple hospitals through that pathway.
  • CEO Dr. Dan Ladizinsky gave two plenary session talks at the American Podiatric Medical Association meeting in Boston in October, highlighting that HEMIGARD closure of diabetic foot amputations has reduced wound dehiscence and subsequent need for above or below knee amputation by over 80%. This improvement in outcomes is especially important since diabetic foot amputations have gone up in frequency post COVID due to poor access to necessary preventative care and to vascular complications of COVID increasing the risk of wound complications.

 

  • Synergic Medical Technologies is enrolling in clinical trials for Parkinson’s Disease through Oregon Neurology in Springfield, Oregon. The trial is for a non-invasive vibrotactile stimulator whose purpose is to address some of the motor issues associated with Parkinson’s disease.

 

  • Thaena, Inc. joined the OBI as a client company in 2021.
  • Joined the OBI mentoring cohort in Summer-Fall 2021 and renewed for the Winter-Spring 2022 cohort.
  • Held a microbiome symposium in December, 2021 about microbial ecosystems, metabolites, and their impact on human health.

 

  • Veana Therapeutics was awarded a Phase I SBIR grant from the National Institutes of Health/National Cancer Institute to conduct proof-of concept studies of its lead product, VIMO in combination with the monoclonal antibody trastuzumab (an equivalent of Herceptin).
  • Closed a seed round with a total of $1.25M raised.
  • Veana is pleased to report that the first patient in the Phase Ib clinical trial of the company’s oral drug, VIMO in combination with Herceptin has been dosed!

 

 

  • Vir Biotechnology and partner GlaxoSmithKline (GSK) announced a joint collaboration to produce an investigational monoclonal antibody for the treatment of COVID-19. The treatment, called sotrovimab, is an FDA EUA-authorized monoclonal antibody which is administered by infusion in the early stages of a COVID-19 infection in eligible patients.
  • Vir and GSK recently announced a $1 billion U.S. government contract to purchase sotrovimab, delivered mid-December. Vir Bio and GSK also have other governmental purchase agreements through the European Commission.
  • Preclinical studies indicate that sotrovimab retains activity against the full combination of spike proteins on the recently discovered Omicron variant. Read press release here.

 

Congratulations to our amazing OBI Client Companies!


OBI Welcomed New Startups in 2021

    

Click here to learn more about our new companies


New OBI Mentoring Cohort Begins

We are pleased to announce that January 3, 2021 was the start date for OBI’s newest Mentoring Program cohort. Seventeen mentees and fourteen mentors will work together in pairs and threes for 6 months. 

MENTORS
Lynn Sheehan, Guillaume Lenormand, Daren Connor, Mel Ellis, Katie Rubino, Sheila Ramerman, Michael Phillips, Anoop Pal, Shannon Heizenrader, Shelly Sweeney, Scott Filer, Keith Daellenbach, Josh Ellison, and Mark Bloom.

 

MENTEES
Priscilla Cheng, Alan Kadish, Alexander Honkala, Sandhiprakash Bhide, Christine Tataru, Mohammad Hissourou III, Alex Tataru, Cory Szybala, Vickie Driver, Manreet Brar, Marco Barcella, Andrea Sommer, Daniel Forbes, Jessy Imdieke, Alison Carrigg, Sydney Quinton-Cox Forbes, and Gus Lawrence. 

Best of luck to the Winter-Spring OBI Mentoring Program cohort! Learn more about the OBI Mentoring Program.


Johnson & Johnson QuickFire Challenges

Johnson & Johnson Innovations/JLABS has some exciting opportunities coming up soon:

  • Immunology Innovations QuickFire Challenge: Precision Medicine in Immune-Mediated Disease
  • Nurses Innovate QuickFire Challenge: Healthcare Transformation through Nurse-Led Tech
  • Food Allergy Prevention QuickFire Challenge
  • Improving Detection of Neurotoxicity in Immunotherapies

Learn more about these QuickFire Challenges here.


New Year, New Job?

Or perhaps a new employee for your Oregon company or organization. If you are hiring or looking for a new role, check out the current listings, and post your open position or resume to the OBI Job Board. It’s easy and free to use.


New Year, New Ideas…
We’d Love to Hear from You in ’22!

Do you have an idea for an OBI Lunch & Learn topic, Happy Hour theme, or Workshop suggestion? Or maybe you know of an awesome speaker (maybe even yourself!). We have a new button at the top of our Events Calendar for you to submit your program ideas and speaker suggestions. And as always, if you have an event you would like us to promote on our calendar, there’s a button for that, too. We’d love to hear from you in ’22!


Missed a Lunch & Learn?

No worries! We have video recordings of most of our Lunch & Learns available in two places: on our website and on our OBI YouTube channel. Now you have 24/7 access to the OBI programs you may have missed. Subscribe to our YouTube channel for notification of new videos uploaded (about once per month).


OHSU Innovation and Commercialization Internship Program

Applications for this real-world educational experience learning technology transfer, business development, or patent law are being accepted until January 16, 2022. Learn more and apply now!


Upcoming Events

OBI Events

Accelerate Biotech + Digital Health
Virtual Happy Hour
January 13, 2022
5:00-6:30 PM
Register here

 

OBI Virtual Lunch & Learn:
OHSU Center for Experimental Therapeutics
January 19, 2022
12:00-1:00 PM
Register here

 

Community Events

 

TAO 2022 Legislative Session Preview
January 18, 2022
9:00-10:30 AM
Register here

 

TiE Oregon Presents: Pitch Oregon 2021
February 11, 2022
12:30-4:00 PM
Register here

OBI & OTRADI December 2021 Newsletter

Seasons Greetings from OBI & OTRADI

All the best to you and yours this holiday season and in the new year!


Vir Biotechnology Tackles COVID-19

Big news in the treatment of COVID-19! Earlier this year, OBI client company Vir Biotechnology and partner GlaxoSmithKline (GSK) announced a joint collaboration to produce an investigational monoclonal antibody for the treatment of COVID-19. The treatment, called sotrovimab, is an FDA EUA-authorized monoclonal antibody which is administered by infusion in the early stages of a COVID-19 infection in eligible patients. Last month, they announced a $1 billion U.S. government contract to purchase sotrovimab, to be delivered this week. Vir Bio and GSK also have other governmental purchase agreements through the European Commission. Preclinical studies indicate that sotrovimab retains activity against the full combination of spike proteins on the recently discovered Omicron variant.

Press releases for these announcements can be found here and here.

Congratulations Vir Bio!


More Exciting OBI Client Company Wins

Rewire Neuro

  • Rewire Neuro is a finalist in the upcoming Pitch Oregon by TiE Oregon, in the Life Science category.
  • Pitch Oregon will take place February 11, 2022.

Hemex Health

  • In November, Hemex introduced an enhancement to its Hb Variant test that enables testing for beta thalassemia in addition to sickle cell disease. Gazelle is now the only point-of-care test for beta thalassemia on the market.
  • Additionally, we were able to update our installed base automatically over the Cloud.
  • Here is the link to our press release that explains more.

ProMedix, Inc.

  • ProMedix was recently accepted into Chicago’s mHub accelerator. Read mHub’s press release.
  • ProMedix is developing HydraSense to provide a rapid, accurate, and noninvasive assessment at the clinical bedside or remote care setting to help diagnose sepsis and monitor patient decline and response to treatment.

Gamma Diagnostics, Inc.

  • What is Gamma Prime Fibrinogen? Dr. David Farrell, Professor of Surgery at OHSU and founder and CSO at Gamma Diagnostics, Inc., shared his poster and abstract at the American Heart Association meeting.
  • COVID-19 patients can develop extremely high levels of gamma prime fibrinogen (GPF), which has several important clinical implications relative to administration of anticoagulants and steroids.
  • Read more here in the American Heart Association Circulation.

SUTUREGARD Medical, Inc.

  • We noted 50% growth in revenue from Q2 to Q3, with a record month to start Q4.   
  • Our SUTUREGARD and HEMIGARD products were placed on the MEDLINE catalog and have now been ordered by multiple hospitals through that pathway. 
  • CEO Dr. Dan Ladizinsky gave two plenary session talks at the American Podiatric Medical Association meeting in Boston in October, highlighting that HEMIGARD closure of diabetic foot amputations has reduced wound dehiscence and subsequent need for above or below knee amputation by over 80%. This improvement in outcomes is especially important since diabetic foot amputations have gone up in frequency post COVID due to poor access to necessary preventative care and to vascular complications of COVID increasing the risk of wound complications.

Congratulations on all of your achievements!


OBI’s Mentor of the Month:
Sheila Ramerman

Sheila Ramerman is one of OBI’s helpful volunteer mentors. With a background and education in Medical Laboratory and Hospital Administration, Sheila is a wealth of knowledge for our OBI mentees. Her primary areas of expertise are in FDA regulatory requirements and quality system basics. Sheila has extensive experience in designing and performing IVD clinical studies. She has worked in multiple start ups, and as a consultant to start ups. Sheila started in product development for an IVD company (point of care diagnostic) and worked into clinical studies, then in regulatory affairs, and into quality systems. Since then she has worked in regulatory/quality/clinical roles in other start ups. Her colleagues describe her as having a practical, pragmatic approach – what is needed now, and what’s needed in the future. They also appreciate her ability to understand the requirements and apply them and adapt as needed to the specific situation.

Thank you Sheila, for helping OBI mentees navigate the complex world of FDA regulation in the OBI Mentoring Program.


Hiring or Seeking?
Post it on OBI’s Job Board 


OBI has launched a Job Board where you can easily list your organization’s open positions. Click here to post your open positions. We’ll approve it on our end, and it will be posted for 30 days (and it’s renewable too).

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


PCC Bioscience Technology Information Sessions

Spread the word to interested persons to attend a Portland Community College info session to learn about the bioscience industry, the BIT program, and the admissions process.

Please review the info slides on this page and RSVP for an upcoming session. (An RSVP is required in order to provide you with the information to join the online session in Zoom.)

Questions? Contact a program advisor.


Preventing the Next Public Health Emergency

COVID-19 is not the first pandemic caused by a novel strain of a virus affecting the upper respiratory tract. Over the past 100 years, pandemics have been caused by novel forms of influenza and other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS) and Middle East Severe respiratory syndrome (MERS). Common complications of each of these infections include pneumonia which can lead to secondary bacterial infections requiring treatment with antibiotics. New evidence demonstrates the need to address microbial resistance to help prevent the next public health emergency. Read more about it here.
 

Life Sciences Trend Report

logo for CBRE Ajay Malhotra and Kristin Hammond

CBRE’s most recent U.S. Life Sciences Trend Report now available. A couple of key takeaways:

  • The market has never been stronger – All-time highs reached in funding, job growth, demand for lab space and new construction.
  • The near-term outlook remains bright – Data trends and sentiment from the field suggest continued active market conditions over the next year. 

Download the full PDF report here, compliments of our friends at CBRE.


Pitch Oregon 2021

“In its 6th year, Pitch Oregon is TiE Oregon’s marquee event, attracting hundreds of entrepreneurs, mentors and investors each year. New this year, we are welcoming companies from around the Pacific Northwest to apply and applicants will compete for an equitable investment!

Applicants in the following categories will have the opportunity to receive an equitable investment. These applicants generate TTM of at least $250,000 or have raised external capital of at least $250,000:

Software / Tech Enabled:  Companies with services or products related to electronics, software, hardware, artificial intelligence, cloud services, etc.
Life Science:  Companies with services or products related to pharmaceuticals, biotechnology, medical devices, biomedical, telehealth, etc.
Clean Technology:  Companies that aim to improve environmental sustainability with products or services related to renewable energy, recycling, green transportation, sustainable manufacturing, etc.”

OBI client company Rewire Neuro is a finalist in the Life Science category.

Additionally, Pitch Oregon has an Early-Stage category.

You won’t want to miss these fun events – pitches take place on February 11, 2022 from 1:00-4:00, and the winners will be announced at the TiE Oregon Annual Awards Dinner that evening.

More information and registration at TiE Oregon.


OHSU Innovates 2021 Impact Report

Oregon Health & Science University has just published their OHSU Innovates 2021 Impact Report. They highlight some of the innovations to come out of OHSU, showing resilience and strength during a particularly challenging time. Special shout-outs to OBI graduate Aronora, and current OBI client companies ProMedix, Inherent Targeting, and Vir Biotechnology, all OHSU spinouts featured in this comprehensive report.


Events

Join Us For These Upcoming OBI Events

Accelerate Biotech + Digital Health
Virtual Happy Hour

January 13, 2022
5:00-6:30 PM
Register now!

Lunch & Learn: Center for Experimental Therapeutics –
Translating Discoveries from Lab to Clinic

January 19, 2022
12:00-1:00 PM
Register now!

 

Other Great Community Events

OSU Advantage Accelerator Webinar:
Intellectual Property Essentials for Startups

December 16, 2021
12:00-1:00 PM
Register here

Zapproved Seminar: Turning Awareness
into Action with Dr. Dana Crawford

January 12, 2022
12:00-1:00 PM
Register here

OBI & OTRADI November 2021 Newsletter

OBI Client Company Wins

Madorra

Caregiven

  • We attended InsureTech Connect in Las Vegas, sponsored by the Global Insurance Accelerator, and had many wonderful calls with customers and investors alike.  Notable conversations occurred with Unum, Northwestern Mutual, MS&AD, Ethos Life, Assurity, and more.
  • Networking at the event resulted in Candice Smith being asked to speak at the Society of Actuaries ElderTech Summit in December and to be interviewed for an upcoming book focused on the future of insurance.  Additionally, 2 podcasts featuring Caregiven were released last month:  Woman to Woman Podcast and The Heart of Hospice.
  • We successfully completed Session #1 of the Creative Destruction Lab – an invite only program with the goal of helping start-ups “build something massive”.  Of the 20 initial companies, Caregiven was 1 of 14 asked to return for Session #2 in December.

Hemex Health

ProMedix

  • We were competitively selected for the mHUB MedTech Incubator in Chicago.

Izon

  • Izon Science is excited to announce the release of our Gen 2 qEV SEC columns as well as our new column size, the qEV1.
  • Izon is confident these columns will perform better in nearly all performance metrics important to the extracellular vesicle community including higher total EV yields, lower levels of contaminating proteins, and higher EV purity as measured by # of EVs/ug of protein when compared to our legacy columns.

HTI

  • Master Service Agreement (MSA) signed with Flare Therapeutics, Atavistik, and IDEAYA Biosciences for Cryo-EM services.

Congratulations on all of your achievements!


OBI’s Mentor of the Month:
Tanya Leavy

Tanya Leavy, JD, is one of our wonderful volunteer mentors. She is experienced in the field of intellectual property law, with a specialty in patent law, practicing in the patent space for over a decade. Her law degree is from the Fordham Law school.

Tanya also has a Ph.D. in chemical biology, with a specialty in organic chemistry, from the University of California at Berkeley. She has worked with a number of startup companies in the biotechnology area to provide strategic patent guidance to help them to develop and protect their innovations.

Her colleagues describe Tanya as hardworking, with attention to detail, a collaborative work style, and a creative problem solver.

Thank you, Tanya, for contributing to the success of our mentees!


Hiring or Seeking?
Post it on OBI’s Job Board 

clipboard with resume next to laptop computer

We’re excited to announce that OBI has launched a Job Board, and we’d love to list your organization’s open positions. Click here to post your open positions.

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


2021 Tech Pay Data Now Available

Technology Association of Oregon logo

Milliman recently released the results of the 30th annual Northwest Technology Compensation Survey featuring updated pay data on more than 200 technology positions, objectively and confidentially compiled from 92 major Northwest Technology employers. The survey results include expanded data on salary trends, turnover, benefit costs, telecommuting, sign-on bonus, hot skills, compensation program elements, and more.

  • Salaries for tech roles have risen between 3-8% based on title and seniority
  • Two of the top six roles at technology companies/within technology organizations are for HR leaders
  • In the 25 years since the NW Tech Compensation Survey started, the entry level salary for a software engineer has gone from $35K to 76K+

To access the full survey results, click here. TAO members get a $50 discount if they use the code TAO2021.


Need an Employer Health Plan?

oregon bioscience association logo in green with gray lettering on white background

Beginning November 1, Oregon Bioscience Association members can request quotes for group health insurance with an effective date of January 1, 2022. The enhanced benefits include:

  • Multiple-Carrier Quoting – Mercer platform will shop several well-known local and national health carriers, discuss your needs and find the best plan options.
  • Low Minimum – Enrollment for as few as 2 employees.
  • Easy Online Enrollment – Paperless enrollment for you and your employees.
  • HR Administrative Portal – Helps you easily manage multiple carriers and plans.
This is part of the BIO Business Solutions program, which is a national buying program through BIO. Please contact Julie Black at Oregon Bio directly, for more information or to request a quote.

Medication Adherence Saves Medicare up to $46.6B

A recent Centers for Medicare & Medicaid Services (CMS) study found that medication use is improving among seniors and vulnerable beneficiary populations. Better adherence to medicines used to treat common chronic conditions such as high cholesterol, high blood pressure and diabetes is estimated to have saved the Medicare program between $27B and $46.6B in avoided health care costs between 2013 and 2018.


Events

Join Us For These Upcoming OBI Events

Virtual Lunch & Learn: The Three Sectors
Where Digital is Transforming Patient Care
November 17, 2021
12:00-1:00 PM
Register now!

 

 

Virtual Lunch & Learn: Utilizing Value Assessments
to Determine Clinical & Cost Effectiveness
December 1, 2021
12:00-1:00 PM
Register now!

 

Accelerate Biotech + Digital Health
Virtual Happy Hour

December 9, 2021
5:00-6:30 PM
Register now!

 

Other Great Community Events

Keiretsu Forum Investor Capital Expo
November 10-11 and 17-18, 2021
Registration details here

 

oregon bioscience association logo in green with gray lettering on white background

Biotech Summit 2021
Biomarker and the Promise of Precision Medicine
November 12, 2021
1:30-3:30 PM
Register here

 

Partners in Diversity Say Hey!~Virtual
November 16, 2021
4:30-6:30 PM
Register here

 

Health Tech Summit with white letters on blue background

Technology Association of Oregon:
Health Tech Summit
November 15-16, 2021
8:30 AM-1:00 PM
More information here

 

Futureproof logo

Oregon Entrepreneurs Network:
OEN Awards 2021 – FUTUREPROOF
November 18, 2021
5:00-8:00 PM
More information here

OBI & OTRADI October 2021 Newsletter

Hiring or Seeking? OBI has a Job Board!

clipboard with resume next to laptop computer

We’re excited to announce that OBI has launched a Job Board, and we’d love to list any open positions your respective organizations may have. Click here to post your open positions.

And, if you’re a job seeker and would like to have your resume reviewed by recruiters in the community, please upload your resume to the “submit resume” section of our job board.


OBI Client Company Wins

stacked rocks

Inherent Targeting

HTI

  • Pfizer is beta testing HTI’s CryoDiscovery ™ – A cryo-EM Automation & Intelligence Platform for Drug Discovery.
  • Nimbus Wadget, Inc signed another service agreement to start a cryo-em 3-D structure determination project.
  • HTI is looking for machine learning software developers.
  • HTI signed MSA (master service agreement) with Flare Therapeutics.
  • CryoDiscovery ™ will be presented at the 4th Annual CryoNET Symposium, October 18-19th 2021.

Izon

  • Izon had two new team members join our Portland office at OBI this month.  Henry Scheffer joined as our new Research Associate and Brennan Van Deren joined as a part time Quality Assurance Intern.

Gamma Diagnostics

  • The Department of Defense’s Peer Reviewed Medical Research Program has a Technology/Therapeutic Development Award, and invited us to submit a full proposal to develop GammaCoeur as a companion diagnostic to track COVID-19 disease severity. We submitted the grant on Sept. 2.
  • We were one of 8 semi-finalists for the Bend Venture Conference in the Impact category.

Veana Therapeutics

  • Veana was awarded a Phase I SBIR grant from the National Institutes of Health/National Cancer Institute to conduct proof-of concept studies of its lead product, VIMO in combination with the monoclonal antibody trastuzumab (an equivalent of Herceptin).
  • Veana closed a seed round with a total of  $1.25M raised.
  • Veana is pleased to report that the first patient in the Phase Ib clinical trial of the company’s oral drug, VIMO in combination with Herceptin has been dosed!

Endosound

  • Our EndoSound Vision System received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Madorra

  • Proud and excited to be a part of the inaugural class of Series P!

Caregiven

  • When you search for Caregiven in Google, our company webpage is the first result! Then below it, our blogs, news, and social. A year of steady content creation, of learning algorithms and key words and pure doggedness by Michele Houck our marketing manager to learn the right way to “rank” while honoring our commitment to only produce content that lifts up the caregiving experience.
  • We were awarded the TAO Start-Up of the Year award in the pre-revenue category.
  • Candice Smith was a guest on the Aging in Portland podcast.
  • Our Chief Revenue Officer, Anthony Mitchell and Candice had the opportunity to present at the ACORD InsurTech Innovation Challenge NY.
  • Anthony also co-hosted a webinar on The Future of Value Adds in Insurance with an insurance luminary, Jason Gross.
  • We also presented at CareTech presented by the Louisville Healthcare CEO’s Council and Aging 2.0. This was a global search for innovations that improve the patient or member experience.
  • We were awarded the second place grant from the American Heart Association’s EmPOWERED to Serve program ($30K), sponsored by the American Heart Association of Oregon & SW Washington.
  • We kicked off the first phase of our first pilot with a national palliative care provider. They will be using Caregiven to expedite the health outcomes their nurses already accomplish, and are including Caregiven as a differentiator for their company in proposals to major health systems nationally.
  • We had over a dozen calls with insurance carriers about Q1 pilots and are under NDA and working on LOIs with several.
  • And lastly, we are moving forward with our seed round and have been speaking with investors.

Congratulations to all our client companies – way to go! Keep the wins coming!


OBI Mentoring Program
Applications Now Open

Mentor and mentee applications are now open for the structured 6-month mentoring program which begins January 3, 2022 and runs through the end of June. Now is the time for YOU to get involved!

Would You Like to be a Mentor?
If you have experience working with startups in the bioscience or digital health industry, consider applying to become a mentor. Benefits of mentoring include:

  • Free mentor training
  • Exclusive access to handpicked startups
  • Exclusive network of mentors
  • Ability to earn mentor certification
  • Give back to your community
  • OBI highlights its mentors in the monthly newsletter

Growing Your Business? Become a Mentee!
We are looking for entrepreneurs who are already in business but would like guidance, accountability, and support from a mentor to help set and reach business goals. Benefits and time commitments for mentees include:

  • Mentoring helps you grow your business! A recent survey from Kabbage found that 92% of businesses who have a mentor say mentoring has directly impacted their business growth and survival
  • Mentee meets with mentor 2 hours a month for 6 months
  • Mentee checks in with OBI once per month and completes a survey at the end of the program

Applications are Open from October 1-31
For more important dates, details, and link to the applications: www.otradi.org/mentoring


Mentor of the Month:
Mike Gursha

Mike is CEO and Chairman of startup company, Rookie Road. In addition, he also currently sits on the board and/or advises a wide variety of early stage companies. Previously, Mike worked at a biotechnology startup as VP of Strategic Initiatives and Director of Business Development. Mike has also served as an advisory council member for the Whitman School of Management at Syracuse University, has been a mentor in various accelerator programs, served on the community advisory board of Oregon Public Broadcasting, and serves as an EIR for the Blackstone Launchpad at Syracuse University, where he is an alum.

Mike’s mentee has glowing things to say about him, including that Mike is a great sounding board to think through strategic decisions.

Thank you Mike, for helping the OBI entrepreneurial community through mentoring!


Take Advantage of OSU’s Fall Iterate Program

Oregon State University Advantage Accelerator lettering in black and orange, with OSU shield logo on white background

Do you have a business idea but need some help? We’re offering Iterate, a free virtual class for researchers, entrepreneurs and prospective entrepreneurs who have a business idea or technology that could become a sellable product or service but aren’t sure what to do next. Come learn how to create a value proposition, find and understand your market, and more. Iterate consists of four workshops on WEDNESDAYS that build on each other: Oct. 27, Nov. 3, Nov. 10, and Nov. 17, all from 3:00 p.m. to 4:30 p.m. Open to OSU and non-OSU members.

Learn more here. 


Business Oregon Matching Grants

Business Oregon logo

News Release from Business Oregon:

“Business Oregon and the Oregon Innovation Council (Oregon InC) have opened a Request for Proposals (RFP) for Oregon matching grants to recipients of the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant programs. This RFP seeks applications for matching grants of either Phase I, Phase II, or Fast-Track federal SBIR/STTR awards. The SBIR and STTR grant programs are designed to stimulate technological innovation and provide new opportunities for small businesses to conduct research and development with commercial potential. The RFP opened on September 8, 2021, and will close on October 14, 2021.

“An Oregon company that has received a Phase I SBIR/STTR award may submit a proposal for projects up to $50,000. A company with a Phase II or Fast-Track award may submit a proposal for projects up to $100,000. Business Oregon intends to make multiple awards under this program and will likely issue another matching grant RFP in 2022.

“A detailed overview of the RFP, selection process, application and supporting resources are on Business Oregon’s SBIR Support Program webpage. Completed applications are due by 11:59 pm PST on Thursday, October 14, 2021.”


Events

Join Us For These Upcoming OBI Events

 

typewriter with paper coming out of it with the words startup investment on the paper

Virtual Lunch & Learn:
Understanding the Investor Mindset
October 14, 2021
12:00-1:00 PM
FREE – Register here

 

black headset on yellow background with the words hello, hello in blue

November Accelerate Biotech + Digital Health
Virtual Happy Hour
November 4, 2021
5:00-6:30 PM
FREE – Register here

 

white letters save the date on green background

Virtual Lunch & Learn:
Past, Present, and Future of Digital Health
November 17, 2021
12:00-1:00 PM
Save the date!

 

Other Great Community Events

 

BendVenture conference logo with brown mountain in background2021 Bend Venture Conference
October 21-22, 2021
More information here

 

Black Women in STEM 2.0 logo

Black Women in STEM 2.0 Summit:
Making HERstory
October 22-23, 2021
More information here

 

Technology Association of Oregon logo

TAO Professional Development Program:
A Conversation About Cybersecurity Hygiene

October 27, 2021
11:00 AM-12:00 PM
Register here

 

PhRMA logo in blue and white

PhRMA Pathways to Success in Biopharma
Virtual Graduate Summit & Career Expo
October 27-28, 2021
More information here

 

group of people attending a seminar

OCTRI Seminar: Demystify the Regulatory Environment
A Roadmap for Healthcare Technologies
October 28, 2021
2:00-3:00 PM
Register here

 

OregonBio Virtual Life Science Career Fair
November 10, 2021
10:00 AM-1:00 PM
Register here

 

Health Tech Summit with white letters on blue background

Technology Association of Oregon:
Health Tech Summit
November 15-16, 2021
8:30 AM-1:00 PM
More information here

 

Futureproof logo

Oregon Entrepreneurs Network:
OEN Awards 2021 – FUTUREPROOF
November 18, 2021
5:00-8:00 PM
More information here

OBI & OTRADI September 2021 Newsletter

OBI Client Company Wins

chessboard with black king still standing

Aronora

  • Aronora reports positive topline data from their phase 2 clinical trial of recombinant antibody therapeutic AB023 in hemodialysis patients.
  • This data was presented at the XXIX Congress of the International Society on Thrombosis and Haemostasias in July.
  • See Aronora’s press release here.
  • Aronora graduated from the OBI earlier this year, after joining the incubator in 2013.

Madorra

Hemex Health

Caregiven

  • We are a finalist in Aging 2.0’s Global Innovation Search, announcement attached.
  • We are a finalist in the ACORD InsurTech Innovation Challenge.
  • We were selected to participate in the American Heart Association of OR/SW Washington’s EmPOWERED to Serve program.
  • The Caregiven team (5 employees and 3 contractors) met in-person for the first time (ever) in August for an on-site retreat that corresponded with our Q3 meeting of the Board of Directors.  Our team is fully remote with employees in North Carolina and Florida, and a contractor who lives in Arizona.  See team photo below.
  • five women and three men posing under a tree

Oncol Drug Discovery Service

  • Made substantial progress in developing optimized SOP for generating CART against targeted cancer.
    • Generated two targeted CART lines of high potency and purity (93-96% purity).
    • Will verify the performance and universality of the optimized SOP by generating another three targeted CART lines by October.

Gamma Diagnostics

  • We’ve been accepted into Expert Dojo’s International Healthcare Startup Accelerator.
    • For companies accepted into the program, Expert Dojo invests $100,000, provides an 8-week training program that trains the members of the company in all aspects of business, and introduces them to investors and mentors.

Rewire Neuro

  • Rewire was awarded our Phase II SBIR from the NIH! This two-year grant will help us develop additional cell detection capabilities and integrate our AI platform into partnering diagnostics devices and applications.

Thank You to our New Corporate Partner

logo for CBRE Ajay Malhotra and Kristin Hammond

We appreciate your support, Ajay Malhotra and Kristin Hammond!


Applications for OBI Mentoring Cohort
Opening Soon

Mentor and mentee applications open on October 1 for this structured, 6-month mentoring program, so save the date for your opportunity to get involved!

Would You Like to be a Mentor?
If you have experience working with startups in the bioscience or digital health industry, consider applying to become a mentor. Benefits of mentoring include:

  • Free mentor training
  • Exclusive access to handpicked startups
  • Exclusive network of mentors
  • Ability to earn mentor certification
  • Give back to your community
  • OBI highlights its mentors in the monthly newsletter

Growing Your Business? Become a Mentee!
We are looking for entrepreneurs who are already in business but would like guidance, accountability, and support from a mentor to help set and reach business goals. Benefits and time commitments for mentees include:

  • Mentoring helps you grow your business! A recent survey from Kabbage found that 92% of businesses who have a mentor say mentoring has directly impacted their business growth and survival
  • Mentee meets with mentor 2 hours a month for 6 months
  • Mentee checks in with OBI once per month and completes a survey at the end of the program

Applications Open October 1-31
For more important dates, details, and link to the applications: www.otradi.org/mentoring


Mentor of the Month:
Katherine Rubino

black and white photo of woman

Katherine (Katie) Rubino is one of our newest OBI Mentors. She is an Intellectual Property attorney who divides her time between the east coast and the west coast. Before becoming an IP attorney, Katie was a compounding pharmacist. She worked an an independent pharmacy creating custom medications for patients, and also in the clinical setting at Tufts Medical Center on the heart transplant team, as well as in the industry setting at Biogen. Having worked as a scientist as well as her experience in IP, Katie is an excellent addition to our mentoring team, and is receiving rave reviews from her mentees, such as this comment: “Katie is fabulous. She listens and provides actionable suggestions on the IP and strategy that aligns with (our) business objectives.”

Katie not only volunteers for the OBI Mentoring Program, she is also going to be a judge for the OHSU-OCTRI BIP Corp final pitches next month. Thank you, Katie, for all you do for our community!


OBI is Launching a Job Board

black chalkboard with white letters spelling opportunity

We’re excited to announce that OBI will be launching our Job Board in the next two weeks and we’d love to list any open positions your organization may have. This will help us pre-populate the job board when we go live. If you are interested, please email info@otradi.org requesting the link to post your open positions.

If you are a job seeker and would like to have your resume reviewed by recruiters in the community, please email info@otradi.org requesting the link to upload your resume.

Thanks for helping us make this job board a success!


Black Women in STEM 2.0 Summit:
Making HERstory

black women in STEM conference flyer
Click on the photo above to register for the Black Women in STEM 2.0 Summit, in person or virtually!

Beaverton Startup Challenge

Apply now for the OTBC, City of Beaverton, and West Side Startup Fund Beaverton Startup Challenge. Five winners each receive a $25,000 convertible note investment; introductions to legal, accounting, HR, and marketing services; OTBC’s top-rated mentoring services, entrepreneur workshops, and more! Applications are accepted through September 30.

More information and application here.


Pitch Oregon – Apply Today!

Pitch Oregon logo with red and black lettering on white background

In its 6th year, Pitch Oregon is TiE Oregon’s marquee event, attracting hundreds of entrepreneurs, mentors, and investors each year. New this year, we are welcoming companies from around the Pacific Northwest to apply and applicants will compete for an equitable investment! Application deadline September 30.

Click here for more information.


Free SBIR/STTR Training Events

The BBC Entrepreneurial Training & Consulting is offering free training events. September 14, 15, and 16 are packed full of free SBIR/STTR training sessions featuring program managers from varying granting and contracting agencies, such as NIH, DOD, NSF, and many others.

Full schedule, details, and registration here.


Take Advantage of OSU’s Fall Accelerate Program

Oregon State University Advantage Accelerator lettering in black and orange, with OSU shield logo on white background

Accelerate is a eight- to ten-week program open to community members and OSU researchers, students and staff who intend to establish a privately held, high-growth entrepreneurial venture. This stage focuses on developing a minimal viable product and engaging in customer discovery to validate your product market fit.

The regular Accelerate program runs three times a year (fall, winter, and spring). Through the scheduled program events, one-on-one sessions with the directors, meetings with mentors, and access to intern assistance on projects, startup teams will receive the support they need to get their concept into the marketplace.

The next session of Accelerate will be a condensed, remote program that meets every week for nine weeks, starting Tuesday, October 5th. Each session runs for two hours from 3pm-5pm.

The Fall 2021 Accelerate application is open now until September 24th.


Technology Association of Oregon’s Founders Investing in Founders Program

brightly colored logo for technology association of oregon

Technology Association of Oregon recently announced their Founders Investing in Founders (FIIF) program. Led by six inaugural founders, this program helps increase diversity and create economic growth by providing support to underrepresented early-stage startups for up to three years.

Learn more about this innovative program here.


PDUFA VII for Biopharma Innovation

blue and white capsules spilling out of a clear glass on a table

The U.S. Food and Drug Administration (FDA) released its performance goals letter for the seventh installment of the Prescription Drug User Fee Act (PDUFA). PDUFA was first enacted in 1992 as a bipartisan solution to the then long FDA regulatory review timelines for new drugs and biologics. PDUFA allows the FDA to collect fees from biopharmaceutical companies to speed and enhance the review process to help ensure patients have timely access to life-saving treatments.

Read more about how critical PDUFA VII is for future biopharmaceutical innovation and for patients.


Columbia Business School’s Executive Education

Join us this semester at Columbia Business School courses

Are you looking to gain a competitive edge in digital health?

Columbia Business School’s 6-day Executive Education Model in Digital Health Strategy [Sept 21-23 & 28-30] is exclusively tailored for healthcare executives like you.

A unique first, the program combines Columbia Business School’s renowned leadership with HITLAB’s expertise in digital health research and education.

As a participant, you will learn about the necessary skills and resources required to successfully find, verify and diffuse these digital health solutions – allowing you to truly embed digital health into the core of your organization.

Learn more about the Digital Health Strategy: Leveraging Emerging Technologies in Healthcare program.

Here is a snapshot of the speaker line-up consisting of industry leaders:

  • Peter Pfeiffer, Senior Partner, Mckinsey & Company
  • Stacy Lloyd, Director of Digital Health Strategy, American Medical Association
  • Robin Roberts, Cofounder, Novartis Biome
  • Shwen Gwee, VP, Bristol Myers Squibb

View the complete agenda, speaker line-up and session topics for the program here.

Ask about a special OTRADI & OBI tuition rate of $999.


Events

Join Us For These Upcoming OBI Events

Accelerate Biotech + Digital Health
Virtual Happy Hour
September 9, 2021 – TONIGHT!
5:00-6:30 PM
FREE – Register in advance here

 

two men and women at table in business meeting

Virtual Lunch & Learn:
Managing Stress & Performance
September 15, 2021
12:00-1:00 PM
FREE – Register here

 

typewriter with paper coming out of it with the words startup investment on the paper

Virtual Lunch & Learn:
Understanding the Investor Mindset
October 14, 2021
FREE – Register here

 

white letters save the date on green background

October Accelerate Biotech + Digital Health
Virtual Happy Hour
October 7, 2021
Save the date

 

Other Great Community Events

 

gray and orange vertue lab logo on white background

VertueLab Fuel 2021:
Catalyzing CleanTech Solutions Summit
September 13-15, 2021
Register here

 

oregon bioscience association logo in green with gray lettering on white background

OregonBio Mini BioPro Lunch & Learn:
Making Your Innovations Shine –
The Magic of Good Data Presentation
September 14, 2021
12:00-1:00 PM
Register here

 

2021 Oregon Technology Awards
(Our own Caregiven is a finalist in the pre-revenue category!)
September 17, 2021
5:00-9:00 PM
View the livestream here

 

Oregon State University Advantage Accelerator in black and orange lettering on white background with OSU shield logo

OSU Advantage Accelerator Speaker Series:
What a CPA Does for your Startup
September 22, 2021
12:00-1:00 PM
Register here

 

AdvaMed MedTech conference logo dark blue with white lettering and a globe symbol

The MedTech Conference,
Powered by AdvaMed
September 27-30, 2021
More information here

 

OHSU Invent-a-thon social hour logo with light bulb and dark blue lettering on a light blue background

OHSU Invent-a-thon Social Hour:
Future of Femtech
September 28, 2021
4:00-5:00 PM
Register here

 

BendVenture conference logo with brown mountain in background2021 Bend Venture Conference
October 21-22, 2021
More information here

OBI & OTRADI August 2021 Newsletter

 

Absci Goes Public!

Photo by Absci

OBI graduate Absci made its debut on the NASDAQ (ticker symbol ABSI) on Thursday, July 22, and founder Sean McClain and his team rang the closing bell. GeekWire has a great article about how Sean founded the company at age 22. Absci was an OTRADI resident client company from 2013 to 2016 – see photos below of their lab space with us. We are happy to be a part of Absci’s journey to success.

 


Thank You to our New Corporate Partner

 


OBI/OTRADI Receives High Impact Opportunity Program Award

The Oregon Innovation Council and Business Oregon have approved OBI/OTRADI for a High Impact Opportunity Project Award to support bioscience companies’ ability to stay and grow in Oregon by adding 6 wet labs and offices to our incubator facilities. Completion expected in Fall 2021. Questions about space availability? Inquire here.


OBI Client Company Wins


The OBI Welcomes Qtonics!

Qtonics LLC was formed to help companies, private research institutes and academic institutions accelerate scientific discovery. Their growing portfolio includes recombinant proteins, antibodies and immunology-based detection kits used in cancer, cell growth and other immunology-based studies. Qtonics understands the needs of the academic research laboratory through to the regulatory requirements of cGMP research and manufacturing facilities.

We are thrilled to have you join us at the OBI!


Biomedical Innovation: Commercialization Readiness Program is Open for Enrollment

The Biomedical Innovation: Commercialization Readiness Program (BIP Corp) is a 5-week course for life science innovators to advance their technology to clinical practice. We’ve made some improvements over the last year, including engaging a national NIH and NSF I-Corps instructor to lead the lectures. The course is ideal for teams, appropriate for clinical and research scientists, engineers, and life science entrepreneurs. Early-stage ideas welcome!

We’re enrolling projects for the Sept 10 – Oct 15 virtual cohort. Learn more and enroll.


Creative Destruction Lab Mentoring

Creative Destruction Lab (CDL) – Seattle Computational Health is an annual program for seed-stage startups working in the areas of digital and computational health. The program brings together world-class entrepreneurs, investors, scientists, and health professionals to mentor participating founders on prioritizing objectives to increase their probability of success. Participating startups work with CDL Mentors to prioritize key milestones, raise capital, and engage with experts working on the frontiers of research in related fields.

The program consists of four in-person objective-setting sessions held once every two months at the University of Washington’s Foster School of Business in Seattle between November 2021 and June 2022. CDL is a non-profit organization. There are no fees for participation and CDL does not take any equity or affect ownership of intellectual property. The deadline to apply for the 2021/22 cohort is August 23, 2021.

For more information: https://www.creativedestructionlab.com/locations/seattle/


COVID-19 Dose Sharing Part of Global Vaccine Equity Strategy

The ongoing COVID-19 pandemic has been met with the most efficient vaccine development process in history. Dose sharing entails working with governments that have directly purchased COVID-19 vaccine doses to contribute to the global supply through COVAX or other efficient, established distribution mechanisms. Collaboration to increase dose sharing has been one of the most immediate steps to close the vaccine coverage gap, redirecting doses to low- and middle-income countries that did not secure agreements with vaccine manufacturers earlier in the pandemic.


Oregon Health Authority: Take Care of Your Mental Health During Stressful Times

“With wildfires across Oregon, we want to acknowledge the importance of taking care of your mental health in stressful situations like these. This is especially important if you’re still recovering from last year’s wildfires. Taking care of your mental health could include making a self-care plan, getting support in your community or talking with people who care about you. For more mental health resources, visit our Safe+Strong website.”


Events

Join Us For These Upcoming OBI Events

 

Virtual Lunch & Learn:
Financial Forecasting & Accounting for
Early Stage Development Companies
August 11, 2021
12:00-1:00 PM
Register here

 

Accelerate Biotech + Digital Health
Virtual Happy Hour
September 9, 2021
5:00-6:30 PM
Register here

 

Other Great Community Events

 

Zapproved Event: Talking to Kids About Racism
August 11, 2021
12:00-1:00 PM
Register here

 

AvaMed MedInvest Life Sciences Conference
September 8-10, 2021
More information

 

2021 Oregon Technology Awards
(Caregiven is a finalist in the pre-revenue category!)
September 17, 2021
5:00-9:00 PM
Register here

OBI & OTRADI July 2021 Newsletter

Absci Files for IPO

Big news for OBI graduate Absci! Last week they filed paperwork with the SEC for an initial public offering. Absci, a biotech company whose technology enables “better, faster, smarter” biologic drug discovery and cell lines, graduated from the OBI in 2016. They’ve grown substantially over the past several years, acquiring other companies, most recently Totient, and expanding their operations and workforce. GeekWire just featured them in an article about biotech in the Pacific Northwest.

We at the OBI & OTRADI are cheering on Absci for many years of continued success and growth.


OBI Client Company Wins

  • Hemex Health
    • We’ve officially launched our newborn release! Gazelle is now able to diagnose newborns for sickle cell disease before they even leave the hospital. Check out the press release.
    • With our product design and engineering partner Tata Elxsi, the Gazelle Reader won the Social Impact Solution of the Year award at the 2021 NASSCOM Engineering & Innovation Excellence Awards in India!
    • In a recent P. vivax clinical study, Gazelle demonstrated higher sensitivity than the only FDA-approved malaria rapid diagnostic test. Press release here.
  • Izon
    • Izon has recently released two new consumables products to the market! We hope these kits will further establish Izon as an industry leader in extracellular vesicle analysis. Please see product pages below:
    • Izon is seeking a Lab Technician/Research Associate for its Portland office. Please see job description and share with interested applicants.
  • Gamma Diagnostics
    • We have a new name – Gamma Therapeutics is now Gamma Diagnostics!
    • David Eastman retired as CEO, we hired Ajay Nair from Perth, Australia as our new CEO, and he hired Chris Venter, also from Perth, as our Chief Finance Officer.
    • We also discovered that our GammaCoeur diagnostic blood test for cardiovascular disease is extremely elevated in COVID-19 patients and predicts the need for hospitalized patients to need extracorporeal membrane oxygenation (ECMO) in order not to suffocate, and it predicts death from COVID-19. We now have a provisional patent on this I.P. that also protects the use of the test as a companion diagnostic for the administration of dexamethasone in COVID-19 patients.
  • Rewire Neuro
    • Rewire secured additional investment from Angel Oregon Tech, and received funding from Elevate Capital’s Oregon Gap Fund. We are excited to have these investors supporting Rewire’s growth and are thankful for Business Oregon and Oregon InC’s funding of early-stage Oregon startups.
  • Caregiven
  • CytoImage
    • Founder Tania Vu presented at the international Innovation Stage at BIO Digital 2021.
  • Inherent Targeting
  • SUTUREGARD
    • We were named a Top 10 Innovation by Podiatry Today, a leading trade journal. This is unsolicited, unlike some trade publication lists which are paid for. We are at the end of the article; they saved the best for last!
    • The Veteran’s Administration is now ordering HEMIGARD. Our Veteran population has a high incidence of wound problems and we will be making a big impact here, reducing wound complications and improving limb salvage efforts. The HEMIGARD is a great tool to not only speed the surgical closure, reduce the need for additional deep sutures, but also to support the healing through the difficult postoperative period when the foot may swell and the wound may open (dehisce).  We are excited to improve outcomes for our veterans!

Meet our Administrative Assistant,
Sarah Vivian

Sarah joined OTRADI in July of 2021. She is a seasoned office specialist with over a decade of administrative experience. In her role, Sarah helps facilitate the everyday administrativia of the office and is the point person for OBI client companies.

Having a background as a technical writer and a passion for nonprofit and social justice work, Sarah served as a committee head and then Board Director of Communications for Pride Northwest, the nonprofit organization that plans and implements the Portland LGBTQ+ Pride Festival and Parade, until 2017.

In her personal time, Sarah is an avid crafter, permaculture gardener, home cook, and true crime fanatic. We are thrilled to have her on the OBI team!


ScienceDocs Interview with
Inherent Targeting’s Connor Barth

Inherent Targeting co-founder and CEO Connor Barth, PhD recently sat down with Claire Sykes for an enjoyable ScienceDocs interview after winning a $2.25 million SBIR grant for their fluorescence-guided nerve detection technology. Watch the 30-minute video and read the transcript here.


Summer-Fall Mentoring Kicks Off

July 1 was the start date for the Summer-Fall 2021 cohort of the OBI Mentoring Program. This 6-month cohort includes mentors and mentees listed below; some are new pairings and triples, and some returning pairings. We are pleased to welcome these participants and wish them much success in making progress toward their goals.

Participating Mentors:

Christa Nicholas

John Tortorici

Katie Rubino

Mel Ellis

Michael Phillips

Mike Gursha

Nathan Lillegard

Sheila Ramerman

Tanya Leavy

Pete Murray

Keith Daellenbach

Shannon Heizenrader

Participating Mentees:

Mary Phillips – Thaena

Carlos de la Huerga – Curazel

Sydney Quinton-Cox – Tonsil Tech

Marina Wolf – Eleutheria Therapeutics

Amanda Brockman – Tryl

Nathan Khosla – Validly

Nicole Tjota – CommuNutri

Thomas Buchanan – Buchanan Science

Franklin Yu – Oncol Drug Discovery

Jeremy Hammer – High Peak Medical Systems

The Lazarus 3D team

Heber Michaels – Kamino Care

We will have a new cohort of mentors and mentees in January, 2022. Keep an eye on the mentoring page on our website and newsletter for more information in the fall on how you can participate in our mentoring program.


Kamino App Has Launched

TeleHeath and wellness company, Kamino Care provides nutrition and health coaching for Latin X clients via video appointment. Bilingual providers assist families and caregivers with the latest nutrition and fitness advice, from a preventative mindset, all from the comfort of home.

Their story begins when a young boy named Heber is asked to translate from English to Spanish for his mother once she was diagnosed with Type-2 Diabetes. She was advised to eat whole grains, whole foods, potatoes, and tofu. Due to cultural differences, the provider failed to recognize the family’s pantry was filled with arroz, frijoles, and tortillas. Kamino Care helps people like Heber’s mom get the health and wellness they need with a provider who understands both their culture and language.

As a young boy, Nick watched his father’s diabetes worsen due to improper nutrition and fitness management, ultimately leading to a stroke and heart attack. He has made it one of his life’s goals to stay fit, healthy and informed on how to best prevent diabetes as much as possible. Kamino Care was an obvious choice for Nick to provide families the tools they need to hopefully avoid the tragedies of Diabetes.

Kamino Care’s mobile appointment app, Kamino, is available for both iOS and Android devices and offers a free 30 minutes appointment with a Nutrition or Fitness provider.


EmPOWERED to Serve
Business Accelerator™

The American Heart Association’s EmPOWERED to Serve Business Accelerator for Oregon and SW Washington empowers and invests in women entrepreneurs, startups and businesses that foster equitable access to good health for all. The national program provides participants tools and support to grow and scale, including business training, grants and a lasting connection to the association.

APPLY JUNE 1 THROUGH JULY 16 for your chance to receive up to $75,000 in grant funding! If you need assistance with the application process, please email Hannah.Frey@heart.org.


OTBC is Hiring an Executive Director

OTBC‘s long-serving Executive Director is preparing to retire, and we are looking for the next leader for this small but ambitious not-for-profit. The Executive Director is responsible for the management of the OTBC facility, staff and programs and for performing diverse tasks ranging from mentoring of entrepreneurs to office operations. This position is full-time and reports to the OTBC Board of Directors.

The position is full-time, based in Beaverton, and offers a wide range of exposure to the Oregon entrepreneurial and funding communities. Highlights of the position include:

  • Develop and oversee OTBC entrepreneur support programs including entrepreneur mentoring, workshops, the Beaverton Startup Challenge, the Rural Oregon
  • Startup Challenge which includes the Virtual Incubation Program, and future programs of the organization.
  • Offer superior startup business coaching to participating entrepreneurs
  • Create the OTBC annual operational plan and execute the plan after approval by the Board
  • Oversee OTBC marketing and outreach programs, including social media marketing
  • Raise funds for OTBC operations
  • Represent OTBC and its client businesses to the community, to investors, and to partner agencies and funding organizations

Apply no later than August 1, 2021. More information here.


How Does the U.S. Patent Process Work?

Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents encouraged the R&D that led to these innovations. Patents are a form of intellectual property protection that give inventors the exclusive right to make, use, sell, offer for sale or import their inventions for a set period of time. Patients are well-served by having more inventions protected by intellectual property – it means more competition so more access to medicines in the long run – and these protections are an investment in the system that fosters innovation. For more information on the patent process, read this blog post and please attend our July 14 Virtual Lunch and Learn.


Events

Join Us For These Upcoming OBI Events

Virtual Lunch & Learn:
Biotech and Biomed Patents by USPTO

July 14, 2021
12:00-1:30 PM
Register here

 

Virtual Lunch & Learn:
Accelerating Global Pharma Licensing & Financing

July 27, 2021
12:00-1:00 PM
Register here

 

Virtual Lunch & Learn:
Financial Forecasting & Accounting for
Early Stage Development Companies
August 11, 2021
12:00-1:00 PM
Register here

 

Other Great Community Events

 

TAO Leader Launchpad: Career Mapping
July 15, 2021
4:00-5:30 PM
More information

 

ULP: International Clinical Trial Negotiation and Management
July 28, 2021
9:00-10:00 AM
Register here

 

Zapproved Event: Talking to Kids About Racism
August 11, 2021
12:00-1:00 PM
Register here

OBI & OTRADI June 2021 Newsletter

John Harkness, PhD, Founder & CEO of Rewire Neuro

Rewire Neuro Wins Angel Oregon Tech 2021!

Big congratulations to OBI client company Rewire Neuro for winning Angel Oregon Tech 2021 and receiving a $125,000 equity investment from AOTech investors. Out of 90 companies who went through the program, nine were selected to pitch at the final AOTech at TechFestNW event on May 21, and Rewire Neuro was the judges’ top pick. Kudos!


OBI Client Company Wins

  • Inherent Targeting
    • Presented at the Angel Capital Association Summit Innovation Showcase, sponsored by the Oregon Bioscience Association.
    • CEO Connor Barth was awarded OHSU’s Early Career Innovator Award. The Early Career Innovator Award is presented to an OHSU employee such as a student, post-doctoral fellow, medical resident or someone else early in their professional career who possesses a passion for innovation and developing technologies to solve real-world problems. They work closely with the innovation ecosystems within and outside of OHSU to prepare their innovations for commercial success.
    • Selected to present a company presentation at the BIO Digital 2021 conference.
  • Hemex Health
    • Selected as a 2021 TiE50 winner as part of the TiECon program for our Gazelle reader diagnostic device! Press release here.
  • Vir Biotechnology
    • Just received EUA for Vir’s Covid antibody. Please read their press release.
  • HTI
    • CryoDiscovery (TM): A Machine Learning Platform for Automated Cryo-electron Microscopy 2D Class Selection paper will be presented at the ACA (American Crystallographic Association) conference in Aug 2021.
    • Is now a member of the Nvidia Inception and Intel AI Builder program.
    • Recently signed a Master Service Agreement (MSA) with Agios.

Welcome New OBI Client Companies

Founder Thomas Buchanan, MD and his company, Buchanan Science, joined the OBI in May. Buchanan Science is developing a rapid COVID-19 immunity test using whole blood or saliva. 

In June, we welcomed Oncol Drug Discovery Service, with founder Franklin Yu, PhD. Oncol DD Service is focused on CAR-T immunotherapy research and reagent development, CAR-T cell generation, and T cell activation and proliferation assays for IO drug discovery, among other things.


Mentor of the Month:
Keith Daellenbach

Keith Daellenbach is one of our current OBI mentors. He has a BSME from Oregon State University and a MSME from Rensselaer Polytechnic Institute. Keith’s experience with startups includes working with startups as part of Principles of Entrepreneurship course while in graduate school, working at the startup Ora Innovations, Inc. developing a high speed dental drill as a Product Development Engineer, serving on the BioPro Workforce Training Steering Committee with Oregon Bioscience Association to create a workforce training program, and serving as an Advisor with the OBI/OTRADI.

Keith is enjoying monthly meetings with his mentees to help them reach their goals, and plans to participate once again in next January’s mentoring cohort. Thank you, Keith, for all you do!


Sparrow Pharmaceuticals

OBI graduate Sparrow Pharmaceuticals recently secured $50 million in Series A financing led by OrbiMed with participation from RiverVest Venture Partners and U.S. Venture Partners.

Funds from this investment will be used to further develop Sparrow’s proprietary HSD-1 inhibitor, SPI-62, for treatment of disorders of corticosteroid excess.

Congratulations to Sparrow Pharmaceuticals!


FDA Office of Minority Health and Health Equity

The FDA’s Office of Minority Health and Health Equity (OMHHE) was established in 2010 with the mission of protecting and promoting the health of racial and ethnic minority and other diverse populations through research, outreach, and communication of science that addresses health disparities. The office’s dedicated staff in the Research and Collaboration and Outreach and Communication programs work with a wide variety of public and private stakeholders to address the needs and concerns of diverse communities through developing tailored educational, outreach, training, and scientific initiatives that advance health equity. Please read Richardae Araojo, Pharm.D., MS, the Associate Commissioner for Minority Health Director, Office of Minority Health and Health Equity, U.S. Food and Drug Administration’s guest post on The Catalyst. 


Events

Join Us For These Upcoming OBI Events

Virtual Lunch & Learn:
Accelerating Global Pharma Licensing & Financing

June 22, 2021
12:00-1:00 PM
Register here

 

Accelerate Biotech + Digital Health
Virtual Happy Hour

July 8, 2021
5:00-6:30 PM
Save the date

 

Virtual Lunch & Learn:
Biotech and Biomed Patents by USPTO

July 14, 2021
12:00-1:30 PM
Save the date

 

More Community & Partner Events

 

BIO Digital International Convention
June 10-11 & 14-18, 2021
More information here

 

TAO Member Mix: June
June 16, 2021
4:30-5:30 PM
Register here

 

Techlandia Summit ’21
June 21 through June 24, 2021
9:00 AM-12:00 PM
Register now

 

Invent-a-Thon Social Hour – FemTech,
Featuring Holly Rockweiler from Madorra
July 13, 2021
4:00-5:00 PM
Register here

OBI & OTRADI May 2021 Newsletter

OBI Client Company Wins

  • Hemex
  • Caregiven
    • Our big news is that we launched our app on April 15th!
    • And we closed our pre-seed with a total of $700K raised.
    • We are also a 2021 Oregon Technology Awards finalist!
  • SUTUREGARD Medical
    • We shipped the most HEMIGARD ever in Q1 2021
    • We have teamed with one of the leading foot and ankle surgeons in the world, Dr Mark Myerson. He has now enrolled 8 colleagues across the country and is initiating a clinical trial of HEMIGARD in ankle replacement/fusion surgery.
    • We just attended the Chicago Lower Extremity Surgery Symposium in April as invited speakers, and we had the HEMIGARD successfully demo’ed on live video by the Symposium Chairman, Dr. Edgardo Rodriguez-Collazo.
  • Gamma Therapeutics
    • David Eastman has retired as CEO of Gamma Therapeutics, and Ajay Nair has signed on as CEO.
    • We are re-branding Gamma Therapeutics to Gamma Diagnostics, since our focus going forward will be on diagnostics.
  • Rewire Neuro
  • Madorra
  • Izon
    • Grazia Abou Ezzi, Ph.D has joined Izon Science at OBI as our Senior R&D Support Scientist.
  • Consano
    • We had our first Consano Speaker Series virtual event featuring one of our crowdfunding researchers from Dana-Farber Cancer Institute on 4/15 utilizing local tech platform Brandlive. It was a great success, raising over $10K for the project which is working to increase health equity for cancer patients by connecting them directly with community resources. Watch recording of the 45 minute event here.
  • OBI graduate AbSci announces completion of $125 million crossover financing to advance AI-powered synthetic biology drug creation platform. Read press release.

Mentor of the Month:
Peter Schuerman

Peter Schuerman is CEO of Open Clearing, LLC and is one of our valuable mentors. With a PhD in Genetics, and experience in ideation, business strategy, and intentional networking, Peter works with start ups in the role of coach, mentor, and advisor. He focuses on customer discovery, team formation and dynamics, business model innovation, and strategy; he enjoys creating environments and partnerships that foster success.

Each month, Peter’s mentee through the OBI Mentoring Program has glowing comments about working with Peter and his help in setting goals and concrete steps, brainstorming, and pivoting when needed.

Thank you Peter, for all you do!


SBIR/STTR Workshop May 25

The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early-stage companies. On May 25 from 10-11:30 a.m., NIH National Cancer Institute SBIR program directors Monique Pond and Jonathan Franca-Koh will deliver a virtual seminar covering eligibility, resources, and investor initiatives. Pre-selected companies will also be speaking with the program directors afterward for 1:1 meetings.

This event is a collaboration between the National Cancer Institute, Oregon Bioscience Incubator, OHSU’s Cancer Early Detection Advanced Research Center, and Oregon Clinical and Translational Research Institute.


Caregiven is Hosting an App Jam Focus Group
June 10 from 5:30-6:30 p.m.

Register in advance to enjoy delicious provisions and participate in Caregiven‘s App Jam!


Portland State Business Accelerator
is Hiring a Director

The Director will oversee and execute a suite of support services for resident companies, including workshops, boot camps, mentors, software tools and programs, and shared resource management. The Director will create and execute the operational plans for the PSBA and contribute to strategic direction for Propel PSU within Research and Graduate Studies, and be accountable for achievement of short-term operational objectives at the PSBA. The tasks for the position require interpretation and application of the PSBA’s strategy to set objectives, and ultimately impacts the achievement of results within the PSBA and Propel PSU. The position includes coordination of the PSBA’s wet-lab facilities, managing the PSBA budget, and seeking additional resources for the PBSA through sponsorships and grant applications.

For more information and how to apply, see the full job posting.


Americans are Relying on Vaccines
to get through the Pandemic

Data shows Americans are relying on vaccines to get us through the pandemic. As we continue to combat the pandemic, America’s biopharmaceutical industry is working around the clock in unprecedented partnerships to manufacture COVID-19 vaccines, reaching billions of doses by the end of the year. Vaccination rates and willingness to receive a vaccine among Americans are also at a high, where half of all adults in the U.S. have received at least one dose of the COVID-19 vaccine.


New Pre-Seed Venture Fund:
Startup Haven

Silicon Florist recently blogged about a new venture fund: the Startup Haven Ventures Fund is a new pre-seed venture fund, investing in North-America-based pre-seed companies with capital-efficient business models and early signs of commercialization. The Startup Haven Ventures Fund also invests in all of the companies who participate in the Startup Haven Accelerator.

Read more about this new fund and how you might get involved here.


Events

OBI EVENTS

SBIR/STTR Workshop
May 25, 2021
10:00-11:30 AM
Register here

 

Virtual Lunch & Learn:
Employees Returning to the Workplace

June 9, 2021
12:00-1:00 PM
Save the date

 

Caregiven App Jam Focus Group
June 10, 2021
5:30-6:30 PM
Register in advance

 

MORE COMMUNITY & PARTNER EVENTS

VertueLab: The ABCs of SBIR/STTR Funding
May 13, 2021
12:00-1:00 PM
Register now

 

TAO: Oregon STEM Week
May 14, 2021
9:00-10:00 AM
Register here

 

Oregon Bio Virtual Career Fair
May 20, 2021
9:00 AM-1:00 PM
More information here

 

Angel Oregon Tech TechFest NW
May 21, 2021
9:00 AM-4:30 PM
Tickets here

 

Tech Oregon Careers: Spring Job Fair
May 24, 2021
11:30 AM-1:00 PM
Details here

OBI & OTRADI April 2021 Newsletter

 

The OBI Welcomes Thaena, Inc.

In April, Thaena, Inc. joined the OBI as its newest client company. Thaena’s four-person team describes their company’s mission and vision:

“Thaena Inc. is a women-led early stage biotech company. Our mission is to reduce suffering by restoring balance to the microbial ecosystems.

“At Thaena we achieve our mission through research and development of all natural pre and postbiotic products derived containing hundreds of compounds and metabolites that work together to balance and restore native microbial ecosystems. Our main focus is to produce and manufacture effective, safe, and reproducible (cGMP) products that are scientifically proven to support health via the microbial ecosystems of the gut and/or skin.

“Thaena’s vision is to be the leading and trusted manufacturer and supplier of naturally derived pre and postbiotic active ingredient products. We are working towards this goal with a data-driven approach researching the molecules (postbiotics) that are found in healthy human stool. This work is based on the pioneering work of our founders in Fecal Microbiota Transplant as well as an experienced research team. We are pioneers in advancing our understanding of microbiome science by providing a research and development platform that will allow for exploration and discovery of what it means to be ‘healthy’ from the lens of the microbes.”

We are thrilled to have Thaena onboard!


Thank you, Autodesk!

Thank you, Autodesk and Greg Fallon, VP of Platforms and Technology at Autodesk’s Portland site, for becoming an OBI corporate partner and for your support of OBI’s mission to provide resources for health innovation companies that impact human well-being and create jobs for Oregon!


Upward Growth

Two of OBI’s client companies are moving on up! Inherent Targeting is moving from an OBI membership to a spot in our co-working space in Suite 200, and Izon is moving from the co-working space to private office suite and lab space, also in Suite 200. We wish them much success on their continued growth and expansion within the OBI.


OBI Client Company Wins

  • Rewire Neuro‘s Pipsqueak AI version 5.5.0 has been released. It features new detection models, smoother model customization, and better co-localization analysis.
  • Health Technology Innovations, Inc. (HTI)‘s CryoDiscovery™: A Machine Learning Platform for Automated Cryo-EM Class Selection for Single Particle Analysis in Structural Biology paper has been accepted by the Microscopy and Microanalysis 2021 conference (M&M), to be presented in August 2021. HTI has also been accepted as a Premier Member into the NVIDIA Inception Program for AI and data science start up.
  • Caregiven crossed another threshold earlier this month when Rogue Venture Partners finalized their pre-seed investment becoming a true partner to our vision and catalyst for the next stage of our company’s growth. Our app is set to launch on April 15.
  • Hemex has two great wins to report:
    • In a recent clinical study conducted in Brazil and published in the Malaria Journal, Gazelle was shown to outperform current RDTs (Rapid Diagnostic Tests) in detection of P. vivax malaria. P. vivax, the most widely dispersed species of malaria, tends to be more difficult to detect with RDTs due to typically low levels of parasitemia. We are excited to share the results of the study with you in our press release.
    • We also won a Phase I grant to add multispectral imaging to our Hb Variant test to lower the limit of detection and allow the test to screen newborns for sickle cell and other hemoglobin variants.

Join the OBI Mentoring Program:
Applications Open Through April 30

Mentor and mentee applications are open until April 30 for this structured, 6-month mentoring program, so now is your opportunity to get involved!

Would You Like to be a Mentor?
If you have experience working with startups in the bioscience or digital health industry, consider applying to become a mentor. Benefits of mentoring include:

  • Free mentor training
  • Exclusive access to handpicked startups
  • Exclusive network of mentors
  • Ability to earn mentor certification
  • Give back to your community
  • OBI highlights its mentors in the monthly newsletter

Growing Your Business? Become a Mentee!
We are looking for entrepreneurs who are already in business but would like guidance, accountability, and support from a mentor to help set and reach business goals. Benefits and time commitments for mentees include:

  • Mentoring helps you grow your business! A recent survey from Kabbage found that 92% of businesses who have a mentor say mentoring has directly impacted their business growth and survival
  • Mentee meets with mentor 2 hours a month for 6 months
  • Mentee checks in with OBI once per month and completes a survey at the end of the program

Apply by April 30
For more important dates, details, and link to the applications: www.otradi.org/mentoring


Mentor of the Month
Douglas Kawahara

Douglas Kawahara is the President & CEO of Elex Biotech and has over 25 years of biotechnology industry experience in business development, M&A, in-/out-licensing, technology assessment, strategic marketing/market analysis, patent portfolio management, and R&D management. His work has spanned the spectrum of the life sciences industry: multiple therapeutic areas, discovery to late-stage development, a range of therapeutic classes, therapeutic and preventive vaccines, platform technologies, diagnostics, and research products. In addition, he has an extensive international network in pharma, biotech, and venture capital communities.

Dr. Kawahara holds a bachelor’s degree in biology from the University of California, San Diego, an MBA in finance from California State University, Long Beach, and a Ph.D. in microbiology (immunology) from the University of Rochester School of Medicine and Dentistry.

His mentee is very pleased with the mentoring and notes that Dr. Kawahara’s experience in negotiating licensing agreements has been extremely helpful.


OHSU Invent-a-thon Post-Hack

Wednesday, April 21 from 3:00-6:00 PM Pacific

Come cheer on the most promising teams from October’s Invent-a-thon, addressing topics ranging from Alzheimer’s to asthma, aging-in-place to efficient trial recruiting. They’ll pitch live to compete for a share of $40k in prizes plus in-kind investor support. Get inspired by brief keynotes from OBI client company Hemex Health, as well as Kiddo and Xploro. Then enjoy some genuinely fun virtual networking and poster session with healthcare entrepreneurs, investors, and researchers while the judges deliberate.

This is an exciting opportunity to connect and catch a glimpse of the future of digital health and med-tech first-hand. Free, learn more and register at inventathon.org


SBIR/STTR Workshop May 25

The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early-stage companies. On May 25, NIH National Cancer Institute SBIR program directors Monique Pond and Jonathan Franca-Koh will cover eligibility, resources, investor initiatives and meet 1:1 with pre-selected companies.

  • 10-11:30 a.m. virtual seminar
  • 11:30 a.m.-3 p.m. 1:1 meetings
  • Register by May 7 to be considered for a 1:1 meeting

This event is a collaboration between the National Cancer Institute, Oregon Bioscience Incubator, OHSU’s Cancer Early Detection Advanced Research Center, and Oregon Clinical and Translational Research Institute.


Biopharma Collaboration is Crucial

As we mark a full year since COVID-19 was declared a global pandemic, it’s impossible to overstate the significance of collaborations. The coronavirus outbreak has brought new attention to the importance of these innovative cross-stakeholder partnerships. A new report from PhRMA looks broadly at the collaborative ecosystem and illustrates biopharmaceutical industry’s long history and vast experience with a diverse breadth of collaborative efforts.


OHSU Research Week 2021

On May 6, learn more about research and innovation at OHSU, hosted by Technology Transfer and Collaborations & Entrepreneurship.

Agenda:

10-11am: Innovation and Commercialization Keynote

11:30am-12:30pm: A Researcher’s Guide to Partnering with Industry

1:00-2:00pm: OHSU Innovation Showcase

2:30-3:30pm: OHSU Startup Company Showcase

More details and registration here!


Events

OBI EVENTS

Virtual Lunch & Learn:
Funding Your Early Stage Bioscience Business

April 22, 2021
12:00-1:00 PM
Register here

 

Accelerate Biotech + Digital Health
Virtual Happy Hour
May 6, 2021
5:00-6:30 PM
Register in advance

 

Virtual Lunch & Learn:
Counterfeit Medicines & Drug Importation’s
Impact on Bioscience Innovation

May 11, 2021
12:00-1:00 PM
More information

 

MORE COMMUNITY & PARTNER EVENTS

TAO Event: Founders Talk Fundraising
April 15, 2021
11:00 AM-12:00 PM
Registration link

 

Zapproved Event: Colonialism in the Workplace
April 15, 2021
12:00-1:00 PM
Register here

 

PSBA Lunch & Learn:
Difficult Conversations and Working Through Tensions
April 27, 2021
12:00-1:00 PM
Register now

 

TAO Event: Resilience Shapes Reputation
April 28, 2021
11:00 AM-12:00 PM
Registration link

 

VertueLab and Women in Science PDX Event:
Badass Women Entrepreneurs
April 29, 2021
12:00-1:30 PM
Register now

OBI & OTRADI March 2021 Newsletter

Congratulations to Aronora on their Graduation from OBI!

Aronora is graduating from the OBI March 31, 2021, after joining the incubator in March 2013. Oregon‐based Aronora is a privately held, early clinical stage translational biopharmaceutical company engaged in the discovery, and commercial development of proprietary biological therapeutics.

Upon graduation, Aronora will relocate their lab and office from OTRADI’s incubator in the Willamette Wharf building, to a brand-new high rise downtown where they will have double the office space, a private wet lab, and conference room. In February, 2021, the Portland Business Journal listed Aronora 31st on their list of the top 37 largest bioscience and health technology companies in Oregon and SW Washington.


OBI Client Company Wins

  • Health Technology Innovations, Inc. (HTI) announced:
    • Dr. Craig Yoshioka is joining HTI as Senior Advisor for Cryo-EM. Read their press release for background information on Dr. Yoshioka and HTI’s innovative Cryo-EM technology.
    • HTI’s CryoDiscovery™: A Machine Learning Platform for Automated cryo-EM Class Selection poster was selected by One World Cryo-EM conference on March 10-11.
  • Promedix had abstracts from their clinical trials selected from a national pool of applications for presentation at both the Society of Academic Emergency Medicine and Pediatric Academic Society national meetings this spring.
  • Inherent Targeting has some big wins to report:
    • They were awarded a fast-track SBIR grant from the NCI at the NIH worth a total of $2.25M to complete lead selection and preclinical testing for investigational new drug approval of their nerve-specific fluorescence guided surgery contrast agents.
    • They were awarded a SBIR matching grant from Business Oregon worth $82k to cover IP and business development expenses.
  • Caregiven is participating in Australian CareFactor Pitch Day 2021 on March 22, part of the Information Technology Across Care virtual summit.
  • Hemex reports: “On Saturday, Feb 27, Ruaraka Neema hospital in Nairobi held a public screening event for families to bring their kids in for sickle cell screening using Gazelle. The team was able to run most of the samples they collected on one day, the rest on the following Monday morning. Running almost 50 samples in one day is what Gazelle was designed to do, and we’re so proud to see this helping the kids who need it most now.”
  • The Portland Business Journal listed the largest bioscience and health tech companies in Oregon and SW Washington. Five OBI client companies made the list:

Mentor of the Month:
Shannon Heizenrader

Shannon Heizenrader joined the OBI Mentoring Program as a Mentor in January, 2021. Shannon has a BA in Communications from Pacific Lutheran University and an MBA from Concordia University in Portland. She brings her experience in project management, as well as marketing and communications, to the mentoring relationship. Her consistency, reliability, patience, and love of learning has been a positive experience for her Mentee, who says her depth of knowledge is amazing and really helpful.

Thank you, Shannon, for being a part of the OBI Mentoring Program!


OTBC Virtual Incubation Program

Date change! OTBC‘s Virtual Incubation Program (VIP) for rural-Oregon entrepreneurs starts its next 8 week series on April 1, 2021. VIP is for early-stage entrepreneurs who need information and advice on how to test, develop and fund their idea so they can take it from concept to the launch of a successful company. The VIP is entrepreneur education and group mentoring in an 8-week program that walks you through the process of testing your idea, starting and funding a company.  Learn more about VIP and register here.


OHSU Invent-a-thon Post-Hack

Come see the future of digital health and med-tech first hand on Wednesday, April 21 from 3-6 PM. Watch the top teams from the last fall’s OHSU Invent-a-thon make their pitch for $40,000 in funding and in-kind investor support. Network with other healthcare innovation enthusiasts in the field while the judges deliberate, and celebrate the winners. Attendance is free and open to all. Register now!


Announcing Angel Oregon Tech at TechFestNW

Angel Oregon Tech offers an integrated program of education on growing and financing your tech startup, peer-to-peer and investor networking, as well as the opportunity to pitch for a direct angel investment of ~$125K.

Virtual workshops will run on Thursday mornings from 9-11 AM from March 11 through April 1, 2021. Each session will feature active local investors, entrepreneurs and experts, and offer plenty of time for Q&A and community-building.

Investment-ready startups can also pitch for investment from a pool of PNW angel investors. Ten finalists will be selected to pitch at the AOTech Finale at TechFestNW on May 21, 2021.

Learn more at www.oen.org.


ScienceTalk ’21 Conference

The challenges of 2020 have shown more than ever how important science communication is to the functioning of society. But, beyond that, it has highlighted our resilience as communicators, and the passion that we share to educate, inform, and entertain. March 24-26, 2021, connect with your community of professional science communicators at SCIENCE TALK ’21 over three days of workshops, panel discussions, presentations, and networking opportunities. Learn, explore, and share with other Science Talkers!


Stanford Drug Discovery Symposium 2021

Stanford Drug Discovery Symposium, founded by Dr. Sanjay Malhotra from OHSU Center for Experimental Therapeutics, has become one of the highest attended events at Stanford. Every year the SDDS has the participation of leaders in the field of biomedical sciences. The speakers in this year’s symposium will include two Nobel Laureates, scientific leaders from NIH, FDA, big pharmaceutical industries and Venture Capitalist groups.

Register here for the April 19-20, 2021 symposium, free of charge.


Biopharmaceutical Industry Leads the Way in Developing Vaccines and Treatments for COVID-19

One year after identifying the novel coronavirus that causes COVID-19, biopharmaceutical researchers have made tremendous progress toward developing safe and effective vaccines. Check out the latest on manufacturing, clinical trials and more.

Strong and reliable IP protections – including patents – have supported America’s robust innovation ecosystem by promoting discovery, development, affordability and access to new treatments and cures. As our industry continues to expand vaccine production and deliver medicines to patients in need, reliable IP protections have been critical in supporting multiple research and development and manufacturing ramp-ups on COVID-19 vaccines and therapeutics. Read why intellectual property protections are vital to research.


Events

OBI EVENTS

Virtual Lunch & Learn: Licensing and Technology Transfer
March 18, 2021
12:00-1:00 PM
Registration Link

 

Virtual Lunch & Learn: From the Lab to the State House
Building Trust in Bioscience
March 30, 2021
12:00-1:00 PM
Register Here

 

Accelerate Biotech + Digital Health PDX
Virtual Happy Hour

April 1, 2021
5:00-6:30 PM
Registration Page

 

MORE COMMUNITY & PARTNER EVENTS

TiE Oregon: Entrepreneurship and the Economy
March 16, 2021
12:00-1:00 PM
Register Here

 

TAO Coffee & Connection: Share Your Skills With Students
March 18, 2021
11:00 AM-12:00 PM
Registration Page

 

PSBA Lunch & Learn: Early Stage Marketing
March 24, 2021
12:00-1:00 PM
Registration Link

OBI & OTRADI February 2021 Newsletter

OBI Client Company Wins

Congratulations on your hard work!


AbSci Collaborates with Xyphos Biosciences

OBI graduate company AbSci has announced an exciting partnership with Xyphos, Inc., a wholly owned subsidiary of Astellas. This collaboration will utilize AbSci’s trademarked Protein Printing technology in the development of Xyphos Biosciences’ cell line, essential for Xyphos’ immuno-oncology program. AbSci specializes in next generation biologics built on complex protein scaffolds. For more information, see full press release here.


BIP Corp Program Begins March 5

Moving your idea or technology beyond the lab or clinic can be challenging. BIP Corp is a five-week experiential course designed to help you and your team assess and validate your biomedical technology. You’ll gain the basic knowledge and tools to initiate innovation and commercialization of your technology, and a competitive business case to secure funding, partnerships and further research opportunities.

Oregon Clinical & Translational Research Institute‘s BIP Corp runs March 5 – April 9, is entirely virtual, and offered at no-cost. Click here for more information and registration.


Mentor of the Month:
Pete Murray

Pete Murray began mentoring in the OBI Mentoring Program last month. He and his mentee have already begun making progress in the mentee’s company goals. Pete has a BS in Mechanical Engineering from University of California Santa Barbara, and MS in Engineering from Boston University, and an MBA also from Boston University. Pete founded Skender Manufacturing in 2018 as President and COO. He is part of Murray Consultants, advising several early stage/start up companies in the Portland area and Western US. Pete’s focus is in commercialization and scaling of products/services/organizational development.

Thank you, Pete, for all you do for our community!


New Data Show Retail Medicine Prices Fell in 2019

In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE) data from the Centers for Medicare & Medicaid Services (CMS) published recently in Health Affairs. While retail prescription medicine spending grew 5.7% that same year, this increase was due to more patients getting the medicines they need, not higher prices. More information here.


Oregon Bio Professional Development

Did you know that Oregon Bioscience Association has several BioPro professional development courses? The Project Management: Foundations and Best Practices online course introduces students to the foundations of successful project management, especially in a technology environment. Students will learn key project management concepts, then immediately apply them in a hands-on team simulation. This course approaches project management from the standpoint of managing a single, stand-alone project that is small to medium in size. It takes students through the project life cycle in the same sequence they would face when managing a real project in the workplace.

Upcoming training dates are February 15, 16, 22, and 23 – four half-days – from 8:00 AM-12:30 PM each day. For more details and registration, as well as information about their other BioPro offerings, see their course page.


OTBC Virtual Incubation Program

OTBC‘s Virtual Incubation Program (VIP) for rural-Oregon entrepreneurs starts its next 8 week series in February. VIP is for early-stage entrepreneurs who need information and advice on how to test, develop and fund their idea so they can take it from concept to the launch of a successful company. The VIP is entrepreneur education and group mentoring in an 8-week program that walks you through the process of testing your idea, starting and funding a company.  Learn more about VIP and register here.


Ensuring Vaccine Safety and Distribution

Less than a year after identifying the novel coronavirus that causes COVID-19, biopharmaceutical researchers have made tremendous progress toward developing safe and effective vaccines. As we enter the next phase of our fight against COVID-19, ensuring sufficient manufacturing capacity, maintaining our commitment to safety, and supporting the effective, equitable distribution of treatments and vaccines is paramount to continued success. Link to full article.


Zoom in on STEM Education
Happy Hour

Support Saturday Academy and have some fun at their annual fundraiser on March 11, 2021, where you’ll Zoom in on STEM education. Use a “foldoscope” with samples, and try desserts and a signature Discovery cocktail during this exciting event.

Tickets are on sale now until March 1. See all the details for Saturday Academy Happy Hour.


Lonza’s Virtual Roadshow

Lonza Pharma & Biotech helps support early development services to prepare a successful transition to the clinic. They have upcoming virtual roadshow dates where you can schedule a tailored discussion with their experts, to help provide benefit to your company’s early stage biologic therapies. See their flyer with additional information and to schedule a time to discuss your project in more detail. Dedicated dates and times are February 8–12 and March 15–19, 2021, from 8:00 AM–1:00 PM PST.


WSU MAP Opportunity

Have you heard about the Business Growth Mentor & Analysis Program (MAP) at WSU Vancouver? Seniors who are majoring in business administration can provide no-cost student consulting for your small business or nonprofit organization. Whether you are looking for suggestions on how to address core challenges or are looking to grow and take your business to the next level, consider letting a MAP team help your organization.

Participating MAP clients receive approximately 500 hours of pro bono student consulting conducted under mentor and faculty supervision. Each MAP team works through proven process that helps them develop detailed recommendations and an implementation plan to help their client address a variety of challenges and goals. Each MAP project can be completed remotely and the time commitment for business owners is around 15 total hours over the course of a 16-week semester.

To learn more about the program from 3 former MAP clients, please watch: https://youtu.be/Dzqf_zd_kZA.

Have questions? Interested in becoming a MAP client this Fall? Contact Nolan Yaws-Gonzalez at nolan.yaws@wsu.edu.


ScienceTalk ’21 Conference
March 24-26, 2021

The challenges of 2020 have shown more than ever how important science communication is to the functioning of society. But, beyond that, it has highlighted our resilience as communicators, and the passion that we share to educate, inform, and entertain. Connect with your community of professional science communicators at SCIENCE TALK ’21 over three days of workshops, panel discussions, presentations, and networking opportunities. Learn, explore, and share with other Science Talkers!


Stanford Drug Discovery Symposium 2021

Dr. Sanjay Malhotra recently joined OHSU and started the Center for Experimental Therapeutics in the summer of 2020. Prior to that, he was at Stanford University and started the Stanford Drug Discovery Symposium, which has become one of the highest attended events at Stanford. Every year the SDDS has the participation of leaders in the field of biomedical sciences. The speakers in this year’s symposium will include two Nobel Laureates, scientific leaders from NIH, FDA, big pharmaceutical industries and Venture Capitalist groups.

Usually this event has a registration fee, but considering its educational importance and networking benefit, the organizers decided to make registration for SDDS 2021 free of charge. Their hope is that people interested in life sciences (business, academia, research, policy, philanthropy, etc.) from across the world will be able to participate and benefit from this event. As such, Dr. Malhotra invites all members and affiliates of the Oregon Bioscience Incubator and OTRADI to attend this event and have an opportunity to network with the wider community. Register here for the April 19-20 symposium.


PCC Bioscience Program Internships

Students in the Bioscience Technology program at Portland Community College are working towards completion of the bioscience technician certificate or degree and are seeking internship opportunities through the college’s cooperative education program. This is a credit‐for‐work experience program in which PCC students earn credit while gaining work experience and/or training, and laboratories and employers gain motivated, skilled workers for part‐time or short term positions. Many find that hiring an intern through the cooperative education program is an excellent way to get acquainted with potential employees.

For more information, visit pcc.edu/bio or contact Bioscience Technology faculty chair Josh Cary at josh.cary@pcc.edu.



Thank you to PhRMA for sponsoring OBI’s new biosafety cabinet!


Events

OBI EVENTS

Accelerate Biotech + Digital Health Virtual Happy Hour
March 4, 2021
5:00-6:30 PM
Register Here

 

Virtual Lunch & Learn: Licensing Deals
March 18, 2021
12:00-1:00 PM
Registration Open Soon

 

COMMUNITY & PARTNER EVENTS

University Lab Partners Presents:
How to Write a Great NSF Project Pitch
February 16, 2021
1:00-2:00 PM
Register Here

 

Cambia and PDXWIT:
Black Futures & Black History Month Happy Hour

February 17, 2021
5:00-6:15 PM
More Info

 

TAO Leader Launchpad: 
Revamp, Reignite, ReLaunch 2021
February 18, 2021
4:00-5:30 PM
Details Here

 

TAO: Support Equitable Funding with Black Founders Matter
February 19, 2021
9:00-10:00 AM
Register Here

 

PSBA Lunch & Learn: Steward Ownership
February 23, 2021
12:00-1:00 PM
Registration Page

 

PDXWIT Presents: Public Speaking
Tips for Empowering Yourself and Others
March 2, 2021
5:00-6:15 PM
Register here

OBI & OTRADI 2020 End of Year Newsletter

Thank you for your support of
OBI & OTRADI over the past year!


OBI/OTRADI Receives High Impact Opportunity Program Award

The Oregon Innovation Council and Business Oregon have approved OBI/OTRADI for a High Impact Opportunity Project Award to support bioscience companies’ ability to stay and grow in Oregon by adding 6 wet labs and offices to our incubator facilities. Space availability inquiries can be made here.


2020 OBI Client Company Wins

  • Caregiven‘s Candice Smith shared her story to over 400 live participants at the Global Insurance Accelerator’s Startup Showcase, which also resulted in several introductions to individuals and funds. You can watch the 6-minute pitch here.
  • Rebecca Campbell joined as Caregiven’s Co-Founder & CTO in March.
  • Caregiven was featured in the AIMed March 5, 2020 special report entitled “Women in AI – DeathTech.” 
  • Caregiven was profiled by HITLab and their Women’s Health Tech Initiative.
  • Caregiven‘s mobile app was “born!” The alpha version of the Caregiven mobile app is now live on over a dozen devices. The alpha testers are using the app to help care for their loved ones, while also giving valuable feedback and ideas for new features.
  • Caregiven filmed two promotional videos, including a 90-second company overview and a 60-second version tailored for insurance carriers, financial services, and health & benefits plan provider audiences for the InsurTech Connect (ITC) Conference September 21-23, 2020.
  • Caregiven was awarded a scholarship to participate in AchieveUnite’s Channel Acceleration Bootcamp. They were a semi-finalist for the Bend Venture Conference Impact competition. Caregiven was reviewed by New York Angels in October; they were a finalist for Springboard’s Digital Health Innovation Hub and presented to a subset of their members; and they were selected to present to CareFactor located in Australia, a program focused on changing aged care in Australia. 
  • Caregiven has been selected to participate in CareFactor for the program that commenced in November and concludes in March, 2021. CareFactor was developed by its partners to rapidly scale innovations that improve the aged-care sector nationally (Australia) and globally.
  • Candice Smith of Caregiven was featured in the newest edition of Techlandia, as The Faces of  Healthcare Innovation. You can read her story on page 44.
  • Candice Smith, Caregiven Founder & CEO, spoke at the DIGIN Conference 2020 on the topic of “Evolving the Home Health and Insurance Paradigm in a Post-Pandemic World.” She also spoke on a panel at the Society of Actuaries Eldertech Summit on the topic of Care for the Caregiver and was also one of five companies who pitched at the Changing Tides Wave Tour.
  • Caregiven has raised $125,000 in funding so far. They have a signed term-sheet for the remainder of their pre-seed capital raise with the strategic partner they’d been searching for (and couldn’t be more excited to collaborate with).
  • Over 70 users are on the Caregiven platform participating in their private beta offering invaluable suggestions and refinements; they will begin pushing out opportunities for public beta participation after the holidays.

  • Consano held an event called Consano PDX at the Portland Art Museum, to honor and raise funds for their 2020 Ripples of Hope Winner, Dr. Alexandra Butler.

  • Floragenex graduated from the OBI in 2020, after joining the incubator in July, 2013. Oregon‐based Floragenex is a privately-owned biotechnology company providing innovative solutions for genomic analysis in the life sciences.
  • The Portland Business Journal listed Floragenex in its list of the top 41 largest bioscience and health technology companies in Oregon and SW Washington.

  • HTI received the NSF Phase1 STTR award for CryoDiscovery ™ : An integrated cryo-EM intelligence solution. Final report approved and Outcome report posted on NSF website.
  • HTI received the Oregon Business Enhanced Innovation and SBIR Phase1 Matching grant awards.
  • HTI presented poster sessions on CryoDiscovery at the ACA 2020 (American Crystallographic Association) and M&M 2020 (Microscopy & Microanalysis) events.
  • HTI announced that Dr. Justin M. Kollman, Associate Professor, Department of Biochemistry at the University of Washington, is joining HTI to Chair its Science and Technology Advisory Board. More information on the announcement can be found here.
  • HTI is listed on @Science Exchange to provide Cryo EM services and automating data processing to help Pharmaceutical and Biotechnology companies accelerate their structure-based drug discovery workflows to reduce time to market.
  • HTI signed the Master Services Agreement (MSA) with a leading drug development vendor for Cryo EM workflow processing.

  • In spite of the challenges presented by COVID-19, Hemex Health had a very productive year.
  • Hemex Health‘s Gazelle platform was formally launched in June, and they are selling the Hb Variant test (for sickle cell and other hemoglobin variants) in India, Ghana, Kenya, and Haiti. They are receiving good press on the product. The Devex Media Platform listed Hemex/Gazelle as one of the top non-COVID global health stories for 2020. Link to full article here.  A study comparing Gazelle Malaria to other malaria testing protocols was published in the Lancet’s EClinicalMedicine. Gazelle was found to be a valuable diagnostic tool, and a fast and cost-effective way to test for malaria in field settings. Read the full text article here.
  • Hemex Health participated in three virtual global health conferences. Hemex was one of 53 companies chosen to participate at the TechEmerge Conference in East Africa. They presented 5 posters at the American Society for Tropical Medicine, and their research partners at Case Western Reserve University delivered a presentation to the American Society of Hematology on new Gazelle technology for diagnosing anemia.
  • Hemex Health won several grants/prizes, including a Phase I SBIR for anemia research, a Phase II SBIR to further develop their malaria diagnostic, and a Business Oregon grant for COVID testing. Hemex and partners won third prize in the NIH Technology Accelerator Challenge for non-invasive finger cuff technology to detect malaria, anemia, and sickle cell disease.

  • Inherent Targeting won the Judges’ and People’s Choice awards at the early-stage startup pitch contest at Oregon Bio Digital Conference.
  • Inherent Targeting presented at the McKinsey & Co. Early Stage Investor Conference on Monday, December 7th.
  • Inherent Targeting received a Business Oregon Matching SBIR Grant award in December for IP protection and further testing and commercialization of nerve-specific fluorescent compound to avoid nerve damage in surgeries.

  • Nelson Bio Lab is providing a wide selection of SARS-CoV-2 recombinant antigens and serological antibodies to support the IVD test manufacturers in COVID-19 related assay development. 
  • OmnEcoil Instruments recently received an NSF SBIR Phase 1 grant that will enable the company to begin a Proof-of-Concept Clinical Trial at OHSU for OmnEcoil’s MRI imaging/biopsy device. 

  • Refeyn closed Series A financing, which will support the introduction of Refeyn’s next-generation instruments, building on the rapid market adoption of the OneMP Mass Photometer by both academic and industrial institutions.

  • RxHomeTest launched a COVID-19 PCR test kit that can be ordered by clinicians for their patients with symptoms
  1. Activation of Cytosolic Calpain, Not Caspase, Is Underlying Mechanism for Hypoxic RGC Damage in Human Retinal Explants.
    Kobayashi-Otsugu M, Orihara K, Nakajima E, Shearer TR, Azuma M.
    Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):13. doi: 10.1167/iovs.61.13.13.
    PMID: 33156340
  2. Segmenting OCT for detecting drug efficacy in CRAO.
    Shearer TR, Hwang TS, Steinkamp PN, Azuma M.
    PLoS One. 2020 Dec 11;15(12):e0242920. doi: 10.1371/journal.pone.0242920. eCollection 2020.
    PMID: 33306701

  • Sirona Dx can accelerate your COVID-19 studies. Their expert team offers the industry’s most comprehensive immune profiling of blood samples using state-of-the-art CyTOF technology. 
  • Sonivate Medical, Inc. is part of a group of institutions (including Duke University Medical School) which submitted a White Paper on 3/21 regarding detection of COVID-19 using artificial intelligence (AI) and Sonivate’s SonicEye Dual-Array Ultrasound System.
  • StoneStable, Inc. received a $100K grant from the Portland State University Venture Capital Fund, and its first institutional dilutive funding from Elevate Capital. 
  • SUTUREGARD published a journal article in JAAD Case Reports about their HEMIGARD device for wound closure. They also recently received orders for devices from Kenya, Jordan, United Arab Emirates, and Zimbabwe after participating in Arab Health in Dubai.
  • SUTUREGARD and their product HEMIGARD was featured in a video on Dermatologist Dr. Dustin Portel’s Tik Tok page. The video received over 10,000 views in the first hour it was posted.
  • SUTUREGARD recently completed 2nd round fundraising.
  • SUTUREGARD signed a distribution agreement with Federated Healthcare Supply.
  • SUTUREGARD sales have returned to pre-COVID19 levels.
  • SUTUREGARD‘s multispecialty use has expanded to include podiatry and emergency medicine.
  • SUTUREGARD has its highest revenue month achieved in October 2020, extending their runway.
  • SUTUREGARD completed Clinical Evaluation Reports for CE mark submission, applications for SUTUREGARD ISR and HEMIGARD devices will be filed this month to Notified Body in Germany for CE mark approval.
  • SUTUREGARD has official approval as vendor for in hospital sales at Moffitt Cancer Center in Tampa, Florida – national leader in melanoma treatment and research.
  • SUTUREGARD has expanded clinical use by podiatry, dermatology, surgical oncology, cardiovascular surgery.
  • SUTUREGARD had its first sales in Australia.
  • Vir Biotechnology announced that “. . . laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people.” Read full STAT article here.
  • Vir Biotechnology announced a collaboration with GlaxoSmithKline for research and development of coronavirus solutions. GSK’s investment and genomics expertise, combined with Vir Bio’s proprietary technology, will work to develop therapies and prevention for coronaviruses. Read their full press release. 
  • Vir Biotechnology announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus (HBV) and has been engineered to potentially also act as a therapeutic vaccine. They have also finalized a process development and manufacturing agreement with Biogen Inc. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir’s SARS-CoV-2 monoclonal antibodies for potential COVID-19 treatment.
  • Vir Biotechnology is one of the ARCH Venture Partners companies fighting COVID-19. See ARCH’s news about two new venture funds with $1.46 billion in funding, to assist in these efforts. Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
  • Vir Biotechnology announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing ability, high-level effector function, extended half-life and tolerability of VIR-2482 in the prevention of influenza A. Read full press release here.
  • Vir Biotechnology announced the clinical trial for the first product using the HCMV vector platform originally conceived and developed at OHSU in Portland, Oregon. This vaccine is an investigational HIV T-cell vaccine with the potential to fight against HIV and other serious diseases. See press release for all the exciting details.
  • Vir Biotechnology’s CEO George Scangos, Ph.D will virtually present at the J.P. Morgan Health Conference on January 12, 2021. The presentation will be live-streamed and archived on Vir’s website.

  • Virogenomics Bio Development (VBD) had a big win in April. In collaboration with Arthur Vandenbark at OHSU and the VA, VBD was awarded a three year, $3M Phase IIB SBIR. This project will advance a recombinant protein, DRhQ, that has the potential to treat multiple sclerosis (MS) and other conditions with neuro inflammatory components. The aims of this project are to transfer production of DRhQ to a GMP manufacturer, determine its potential toxicity in two species and develop assays for evaluating its safety and efficacy after administration. These aims will provide preclinical data for an IND submission, a critical step in creating an FDA approved drug.
  • Virogenomics Bio Development (VBD) is developing an oral rinse – the HyperHex rinse – that is composed of a hypertonic solution with a safe and effective microbicide. The HyperHex rinse would be an easier, safer and more effective way to collect samples to screen millions of people to monitor transmission and to evaluate immunity to the SARS-CoV-2 virus. 
  • Virogenomics Bio Development (VBD) presented at the Oregon Bioscience Association Digital Conference in November.
  • Virogenomics Bio Development (VBD) was awarded a Business Oregon SBIR matching grant to support the development of an in vitro diagnostic for the detection and monitoring of aortic aneurysms.  

Congratulations to our amazing OBI Client Companies!


OBI Welcomed Three New Startups in 2020

      

Click here to learn more about our new companies


3D Virtual Tours of OBI Spaces

We have exciting news! We now have interactive, virtual 3D tours of Suites 130 and 200, our largest spaces. Check them out on our Facilities page. And if you have any lab or office space needs, fill out the Facilities Request form for more information.


New OBI Mentoring Cohort Begins

We are pleased to announce that January 4, 2021 was the start date for OBI’s newest Mentoring Program cohort. Twelve mentees and thirteen mentors will work together in pairs and threes for 6 months. 

MENTORS: Joseph Volpi, Sandra Shotwell, Keith Daellenbach, Nathan Lillegard, Andrew Owen, Pete Murray, Christa Nicholas, Shannon Heizenrader, Peter Schuerman, Kabir Bhatia, Will Marshall, Douglas Kawahara, and Curt Jennewine.

 

MENTEES: Jeremy Hammer, Carin Berg, Gabriella Kiss, John Harkness, Claude Goodman, Paul ReFalo, Heber Michaels, Smriti Zaneveld, Megan Meinel, Carl Ruby, Daniel Freed, and Ray Browning.

Best of luck to the Winter-Spring OBI Mentoring Program cohort. Find out more about our Mentoring Program.


Portland Area Bioscience is Growing

Twist Bioscience Corp. is planning to lease a 111,000 square foot site to be a “factory of the future” in Wilsonville and employ up to 400 people, starting in 2022. Twist Bioscience makes synthetic DNA on silicon chips, used in healthcare and other industries.

The Portland Business Journal has a story about this exciting development for the Portland area, reflecting its prominence as an up-and-coming bioscience nerve center in the country.


Business Oregon and Oregon Innovation Council’s Innovation Awards

In addition to the High Impact Opportunity Project (HIOP) Award to OBI/OTRADI listed above, Business Oregon and Oregon InC granted several other HIOP awards to Oregon organizations, including Portland State Business Accelerator.

They also awarded 17 companies a Matching SBIR Grant Award, including three OBI Client Companies: Health Technology Innovations (HTI), Inherent Targeting, and Virogenomics Bio Development.

Congratulations to all awardees!


MedTech Innovator Applications Due January 25

MedTech Innovator is looking for outstanding early- to mid-stage medical device, diagnostic, and digital health companies who are transforming healthcare to apply for their 2021 program.

MedTech Innovator is a highly selective and unique opportunity for start-ups and emerging growth companies to gain access to stakeholders across the healthcare industry including investors and industry leaders such as Johnson & Johnson, Baxter, Olympus, W.L. Gore, Fujikura, Nipro, Edwards Lifesciences, Maxim, and Asahi Intecc. Additionally, in 2021, they will give out $500,000 in non-dilutive cash prizes. More information about the strategic interests of their stakeholders can be found here.

MedTech Innovator does not charge or take equity for participation, and there is no application fee. Deadline to apply is January 25. Link to application.


Upcoming Events

OBI Events

OBI Virtual Lunch & Learn:
Best Practices in Medical Device Software & Firmware Design
January 14, 2021
12:00-1:00 PM
Register here

 

OBI Virtual Lunch & Learn:
Is Your Brand Story Due for a Tune Up?
February 10, 2021
12:00-1:00 PM
Registration open

 

Community Events


PSBA’s DEI Training with Christine Slattery
January 21, 2021
1:30-3:00 PM
Register here

 

TAO Event: I Am Tech Oregon
January 14, 2021
11:00-11:30 AM
Registration page

TAO Panel Discussion: Data Privacy in 2021
January 28, 2021
9:00-10:00 AM
Register here

TAO Event: Strategic Plan for Exit
January 28, 2021
11:30 AM-1:00 PM
Registration

 

ULP Event: Market Access and Life Cycle
Aspects of Medical Technology Products
January 20, 2021
3:00-4:00 PM
Register here

ULP Event: Lifesciences Innovators Forum
January 27, 2021
3:00-4:30 PM
Registration

 

Cambia Grove: Incentivizing Health Hackathon
February 4-5, 2021
9:00 AM-2:00 PM
Register/apply here

OBI & OTRADI December 2020 Newsletter

Happy Holidays from the OBI

What a year 2020 has been! We have been through a lot together, and we at the OBI are celebrating the holiday season and the end of a most unusual year. Look for a 2020 OBI recap in next month’s newsletter. Happy Holidays to you and yours!

2021 is almost here. Stay healthy and safe and we hope to see you in person in the new year!


OBI Client Company Wins

SUTUREGARD Medical has some great recent wins: 

  • Highest revenue month achieved in October 2020, extending our runway
  • Completed Clinical Evaluation Reports for CE mark submission, applications for SUTUREGARD ISR and HEMIGARD devices will be filed this month to Notified Body in Germany for CE mark approval
  • Official approval as vendor for in hospital sales at Moffitt Cancer Center in Tampa, Florida – national leader in melanoma treatment and research
  • Expanded clinical use by podiatry, dermatology, surgical oncology, cardiovascular surgery 
  • First sales in Australia

Veana Therapeutics, Inc. Founder and CEO, Emmanuel Akporiaye, Ph.D won the Judges’ Award at the Oregon Bio Digital 2020 Conference held from November 17 -19.

Caregiven is on a roll! Their wins include:

  • The humbleness and excitement that came with two new investments from extraordinary women
  • Seeing our expaning team coalesce as we refine our business model together (special thanks to CareFactor for providing access to Strategyzer)
  • Receiving feedback from The Wave Pitch Showcase judges (Canaan, GingerBread Capital, Outlines Venture Group) that “with the right business model, nothing will stop you!”
  • Since the end of October, we have been inviting 25 new beta testers each week onto the Caregiven platform
  • We’ve received two new investments and have raised $150,000 on our convertible note
  • Support me (Candice Smith, Founder & CEO) as I speak at the DIGIN Conference 2020 on the topic of “Evolving the Home Health and Insurance Paradigm in a Post-Pandemic World.”

Inherent Targeting won the Judges’ and People’s Choice awards at the early-stage startup pitch contest at Oregon Bio Digital Conference. Additionally, Inherent Targeting has been invited to present at the McKinsey & Co. Early Stage Investor Conference taking place Monday, December 7th.

Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting. For more information, see the December 2, 2020 Newswire press release.

Promedix has had 3 large wins that have accelerated clinical adoption and validation:

  • We have an ongoing clinical trial in the ICU and launching a trial in the ED to study our technology’s ability to both improve detection and monitoring of sepsis
  • We had an abstract accepted and presented at the American Heart Association National Conference on our technology and patient data
  • We had a manuscript accepted in a peer-reviewed journal

Keep the wins coming. We love to celebrate your successes!


Program Recordings on Demand

Great news! You now have the ability to view all of our Lunch and Learns from October, 2019 to the most recent program. These closed caption-enabled videos are available on our website and on our YouTube channel. Subscribe to the Oregon Bioscience Incubator YouTube channel to be notified when new videos are posted, approximately once per month. 


Welcome to Our Newest Client Company

Izon Science is the world leading manufacturer of nano-biological separation and characterization tools. Its TRPS measurement system is the most accurate, standardizable and practical method of measuring complex nano-bio particles, while its qEV platform has rapidly become the gold standard in extracellular vesicle separation.

Izon Science joined the OBI on December 1. Welcome, Izon!


Mentor of the Month:
Michael McGarry

Michael McGarry is one of our helpful and engaging mentors in our current Mentoring Program cohort. He is the Founder and President of Forvida, a customer-focused consulting firm passionate about developing health solutions that engage individuals and make health and every day event. Before founding Forvida, Michael had more than 20 years experience in the health care industry, developing innovative programs and medical devices from prototype through FDA approval within small start-up organizations as well as Fortune 500 medical companies.

Michael has been very supportive of the OBI and the larger health sciences ecosystem through his mentoring with OBI, assistance with last spring’s MIT COVID-19 Challenge, the OHSU Invent-a-Thon, and more recently as the presenter for an OBI Virtual Lunch and Learn.

Thank you, Michael, for all you to do to support the community!


Congratulations to Pitch Winners at Oregon Bio’s Digital Conference 2020

Two of OBI’s client companies were winners in the Oregon Bioscience Association’s Digital Conference 2020 pitch event:

  • Connor Barth, PhD from Inherent Targeting won the Judges’ award and People’s Choice award for the Early-Stage Startup category
  • Emmanuel Akporiaye, PhD from Veana Therapeutics won the Judges’ award for the Later-Stage Startup category

Ken Bates, PhD from Bates Medical Systems and Jeff King, PhD from Virogenomics Bio Development also pitched in this fantastic event.

Congratulations to all – you did a great job!


Events

OBI EVENTS

Virtual Lunch & Learn: The 7 Habits of Highly Effective People in R&D
December 9, 2020
12:00-1:00 PM
Register Now – It’s Almost Full!

 

COMMUNITY & PARTNER EVENTS

University Lab Partners Presents:
Getting Your Tech Out of the Lab and Onto the Market
December 10, 2020
12:00-1:00 PM
Register Here

 

PDXWIT Event: From Vision to Game Plan
December 10, 2020
12:00-1:00 PM
Registration Page

 

TAO CEO Leadership Exchange: 
Strengthening Oregon’s Innovation Economy
December 15, 2020
4:00-5:15 PM
Details Here

 

PDXWIT: Annual Celebration + Awards Ceremony
December 15, 2020
5:00-6:15 PM
Register Here

 

Oregon Bio’s Holly Jolly Finale
December 17, 2020
4:00-5:30 PM
Happy Hour Registration Page

OBI & OTRADI November 2020 Newsletter

AbSci Receives Series E Funding

Congratulations to OBI graduate AbSci for raising $65 million Series E equity financing. AbSci is a synthetic biology company focused on their Protein Printing™ technology for protein biomanufacturing. This financing round will enable AbSci to increase production, expand their facility, and fund research and development.

For more information on AbSci and their exciting news, please read the recent press release.

 


OBI Client Company Wins

Caregiven has been selected to participate in CareFactor. This represents a significant opportunity for us and we are very excited for the program that commences in November and concludes in March, 2021. CareFactor was developed by its partners to rapidly scale innovations that improve the aged-care sector nationally (Australia) and globally.

Vir Biotechnology announced the presentation of preclinical and Phase 1 data demonstrating the broad neutralizing ability, high-level effector function, extended half-life and tolerability of VIR-2482 in the prevention of influenza A. Read full press release here.

Candice Smith of Caregiven and Emmanuel Akporiaye of Veana Thereapeutics and were featured in the newest edition of Techlandia, as The Faces of  Healthcare Innovation. You can read their stories on pages 44 and 45.

Madorra was a keynote presenter at Springboard Enterprise’s Women’s Health Innovation Coalition Menopause Round Table

 


Welcome New Client Companies

Inherent Targeting is developing nerve targeted fluorescent contrast agents to improve surgical outcomes. Nerve injury is a feared surgical complication affecting 50 million patients and incurring a $5 billion cost to the healthcare system annually. Currently, surgeons are entirely unassisted in nerve identification and preservation, relying solely on naked eye visualization or anatomical knowledge. Our technology provides direct highlighting of nerves during surgery in real time and is currently under clinical translation. 

 

Forbie, Inc. is developing an AI & NLP enabled solution that helps connect patients and providers in real-time offering full visibility into patient state and changing needs, thereby improving quality of care and enabling better outcomes.

Inherent Targeting and Forbie joined the OBI on November 1. Let’s give them a warm welcome!

 


Mentor of the Month: Sandra Shotwell

Sandra Shotwell has co-founded three startup companies: Alta Biomedical, DesignMedix, and Elex Biotech, and played a leadership role in all three. Her life sciences experience includes technology transfer, early-stage commercialization, and company startup operations and leadership. Sandy and her mentee are making great progress in their mentoring program, and her mentee always has glowing feedback. Sandy is also an OTRADI & OBI Board Member.

Of the OBI Mentoring Program, Sandy says, “The program has been great. It is rewarding to work with an early-stage entrepreneur and watch them spread their wings. I’d highly recommend it for both the entrepreneurs and the mentors.”

Thank you, Sandy, for all you do for the bioscience community!

 


Business Oregon SBIR Phase 0/00 Application Support Grants

From Business Oregon:
“Because the SBIR/STTR programs are very competitive, Business Oregon also provides application support grants to help businesses prepare better applications to give companies a better chance to receive federal funding. These grants are called Phase 0 and 00 grants. Phase 0 grants go to businesses that are pursuing federal Phase I SBIR/STTR grant funds, while Phase 00 grants help businesses pursuing federal Phase II or Fast-Track grants. Phase 0 or 00 grants can be for up to $5,000. Business Oregon has provided approximately $280,000 of these grants to companies that have then won approximately $10M in federal grant awards.

“Phase 0 Grants Can Be Used For:

  • Professional fees to develop the SBIR/STTR Phase I application (e.g., technical consultants, writer, reviewer)
  • Other professional fees (e.g., legal, accounting) directly related to preparing the SBIR/STTR Phase I application
  • Other out-of-pocket costs directly related to preparing the SBIR/STTR Phase I application (e.g., market research, technical database research or statistical analyses)

“Phase 00 Grants Can Be Used For:

  • Professional fees to develop the SBIR/STTR Phase II application (e.g., technical consultants, writer, reviewer)
  • Other professional fees (e.g., legal, accounting) directly related to preparing the SBIR/STTR Phase II application
  • Other out-of-pocket costs directly related to preparing the SBIR/STTR Phase II application (e.g., market research, technical database research or statistical analyses)

“How To Apply
Business Oregon is now offering application support grants as long as funding is available. To apply for a grant, please review the program guidelines document, complete an application form, gather the supporting documentation, and submit the materials. Details are in the guidelines.”

 


Technology Association of Oregon 
Digital Health Week

What an informative and interesting line up of topics at TAO’s Digital Health Week. Dates and topics include:

  • AI & Data – Monday, November 16 9-10 a.m.
  • International Digital Health Roundtable – Tuesday, November 17, 9-10 a.m.
  • Human Centered Design – Tuesday, November 17, 11 a.m. to noon
  • Innovation in Healthcare Delivery Models – Wednesday, November 18, 9-10 a.m.
  • Policy & Innovation – Thursday, November 19, 9-10 a.m.

Speakers include OBI client company founders John Harkness from Rewire Neuroscience and Anil Kumar from RxHomeTest.

Register soon!
OTRADI & OBI is a proud sponsor of Digital Health Week.

 


Oregon Bioscience Association
Digital Conference 2020

Registration is now open for one of OregonBio’s biggest events of the year! Keynote, networking, Pitch & Partner event, and a Career event are the highlights of this multi-day program.

Four of OBI’s client companies are participating in the pitch event: Emmanuel Akporiaye, PhD from Veana Therapeutics, Ken Bates, PhD from Bates Medical Systems, Connor Barth, PhD from Inherent Targeting, and Jeff King, PhD from Virogenomics Bio Development.

OTRADI & OBI is a proud sponsor of the OregonBio Digital Conference 2020, and we hope to see you there!

 


Oregonian Cares Grant Program

To help local area businesses during these uncertain times, the Oregonian and Oregon Live is pledging up to $2.5 million in a matching marketing grant program called Oregonian Cares. Individual grants range from $500-1500 per month. Businesses are encouraged to fill out the application form now, for a quick turnaround.

 


Events

 

OBI EVENTS

Virtual Lunch & Learn: Market Research Deep Dive
November 10, 2020
12:00-1:00 PM
Free to Attend – Register Here

 

Virtual Lunch & Learn: The 7 Habits of Highly Effective People in R&D
December 9, 2020
12:00-1:00 PM
Registration Now Open

 

COMMUNITY & PARTNER EVENTS

PSU Event: The Cube Demo Day
November 6, 2020
11:00 AM-1:00 PM
Free – Tickets Still Available

 

OEN Entrepreneurship Awards 2020: Disruption Edition
November 19, 2020
5:15-8:00 PM
Register Now

 

OTBC Event: SBIR-STTR Success Panel – the Inside Story
November 20, 2020
12:00-1:30 PM
Register Here

 

TechFest NW + PitchFest NW
December 2-4, 2020
$15 Early Bird Tickets Here

 

McKinsey & Co Early Stage Investor Conference
December 7-11, 2020
Information Here

OBI & OTRADI October 2020 Newsletter

OBI Companies Working on COVID-19

Virogenomics BioDevelopment (VBD) is developing an oral rinse – the HyperHex rinse – that is composed of a hypertonic solution with a safe and effective microbicide. The HyperHex rinse would be an easier, safer and more effective way to collect samples to screen millions of people to monitor transmission and to evaluate immunity to the SARS-CoV-2 virus.  Optimal sample collection is one that is safe and simple for health care workers and those being tested as well as being more comfortable than nasal swabs or blood draws.  Hypertonic oral rinse solutions increase the yield of analytes such as immunoglobulins that can be used to detect exposure and immunity to coronaviruses.  To develop the HyperHex rinse, VBD is working with Andrew Goldstein, a founding officer and director of Epitope, Inc. (now OraSure Technologies, Inc.), and was intimately involved in developing FDA approved saliva-based diagnostic assays for HIV antibodies, HIV and HCV point of care tests.

Vir Biotechnology has published an article which will appear in the November 12, 2020 print issue of Cell, focusing on differing antibody responses based upon COVID-19 disease severity, as well as structural characteristics of six different neutralizing antibodies. This study, conducted in the US, Switzerland, and Italy, was the largest of its kind with serum samples from nearly 650 patients infected with SARS-CoV-2, will aid in the development of vaccines, therapeutics, and other strategies. In addition, Vir and GlaxoSmithKline have announced Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) study for treatment of COVID-19 patients who are at high risk for hospitalization. For more information on their research, please see Vir Biotechnology’s September 24, 2020 press release and October 6, 2020 press release.


OBI Client Company Wins

Caregiven was awarded a scholarship to participate in AchieveUnite’s Channel Acceleration Bootcamp. They were a semi-finalist for the Bend Venture Conference Impact competition. Caregiven will also be reviewed by New York Angels in October; they are a finalist for Springboard’s Digital Health Innovation Hub and presented to a subset of their members; and they were selected to present to CareFactor located in Australia, a program focused on changing aged care in Australia.

ProMedix, Inc. was selected from a large group of startup company applicants to join the Creative Destruction Lab Accelerator. This will significantly help business development and achieving high level milestones to further commercialization and fundraising efforts. ProMedix was also one of five projects selected as winners for CTIP’s Catalyzing Pediatric Grant (CPI) competition. ProMedix is a medical device company aiming to develop technology to simplify diagnostic home healthcare as well as ER/Critical Care.

Rewire Neuroscience was a semi-finalist in the 2020 Bend Venture Conference Growth competition. Rewire Neuroscience offers artificial intelligence services for biomedical image analysis in clinical, veterinary and research applications. Rewire has a machine learning platform, Sightologist.ai as well as a consumer-facing analysis software, called Pipsqueak AI, which is used by thousands of researchers around the world to quantify tissue samples.

Madorra will be presenting an oral abstract presentation at the North American Menopause Society Annual Meeting this month. The topic of their research is “A novel, non-hormonal, non-invasive ultrasound device is effective in treating the symptoms of vaginal dryness associated with genitourinary syndrome of menopause (GSM).” Madorra’s abstract will also be published in the December 2020 issue of Menopause.

Congratulations to Hemex Health and Medtronic for winning third prize at the NIH Technology Accelerator Challenge. They won $100K for their finger cuff technology to detect malaria, anemia, and Sickle Cell Disease.


Mentor of the Month: Lynn Sheehan

Lynn Sheehan, Business Strategist from Evolve Strategic Ventures, joined our Mentoring Program in June and hit the ground running with his mentee. Lynn is a consultant working with startups and fortune 500 companies globally. He has a special focus on the startup community in the Portland/Vancouver area. He’s a member of the MAPS Program at WSU Vancouver Carson College of Business both as a mentor and a board member. Lynn has been a guest lecturer at PSU’s business programs, and is an Executive in Residence with Technology Association of Oregon, supporting members through mentorship.

Lynn says, “The OBI Mentoring Program is a great way for entrepreneurs to receive guidance from industry veterans. The complex areas these companies work in really benefits from mentor experience. In the end this accelerates them to revenue and team growth.”

Thank you, Lynn, for all you do for the startup community!


Applications Now Open for Mentoring

We are now accepting Mentee applications for OBI’s structured, 6-month program. Are you an entrepreneur who has a company (or are seriously considering starting one) and need guidance, accountability, and support from a Mentor to help you set and reach your goals? This program is free for Oregon entrepreneurs and runs from January – June, 2021. Take your business to the next level by joining OBI’s Mentoring Program.

Here is what some of our current Mentees are saying:

  • “[My Mentor] worked with me to hone my pitch, participated in pitch presentations to three investment groups, one of which has now expressed an interest in investing in [my company]!”
  • “Obtained very helpful advice and guidance on the strategy from a business and clinical perspective going forward.”
  • “[My Mentor] introduced me to a potential collaborator.”
  • “Exceeded my expectations. We are on track to meet the goals I set.”

Applications are being accepted until October 31, so apply now! 
See important details here


OBI’s Advising Program

Did you know? 

We have a network of more than 90 Advisors who are available to provide short-term free advice and assistance to promising life science and digital health entrepreneurs across the state of Oregon. Our Advisors have valuable expertise in a wide range of business topics that are integral to the success of early-stage life science companies, including:

  • Accounting
  • Business Plans
  • Digital Health
  • Government Funding
  • Health IT
  • Legal/IP
  • Licensing
  • Machine Learning/AI
  • Management, including HR/Talent
  • Manufacturing
  • Market Analysis
  • Marketing
  • Private Funding
  • Product Development
  • Regulatory/FDA

To request assistance, please fill out this entrepreneur registration form and we’ll match you with an Advisor who can help. This service is free of charge.



Business Oregon Launching Funding Opportunities

From the October 7, 2020 press release: “The Business Oregon Small Business Innovation and Research (SBIR) Matching Grants are intended to help Oregon companies that have received a federal award be successful as they move forward. Companies can use matching funds to fill gaps in the federal award or further commercialize or scale their technology. Oregon-based businesses with more than half of employees based in Oregon who have been awarded a federal SBIR or STTR grant on or after Jan. 1, 2019 are eligible to apply.

“The application will be open through November 8, 2020. Awards can range up to $100,000 depending on eligibility and other parameters, with a total of approximately $1,000,000 available for funding.

“The High Impact Opportunity Project (HIOP) program looks for proposals that support the growth of emerging industries that individual businesses cannot address on their own. Projects could support these industries by addressing barriers to commercialization or support product development and testing. Projects must directly support the growth of an industry sector, not an individual business or its proprietary technology.

“Oregon-based organizations with at least half its employees based in Oregon are eligible, and the application period will be open through November 4. There is approximately $1,500,000 available for funding in this round of the HIOP program.”


OHSU Invent-a-Thon

Applications open for OHSU Invent-a-thon
Online event, October 23–25, 2020

Make Healthcare Better. From anywhere. 

Grab your virtual raincoat and apply for our first Pacific Northwest-focused event, in partnership with Oregon Health Sciences University.

Building on MIT Hacking Medicine’s successful model, this weekend convenes teams and a wide range academic and industry partners to address problems in the medtech tracks of surgical care and early disease detection, and digital health/health IT tracks of rural and low resource setting health care and management of chronic conditions.

$40,000 in prizes will be awarded to the most promising teams, with a special emphasis on reducing health disparities and addressing COVID-19. Anyone with an interest in improving healthcare is invited to join the clinicians, researchers, designers, investors, and many others joining this dynamic weekend event.

Propel an idea into action!

Learn more and apply by October 14 at inventathon.org#OHSUInventathon


Pitch Oregon 2020

In its fifth year, Pitch Oregon is TiE Oregon’s marquee event, attracting hundreds of entrepreneurs, mentors and investors each year. Entrepreneurs from all around Oregon pitch for free services and a cash prize of $2,500! We are looking for traded sector businesses in technology, new market innovation, and CPG in two categories – Concept and Seed.

Concept – you either have an idea or you’ve just started working on your product
Seed – you have a product and have taken some funding or are bootstrapping

Timeline
October 16, 2020 —  Application Deadline
October 30, 2020 — Finalist Announcement
December 1, 2020 — Pitch Oregon

Details
When: Tuesday, December 1, 2020
Time: 5:30 PM – 9:00 PM
Where: Zoom Webinar (login available after registration)
Cost: Application Fee – $10 members | $25 Nonmembers; Registration Fee – $15 members | $30 Nonmembers


McKinsey & Company Early Stage Investor Conference

December 7-11, 2020

Grow. Connect. Expand.

Early Stage Investor Conference (ESIC) is an annual flagship event designed to inspire and advance innovation across industries. Each year, we bring together an ecosystem of entrepreneurs in emerging technology, established industry-leaders, researchers from top universities, and individual and corporate investors looking for the next big idea.

Building off our 2019 success with more than 300 attendees and 50 presenting startups, in 2020 we are raising our ambitions even further by introducing new investor tracks that include biotech, medtech, healthtech, fintech, femtech, and sustainability. We are also holding a virtual forum to create a truly global community of ideas, expertise, and investors.

Applications accepted through October 31. For more information on applying or attending, see Overview page.


Upcoming Events

TiE Women: Functional Working Session on Marketing
October 13, 2020
2:00-3:30 PM
Register here

 

Oregon Bio, Business and Good Beans:
Latest Updates on PPP Loans and COVID Paid Leave Tax Credits

October 14, 2020
9:15-10:00 AM
Free – register here

 

TAO Leadership Exchange Fall Series:
Liability & Returning to Work

October 15, 2020
9:00-10:00 AM
All the details here

 

Bend Venture Conference
October 15-16, 2020
8:00 AM-5:30 PM
Register now

 

Under the Boughs with Dr. Thomas Lynch Jr., Fred Hutch
October 21, 2020
9:30-10:45 AM
Free to attend

Women in Science Lunch and Learn:
BIPOC Imposter Syndrome in STEM

October 21, 2020
12:00-1:00 PM
Free to attend

 

TiE Event: Confessions of an Entrepreneur
October 27, 2020
5:30-7:30 PM
Details and registration

 

TAO PDX Lunch & Learn: Strategic Plan for Exit
October 28, 2020
11:30 AM-1:00 PM
Register here

 

TAO Resilient Leadership Workshop Series: Gathering Well
October 29, 2020
4:00-5:30 PM
Series and registration information

 

Oregon Bio Digital 2020 Annual Conference
November 17-19, 2020
Read all about it and register

OBI & OTRADI September 2020 Newsletter

Alpha Version of the Caregiven App is Launched

OBI client company Caregiven has some very exciting news: their mobile app has been “born!” The alpha version of the Caregiven mobile app is now live on over a dozen devices. The alpha testers are using the app to help care for their loved ones, while also giving valuable feedback and ideas for new features. Caregiven is also seeking private beta testers: people who are currently giving care or who have recently lost a loved one. Contact candice@caregiven.co for more information about the beta testing program.

Caregiven recently filmed two promotional videos, including a 90-second company overview and a 60-second version tailored for insurance carriers, financial services, and health & benefits plan provider audiences. To visit with Caregiven in a virtual kiosk, see the promotional videos, and maybe even get a sneak peek at the beta version of their new mobile app, register for the InsurTech Connect (ITC) Conference September 21-23, 2020. 


OBI Client Company Wins

RAW Molecular Systems finished recruiting for their GWAS study of microbiomes and genetics in recovered COVID-19 patients, received ICorp funding from UW, and hired new engineers to work on detection devices.

Veana Therapeutics and University of Washington Medicine are conducting a phase 1 clinical trial of a new oral therapy for advanced HER2 positive breast cancer patients. See press release for all the details.

Health Technology Innovations, Inc. (HTI) announced that Dr. Justin M. Kollman, Associate Professor, Department of Biochemistry at the University of Washington, is joining HTI to Chair its Science and Technology Advisory Board. More information on the announcement can be found here.


Mentor of the Month: Curt Jennewine

OBI launched its revamped Mentoring Program this summer and is proud to give a September Mentor of the Month shoutout to Curt Jennewine. Curt is the President of Asia MedPartners, which provides consulting services for a variety of medical start-ups looking to introduce their technologies into the US market.

Curt’s background in consulting for many different medical fields combined with his insightful input, creative problem-solving, good understanding of the customer, systems-approach, strong understanding of business strategy, and excellent communication makes Curt an ideal mentor. Curt is currently mentoring two mentees in OBI’s 6-month structured mentoring program. He’s receiving high praise from his mentees, too. As one of his mentees, Anil Kumar of RxHomeTest states, “We went through our business in more detail, brainstormed ideas that needed help, and came up with strategies for further growth. We specifically planned few action items for me to follow. This mentoring program has been extremely helpful for my business, thanks to OBI and my mentor!” 

Thank you Curt, for volunteering as a mentor. We appreciate you!


Mentoring Program Seeks Applicants

OBI is gearing up for our January, 2021 mentoring cohort. We will begin accepting Mentor and Mentee applications for this structured, 6-month program next month, so now is your opportunity! If you have experience working with startups in the bioscience and digital health industry, please consider applying to become a Mentor. We are also looking for entrepreneurs who already have a company but could use guidance, accountability, and support from a Mentor to help you set and reach your goals.

Here is some nice feedback we’ve received from Mentees in the program:

  • “[My Mentor] worked with me to hone my pitch, participated in pitch presentations to three investment groups, one of which has now expressed an interest in investing in [my company]!”
  • “Obtained very helpful advice and guidance on the strategy from a business and clinical perspective going forward.”
  • “[My Mentor] introduced me to a potential collaborator.”
  • “Exceeded my expectations. We are on track to meet the goals I set.”

Applications accepted in October. Details about the OBI Mentoring Program here!


OHSU Invent-a-Thon Applications Open Now

Applications open for OHSU Invent-a-thon 
Held online, Oct. 23–25

Make Healthcare Better. From anywhere. 

Grab your virtual raincoat and apply for our first Pacific Northwest-focused event, in partnership with Oregon Health Sciences University.

Building on MIT Hacking Medicine’s successful model, this weekend convenes teams and a wide range academic and industry partners to address problems in the medtech tracks of surgical care and early disease detection, and digital health/health IT tracks of rural and low resource setting health care and management of chronic conditions.

$40,000 in prizes will be awarded to the most promising teams, with a special emphasis on reducing health disparities and addressing COVID-19. Anyone with an interest in improving healthcare is invited to join the clinicians, researchers, designers, investors, and many others joining this dynamic weekend event.

Propel an idea into action!

Learn more and apply by October 7 at inventathon.org#OHSUInventathon


OMSI’s New Fall Programs and Fundraising Goals

Oregon Museum of Science and Industry is answering the call to help during the COVID-19 pandemic, by providing new programming to support K-8 students, teachers, and caregivers. Their OMSI Homeroom program will serve 120 students per week with hands-on learning and STEAM enrichment education.

Any financial assistance you can give toward their fundraising goals for families in need will be much appreciated. See the link to their flyer describing OMSI Homeroom and their other virtual programs, and the financial support needed to bring this important education to those who need it most. 


Upcoming Events

OBI Virtual Lunch & Learn: Bioscience Career Panel
Join us for this interactive event
September 23, 2020
12:00-1:00 PM
Register now!

 

OBI Virtual Lunch & Learn: Cultivating High-Performance Teams
October 6, 2020
12:00-1:00 PM
Free – register here

 

VertueLab Cleantech Innovation Summit FUEL 2020
September 9-25, 2020
All the details here

 

Oregon Bioscience Association Biotech Summit
September 16, 2020
9:00 AM-1:30 PM
More information

 

Technology Association of Oregon 2020 Technology Awards
September 23, 2020
3:00-5:00 PM
Register here

 

Oregon Bio Coffee Talk: Retirement Benefits
September 24, 2020
9:15-10:00 AM
Link to registration

 

Founders Live PDX Virtual Experience
September 24, 2020
5:30-8:00 PM
Free – more information here

 


Oregon Bioscience Association has converted their
BioPro classes to a new virtual format!

Link to full class schedule

OBI & OTRADI August 2020 Newsletter

OBI Appoints Two New Members to Its Board of Directors

 

Aditi Martin was recently elected as an OBI/OTRADI Board Director. She is the Senior Director of Collaborations and Entrepreneurship at Oregon Health and Science University (OHSU). Aditi is a strategy and innovation professional with extensive experience in building partnership and negotiating a variety of commercialization agreements. She was also a recipient of Portland Business Journal’s 2018 Forty under 40.

 

Ken Wilson was recently elected as an OBI/OTRADI Board Director. He is the Vice President of Campus Development at Oregon Museum of Science and Industry (OMSI). Ken is a multifaceted real estate executive with expertise in transactions, project management, portfolio management, sourcing and managing outside vendors, managing in house real estate departments as well as third party providers. In his role at OMSI he is responsible for leading the organization’s development of 11 riverfront acres around the museum’s primary facilities.


Welcome RAW Molecular Systems to the OBI!

Our newest client company is RAW Molecular Systems. Their services include biological pathogen monitoring to tackle untreatable antibiotic/antifungal resistant diseases or diseases without current therapy for plants, animals, and people. We are excited to have them join us, and they have hit the ground running with some great wins last month:

  • Successfully filed an IRB for a COVID19 study and got it approved
  • Acquired lab space at OBI
  • $36,000 contract with a private sponsor
  • $15,000 award from Jones Milestone Accelerator
  • $2500 from iCORE at UW
  • 450% RAW team expansion

Congratulations to the team at RAW!


More OBI Client Company Wins

Veana Therapeutics is pleased to share a joint Veana Therapeutics-University of Washington press release of a Phase 1 trial in HER2+ breast cancer patients at the University of Washington. The trial is now open and is enrolling patients.

Promedix, Inc. was awarded a 2021 Pediatric Medical Device Funding Grant from the Consortium for Technology and Innovation in Pediatrics, an FDA pediatric device consortium. This funding will further develop regulatory strategy and a recently launched clinical trial at OHSU in the intensive care unit.

SUTUREGARD Medical, Inc. shares their wins:

  • Recently completed 2nd round fundraising
  • Signed a distribution agreement with Federated Healthcare Supply
  • Sales have returned to pre-COVID19 levels
  • Multispecialty use has expanded to include podiatry and emergency medicine

Health Technology Innovations, Inc. presented poster sessions on CryoDiscovery at the ACA 2020 (American Crystallographic Association) and M&M 2020 (Microscopy & Microanalysis) events August 2nd-7th. CryoDiscovery is a machine learning platform for cryo-electron microscopy (cryo-EM) image processing, currently in Alpha stage testing at OHSU and University of Washington, showing strong results.

Caregiven was recently profiled by HITLab and their Women’s Health Tech Initiative. This profile includes the creation of a case study they are planning to share with their stakeholders in the coming weeks. Caregiven is also making great strides in their platform content following their research with Particle Design.

Last month we reported on Hemex Health‘s release of their Gazelle Diagnostic platform for malaria and sickle cell disease. Hemex Health also has a strong collaboration with Novartis, which is focused on Sickle Cell Disease treatment in Ghana. Novartis recently featured Hemex in their company’s World Sickle Cell Day video.

Madorra‘s recent wins:


Bend Venture Conference Applications Open Until August 13

One of the features of the Bend Venture Conference (BVC) is an Early Stage competition. Companies applying in the early stage competition typically:

  • Have a great idea, and are close to “proof of concept”
  • Are pre, or very early, revenue
  • Are in the process of testing their product in the market

All applicants, regardless of whether or not they are a finalist, have the opportunity to receive feedback from the investor group. The winner of this category could be awarded a minimum $30,000* investment, courtesy of Portland Seed Fund. Applications must be received by August 13, 2020. See details and apply here.

In addition, Portland Seed Fund is also offering limited Early Stage Access Scholarships and coaching. To be considered for a scholarship, at least one company founder should identify as BIPOC (Black, Indigenous, People of Color) and have a financial barrier to the company’s ability to participate in the conference. For more detailed information and how to apply, please see the BVC Early Stage Competition and Scholarship page.


Apply Now for the 2021 Beaverton Startup Challenge

In its 6th year, the Beaverton Startup Challenge is a collaboration of the City of Beaverton, the Westside Startup Fund, and the Oregon Technology Business Center (OTBC). Each year, they select five Startup Challenge companies who receive:

  • A $25,000 convertible note investment
  • Introductions to Legal, Accounting, HR and marketing services
  • OTBC’s top-rated mentoring services
  • OTBC entrepreneur workshops
  • … and more!

For more information, see the Beaverton Startup Challenge FAQ. To apply, use this link.


Need Seed Funding? Deadlines Approaching Soon

National Science Foundation’s America’s Seed Fund (SBIR-STTR) invests up to $1.75 million in seed funding for early-stage research and development, and takes no equity in your company. Submit a project pitch now, before September 3, 2020. Details here.

The National Institutes of Health (NIH) SBIR/STTR funding application proposal dates are September 5, 2020; January 5 and April 5, 2021. For more information on what the NIH funding entails, see this link.


Upcoming Events

OBI Virtual Lunch & Learn: Valuation of Life Science Companies
August 11, 2020
12:00-1:00 PM
Register soon – nearly sold out!

 

TIE Women Pitch Competition
Applications due August 14, 2020
Pitch Competition September 2, 2020
Details here

 

TAO Virtual Cybersecurity Meetup
August 20, 2020
11:00 AM-12:00 PM
More information and registration

 

Badass Womxn Entrepreneurs
August 25, 2020
4:00-5:30 PM
Free to attend

 

TRAILS Competition Launch: Bringing Solutions to Palliative Care
Kicks off September 9, 2020
12:00-1:00 PM
More information here

 

VertueLab Cleantech Innovation Summit FUEL 2020
September 9-25, 2020
All the details here

 

Oregon Bioscience Association Biotech Summit
September 16, 2020
9:00 AM-1:30 PM
More information

 

Technology Association of Oregon 2020 Technology Awards
September 23, 2020
3:00-5:00 PM
Register here

 


Oregon Bioscience Association has converted their
BioPro classes to a new virtual format!

Link to full class schedule

OBI & OTRADI July 2020 Newsletter

Congratulations to Floragenex!

Floragenex graduated from the OBI last month, after joining the incubator in July, 2013. Oregon‐based Floragenex is a privately-owned biotechnology company providing innovative solutions for genomic analysis in the life sciences. Since 2007, Floragenex has been a leader in genomics and next-generation DNA sequencing. From the early days when generating a million sequence reads was considered impossible to the 200M read runs of today, they have been helping scientists by providing expert guidance and support in genomics research.

Upon graduation, Floragenex relocated their lab and offices from OTRADI’s incubator in the Willamette Wharf building, to Nimbus Corporate Center in Beaverton where their parent company, Sedia Biosciences has a presence. In February, 2020, the Portland Business Journal listed both Floragenex and Sedia Biosciences on the list of the top 41 largest bioscience and health technology companies in Oregon and SW Washington, at rankings 38 and 10, respectively.


Hemex Health and HTI Awarded Business Oregon Enhanced Innovation Grants

OBI companies Hemex Health and Health Technology Innovations (HTI) have some great news! Out of 66 proposals Business Oregon received for their Enhanced Innovation Grant, they were two of the six awardees. Congratulations!

From the Business Oregon press release:
“Hemex Health is a medical diagnostic device company making tests for malaria and sickle cell disease. Enhanced Innovation Grant funds will be used for developing and validating a rapid test to detect COVID-related infection that targets viral proteins.

“HTI is developing digital imaging technologies to capture high-resolution 3D images from the molecular level up to the tissue level. Enhanced Innovation Grant funds will be used to integrate their CryoDiscovery product (Cryo-electron microscope that uses machine learning) with the CryoSPARCTM, a commercial grade software product.”


More OBI Client Company Wins

SUTUREGARD and their product HEMIGARD has been featured in a video on Dermatologist Dr. Dustin Portel’s Tik Tok page. The video received over 10,000 views in the first hour it was posted! Check out the video and feel free to share it with others:

https://www.facebook.com/2527185233964626/posts/3589175797765559/?vh=e&d=n

 

Vir Biotechnology is one of the ARCH Venture Partners companies fighting COVID-19. See ARCH’s news about two new venture funds with $1.46 billion in funding, to assist in these efforts. Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

Hemex Health announced the launch of their Gazelle diagnostic platform. Gazelle is a multi-test platform to test for malaria and sickle cell disease. Its affordability and portability makes it an important tool for use in low resource, remote areas of the world, and it was featured in this Devex article as well as this article in Lancet eClinicalMedicine. Watch the Gazelle video to see it in action. #GazelleTakesOff

OBI Alumni Sparrow Pharmaceuticals, Inc. won the Start-Up Stadium pitch competition that was held during BIO Digital in June. Out of the 30 finalists who submitted a pitch presentation, Sparrow was one of five winners. Here’s a link to BIO’s press release. Sparrow Pharmaceuticals is developing novel, proprietary new standards of care for Cushing’s syndrome.

Congrats to all!


New Mentoring Program Begins

July 1 marked the start of our new and improved mentoring program at OBI. This 6-month cohort consists of 7 mentors and 6 mentees. Mentor-mentee pairings are one-to-one or two-to-one. They are all excited to begin working together to set and reach the mentees’ business goals.

Participating Mentors:

 
Eric Distad, Cerebral Therapeutics

 
Lynn Sheehan, Evolve Strategic Ventures

 
Michael McGarry, Forvida

 
Sandra Shotwell, Alta Biomedical

 
John Tortorici, Chart Solutions

 
Curt Jennewine, Asia MedPartners

 
David Forman, Tonkon Torp, LLP

Participating Mentees:

 
Connor Barth, Inherent Targeting, LLC

 
Anil Kumar, RxHomeTest

 
Pabel Delgado, Asterism Healthcare

 
Holly Rockweiler, Madorra

 
Emmanuel Akporiaye, Veana Therapeutics

 
Heber Michaels, Kamino Care

 

We will have a new cohort of mentors and mentees in January, 2021. Keep an eye on the mentoring page on our website and newsletter for more information in the fall on how you can participate in our mentoring program.


OBI’s Advisors Help Entrepreneurs

In addition to mentoring, OBI has a list of over 80 Advisors who are ready and willing to help entrepreneurs seeking assistance. If you are an entrepreneur with a question or needing advice in the areas of…

  • Accounting
  • Legal/IP
  • Licensing/Partnering
  • Private Investment Funding
  • Government Funding
  • Product Development
  • Regulatory/FDA
  • Manufacturing
  • Market Analysis
  • Marketing
  • Management
  • Business Plan/Strategy

… simply fill out this form and we will match you with an Advisor with expertise in the areas you need assistance in. This service is free of charge, and designed to help entrepreneurs build thriving businesses in Oregon! 


Looking for Seed Capital for Early-Stage Product Development?

NSF’s America’s Seed Fund (SBIR-STTR) invests up to $1.75 million in seed funding for early-stage research and development, and takes no equity in your company. Submit a project pitch now, before September 3, 2020.

Details here.


Upcoming Events

OBI Events


Virtual Lunch & Learn: They Said it Couldn’t be Done!
De-Risk Your Projects
 
July 22, 2020
12:00-1:00 PM
Free – register here


Virtual Lunch & Learn: Valuation of Life Science Companies 
August 11, 2020
12:00-1:00 PM
Free – more information


Other Community Events


Bio, Business and Good Beans: Virtual Facilitation with Finesse
July 15, 2020
9:15-10:00 AM
Free to attend – more info here


Oregon Bioscience Association has converted their
BioPro classes to a new virtual format!

The next class begins July 21, 2020
Link to full class schedule


TAO Virtual Lunch & Learn: Marketing in Times of Crisis
July 23, 2020
11:00 AM-12:00 PM
More information here


PSBA Virtual Lunch & Learn: Allyship and Confronting Prejudices in the Workplace
July 23, 2020
12:00-1:00 PM
Free to attend


TAO and Catalyte Webinar: Process Resiliency | Keeping Everything
from Hitting the Fan
July 28, 2020
11:00 AM-12:00 PM
More information and registrationSciEducate Webinar: Business Plans are a Research Endeavor
July 28, 2020
1:00-2:00 PM
More info here


Oregon Bio Event: Diversity, Equity and Inclusion Dialogue
July 30, 2020
11:30 AM-1:00 PM
Registration is free


PSBA Virtual Lunch & Learn: Conflict to Conversation
August 4, 2020
12:00-1:00 PM
Registration is free


Founders Live PDX
August 5, 2020
5:30 PM-8:00 PM
Free to attend – register here

Introducing OTRADI and OBI’s New Executive Director

Our new executive director will likely be an incredibly familiar face for many of you. 

That’s because OTRADI and OBI are pleased to report that our board of directors has unanimously ratified the proposal that Heather Ellis, former interim executive director for the organization, be promoted to the position of full-time executive director for OTRADI and OBI.

“Over the past three years, we have admired and appreciated Heather’s exceptional work at OTRADI and OBI, including her immediate willingness to step into the role of interim executive director,” said Joseph Janda, chairman of the OTRADI and OBI board of directors. “The board is thrilled to continue our work with her as she takes on the full-time role of executive director for our organization. We have the utmost confidence in her ability to lead the organization in this next chapter of its continuing evolution.”

After joining OTRADI and OBI in 2017, Heather was promoted to assistant director in early 2019. She assumed the role of interim executive director for the organization in July of that same year. She steps into the role as the third executive director for the organization. As part of assuming that role, she also joins the boards of the Oregon Bioscience Association and the Portland Innovation Quadrant. 

“I’m incredibly excited to begin this new phase of OTRADI and OBI,” said Ellis. “As an employee of OTRADI, I’ve had the honor and privilege to be at the forefront of healthcare innovation here in Oregon. Recognizing the decade long effort it has taken to get here, I am ecstatic to have the opportunity to lead our organization into its next chapter.” 

“In times like this, it’s especially humbling to have the opportunity to do this work. I look forward to working with each and every one of you as we continue to support Oregon entrepreneurs in improving healthcare for people around the world.”  

 

By Rick Turoczy

OBI & OTRADI June 2020 Newsletter

Heather Ellis Named as Executive Director

OTRADI/OBI’s board of directors has promoted Interim Director Heather Ellis to the position of full-time Executive Director for OTRADI and OBI.

“During my time at OTRADI and OBI, I have gained an even greater appreciation for the potential for innovation in healthcare – and Oregon’s opportunity to play a part in that innovation. OTRADI has been the forefront of healthcare innovation in the state of Oregon for more than a decade. I am honored and excited to leverage that history of work as we continue to support Oregon entrepreneurs in improving healthcare for people everywhere. I am incredibly excited to step into this role and continue supporting OBI and Oregon health innovation companies in my new position,” said Ellis. Read full press release here.

Big congratulations to Heather!


OBI Client Company Wins

Veana Therapeutics presented a poster at the American Society of Clinical Oncology annual meeting, which was held virtually May 29-31. The poster abstract titled “A phase I dose escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer” was presented by William Gwin, MD from the University of Washington, who is overseeing the clinical trial as its lead physician.

Madorra was featured in the May issue of Oprah Magazine, as a rising star in women’s health technology, improving the quality of women’s lives after breast cancer or menopause with their non-hormonal medical device to reduce vaginal dryness.

Caregiven‘s Candice Smith recently shared her story to over 400 live participants at the Global Insurance Accelerator’s Startup Showcase, which also resulted in several introductions to individuals and funds. You can watch the 6-minute pitch here.

Vir Bio announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus (HBV) and has been engineered to potentially also act as a therapeutic vaccine. They have also finalized a process development and manufacturing agreement with Biogen Inc. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir’s SARS-CoV-2 monoclonal antibodies for potential COVID-19 treatment.

Hemex Health‘s medical diagnostic device, Gazelle, was tested in the field alongside other malaria testing protocols, as published in the Lancet’s EClinicalMedicine. Gazelle was found to be a valuable diagnostic tool, and a fast and cost-effective way to test for malaria in field settings. Read the full text article here.


COVID-19 Resources for our Business Community

Business Oregon, alongside the Oregon Employment Department, the Oregon Secretary of State, and the Oregon Department of Consumer and Business Services compiled the information on this page to assist Oregon small business owners, employees, and others dealing with the impacts of COVID-19.

Oregon Manufacturing Extension Partnership (OMEP) has a COVID-19 Workplace Preparedness Assessment. The purpose of this assessment is to recommend/suggest ideas you may wish to consider as Oregon moves toward reopening in the aftermath of the COVID-19 pandemic. Take the assessment here.


Upcoming Events

OBI Events

Virtual Lunch & Learn: Pivot with Purpose –
Build Your Business Around Your Greatest Strength
 
June 17, 2020
12:00-1:00 PM
Register here – Free to attend

 

Virtual Lunch & Learn: They Said it Couldn’t be Done!
De-Risk Your Projects
 
July 22, 2020
12:00-1:00 PM
Free – Register here


Other Community Events

Cooley Healthtech Talks: Funding for Your Early Stage Startup:
A Roadmap to Seed + Series A Financing

 June 11, 2020
9:00-10:00 AM
Register to attend – Free

 

Current Trends in Venture Funding:
Perspective on Investments Post-Pandemic
June 16, 2020
10:00-11:00 AM
Register now – Free to attend

 

FAN BASE: Competitive Edge
 [PREGAME] Summer Business Coaching Series
 June 16, 2020
12:00-1:30 PM
More information

 

PDXWIT and PIE June Happy Hour
June 16, 2020
5:00-6:30 PM
Registration – Free to attend

 

University Lab Partners: 3 Steps to Make Your Boardroom
Team a Competitive Weapon
June 18, 2020
3:00-4:30 PM
Register here – Free

 

Founders Live PDX Virtual Experience
June 18, 2020
5:30-8:00 PM
Free to attend – Register here

 

Oregon Science Startup Forum
June 20, 2020
8:00 AM-7:00 PM
More information here

 

Bio, Business and Good Beans – Data Security and Privacy:
Managing Risks of Remote Work
June 24, 2020
9:15-10:00 AM
Free to attend – Registration link

 

OHSU INVENT Seminar: How to Leverage Market Research and
Customer Outreach to Successfully Launch Your Idea
June 25, 2020
Panelists include OBI client company leaders from Maddora and Hemex
Free to attend – Register here

 

NOW CFO Roadmap to Recovery Weekly Webinars
Wednesdays at 2 PM, Fridays at 12 noon
Learn more here

 

SciEducate Webinars
Series of upcoming webinars
More info here

OBI & OTRADI May 2020 Newsletter

Business Oregon Announces Enhanced Innovation Grant Program

The May 6, 2020 memo from Business Oregon states: “The Oregon Innovation Council (Oregon InC) supports companies with high-growth potential emerging from science and research. In 2018-2019, Oregon InC invested in 27 companies through the Enhanced Phase 0 program, providing critical gap funding between very early research and development funding sources and larger federal grants and/or private investment. These early investments supported innovative companies to scale up in Oregon, develop new technologies and products, create or retain jobs, and move products and services closer to market.

“Given the unprecedented COVID-19 crisis, continuing this support of innovation-based entrepreneurship is vital for Oregon’s economic recovery. In recognition of this crisis, Oregon InC is re-launching the Enhanced Phase 0 program, now named the Enhanced Innovation Grant program. The Enhanced Innovation Grants will be awarded to early-stage Oregon companies that:

  • are advancing innovation-based solutions related to the resolution or the management of the impacts of the COVID-19 pandemic or
  • have received previous Oregon InC funding and has made progress toward commercialization since that funding

“Proposals will be accepted until Wednesday, May 20th and will go through a formal review process. Full details can be found in the RFP document on Business Oregon’s website.”


OBI Client Company Wins

Health Technology Innovations, HTI, received the NSF Phase1 STTR award for CryoDiscovery ™ : An integrated cryo-EM intelligence solution. CryoDiscoveryTM: A Machine Learning Platform for Automated Cryo-electron Microscopy Particle Classification paper has been accepted to the Microscopy & Microanalysis August 2020 Conference. CryoDiscovery ™ Alpha released and being tested at OHSU. HTI LLC is now HTI Inc. Dr. Gershon Wolfe joined HTI as Director of R&D. HTI is looking for a machine learning development engineer and computer science interns.

On April 6, 2020, Vir Biotechnology announced a collaboration with GlaxoSmithKline for research and development of coronavirus solutions. GSK’s investment and genomics expertise, combined with Vir Bio’s proprietary technology, will work to develop therapies and prevention for coronaviruses. Read their full press release.

Hemex Health is partnering with PAI Life Sciences in Seattle to create a rapid COVID-19 test on Hemex’s Gazelle Diagnostic platform. The test is designed for affordable use in remote locations with limited resources. The Portland Business Journal recently reported on this important collaboration. Link to full article here.

Virogenomics Bio Development, VBD, had a big win in April. In collaboration with Arthur Vandenbark at OHSU and the VA, VBD was awarded a three year, $3M Phase IIB SBIR. This project will advance a recombinant protein, DRhQ, that has the potential to treat multiple sclerosis (MS) and other conditions with neuro inflammatory components. The aims of this project are to transfer production of DRhQ to a GMP manufacturer, determine its potential toxicity in two species and develop assays for evaluating its safety and efficacy after administration. These aims will provide preclinical data for an IND submission, a critical step in creating an FDA approved drug.

Madorra‘s first patent has issued. This is the original patent they submitted while in the Stanford Biodesign Fellowship program. It has broad coverage of the use of ultrasound for treating vaginal dryness. They also presented during Avestria’s women’s health breakfast at the JP Morgan Healthcare conference in January. Madorra was featured in the Fogarty Institute’s February Newsletter. And later that month, the Portland Tribune wrote an article about how they are leading a revoluation in women’s healthcare.


OBI’s Mentoring Program Now Accepting Mentee Applications

Last month we told you about our newly expanded Mentoring Program. We are pleased to announce that we’re now accepting applications to become a mentee.

Are you an entrepreneur with an early-stage or developing company in the bioscience or digital health industry? Did you know that mentoring helps you grow your business? A recent survey from Kabbage found that only 22% of businesses had mentors when they started their company, and 92% of business who have a mentor say mentoring has directly impacted their business growth and survival.

OBI’s mentoring program is a 6-month structured program, with our next cohort beginning July 1, 2020.

Apply now to become a Mentee! But act quickly – mentee applications are only open until May 15. Note: This program is open to all; however, priority will be given to OBI client companies.

Please see our Mentoring page for Fast Facts about mentoring, and a link to the application.


Welcome to our new Administrative Assistant, Kaci Garcia!

Ms. Garcia joined OBI in March 2020 as an Administrative Assistant. She is responsible for daily operations, the main point of contact for the companies in the incubator, and will be the office receptionist when we’re back in the office after Governor Brown’s Stay Home order is lifted.

Ms. Garcia graduated summa cum laude in 2019 from Portland State University with a B.A. in Arts and Letters and a minor in Art History. She also has an AAS in paralegal studies and an AGS from Portland Community College. Her professional background includes general office administration and work as a legal assistant in the field of business immigration law.


Upcoming Events

TAO Event: Virtual Lunch & Learn: Preventing Burnout
May 13, 2020
11:30 AM-1:00 PM
Details here

 

VertueLab/BBC Webinar: ABCs of SBIR/STTR Funding
May 13, 2020
12:00-1:30 PM
Register to attend – Free

 

OEN Event: BYOB May Pubtalk – It’s Time to Build
May 13, 2020
5:30-7:00 PM
Information here

PSBA Virtual Lunch & Learn: What Leaders Need to Know About Negotiation
May 20, 2020
12:00-1:00 PM
More information here

PSBA Virtual Lunch & Learn: Conflict to Conversation
June 3, 2020
12:00-1:00 PM
More information here

 

NOW CFO Webinars: Roadmap to Recovery Weekly Webinars
Wednesdays at 2 PM, Fridays at 12 noon
Learn more here

 

SciEducate Webinars: SBIR Miniseries
Series of 4 webinars
More info here

 

BIO International Event: BIO Digital
June 8-12, 2020
For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive your business, and the insights you need to continue critical research and development.
Register here

 

OBI Event: Virtual Lunch & Learn – Pivot with Purpose: Build Your Business Around Your Greatest Strength
June 17, 2020
12:00-1:00 PM
More information here – Free to attend

OBI & OTRADI April 2020 Newsletter

Stay Home. Save Lives.

OBI staff is complying with Governor Kate Brown’s directive to Stay Home, Save Lives. The employees in the administrative office of OBI/OTRADI is teleworking during this time, but please know that we are still here for you. Some of our client companies have staff working from home, while their staff working on essential research may continue working in their offices and laboratories, utilizing safe distancing and hygiene practices. We’re all working diligently to take steps to reduce the spread of Coronavirus and avoid getting sick with COVID-19.


Oregon and Federal Resources for Business

This pandemic is affecting businesses large and small. Here are some resources that we hope you find helpful during this time:


Caregiven Featured in Artificial Intelligence in Medicine

Caregiven, one of OBI’s digital health startup companies, was featured in the AIMed March 5, 2020 special report entitled “Women in AI – DeathTech.” Caregiven’s digital health platform guides families to the appropriate end-of-life support and services so they can spend less time overwhelmed by administrative tasks and more meaningful time with their loved one. If you are unable to view the entire article, please email candice@caregiven.co (not .com) for a PDF copy.


Dr. David Farrell of Gamma Therapeutics gives TEDx Talk

Can We More Accurately Predict Heart Attacks and Strokes? Dr. David Farrell, TEDxMcMinnville, March 6, 2020


“Can we more accurately predict heart attacks and strokes? The clot thickens…” (Read full OHSU article here)


OBI Companies Combat Covid-19

Hemex Health is working on a fast, low cost and accurate point of care diagnostic for COVID-19. It is built on our miniaturized electrophoresis platform. We are applying for grants to do the needed work.

Nelson Bio Lab is working with other companies to develop COVID-19 diagnostic kits. We already have samples and have obtained samples from other Chinese companies. The FDA has accepted them. If necessary, we can provide kits.

Rewire Neuroscience is a provider of artificial intelligence technologies intended to quickly and accurately detect biomarkers for diseases and other physiological states in tissue samples and cell cultures. We offer core AI, machine learning, and computer vision services for integration into biomarker detection workflows. This technology can be used for automated analysis of diagnostic testing kits and assays. Rewire Neuroscience is an Oregon startup that is funded by state and federal grants and located at the Oregon Bioscience Incubator.

RxHomeTest has launched a COVID-19 PCR test kit that can be ordered by clinicians for their patients with symptoms (not available for direct-to-consumer yet). You can contact them at test@rxhometest.com for more information.

Sirona Dx can accelerate your COVID-19 studies! Our expert team offers the industry’s most comprehensive immune profiling of blood samples using state-of-the-art CyTOF technology. We’ll help you maximize results from precious blood samples of COVID-19 patients and translate new discoveries into better clinical outcomes. Using antibody panels developed for single-cell mass cytometry, we can simultaneously analyze 44 immune markets in less than 300 µL of blood and help you identify immune signatures to reveal the best treatment and immunization strategies.

Sonivate Medical, Inc. is part of a group of institutions (including Duke University Medical School) which submitted a White Paper on 3/21 regarding detection of COVID-19 using artificial intelligence (AI) and Sonivate’s SonicEye Dual-Array Ultrasound System.  The approach is to use Sonivate’s High Frequency Linear array to scan the lung. Up to 80 participants will be evaluated in North Carolina comparing their ultrasound images to those of their CT-Scans. The AI algorithms will be based on these findings and integrated with early images/findings from China. It is expected to be a 6-9 month program. The objective is to evaluate a patient’s condition on a 20 point scale with a minimally trained clinician. This is a proposal and does not have any certainty of being awarded.

StoneStable, Inc. is not directly working on SARS-CoV-2, but are working on how to make vaccines better, including potential SARS-CoV-2 vaccines and testing kits.

Vir Biotechnology announced that “. . . laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and that it would pursue testing them in people.” Read full STAT article here.


OBI’s NEW Mentoring Program

Exciting news! We have listened to your feedback and have ravamped our biomentor program!

The newly expanded program is in two separate parts:

  • A structured 6-month Mentoring Program
  • And a more informal Advising Program

Apply now! Applications to become a Mentor are open now! Applications for Mentees will open in May.

Please see our Mentoring page for Fast Facts about both programs and links to the applications.


Upcoming Events

OBI Event: Virtual Lunch & Learn – Negotiate Like a Boss by Being Yourself
April 14, 2020
12:00-1:00 PM
Register here
Free to attend – join us from the comfort of your home or office,
but register soon because tickets are going fast!

 


OBI Event: Virtual Lunch & Learn – Financial Projections in the Time of Coronavirus

April 21, 2020
12:00-1:00 PM
Register here
Free to attend – join us from the comfort of your home or office!

 

OBI Partner Event: Pacific Northwest Healthcare Demo Day
This virtual event launches April 8, 2020
Information and Registration

OBI Companies pitching in this event include: 

Bates Medical Systems
Caregiven
Hemex Health
Madorra
OmnEcoil Instruments
StoneStable
Suturegard Medical, Inc.
HealthSaas (OBI Graduate)
Sparrow Pharmaceuticals (OBI Graduate)

 

TAO Webinar: Maintaining Connection & Collaboration While Teleworking
April 9, 2020
11:00 AM-12:00 PM
Information and Registration

 

BIO International Event: BIO International Convention
June 8-11, 2020
San Diego, CA
Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology event. Apply now.

OBI & OTRADI February/March 2020 Newsletter

Boulder Care Partnering with Blue Cross for Addiction Treatment

The Portland Business Journal featured Boulder Care‘s new partnership with Blue Cross in helping its members access opioid addiction treatment. “Portland startup . . . Boulder Care is trying to make medication-assisted treatment accessible to more people, especially those in rural areas, with the hope of scaling its telemedicine-based buprenorphine program to hundreds of thousands, if not millions, of Americans in the next couple of years.” (Read article here)


OBI Client Company Wins

  • Rewire Neuroscience (photo of Founder & CEO John Harkness, above) was recently featured in a Portland Business Journal article about how artificial intelligence is changing the way humans and machines work.
  • Hemex Health was highlighted in the Elevate Capital monthly newsletter. The article discussed Hemex Health’s efforts in a clinical study in Ghana, to screen for and monitor sickle cell disease.
  • OBI graduate AbSci had an Expansion Celebration and ribbon cutting at its new location.
  • Senju Pharmaceutical Co. recently launched a new treatment with Otsuka for glaucoma and ocular hypertension.
  • On February 8, Consano held an event called Consano PDX at the Portland Art Museum, to honor and raise funds for their 2020 Ripples of Hope Winner, Dr. Alexandra Butler.
  • SUTUREGARD Medical just published a journal article in JAAD Case Reports about their HEMIGARD device for wound closure. They also recently received orders for devices from Kenya, Jordan, United Arab Emirates, and Zimbabwe after participating in Arab Health in Dubai.
  • Want to know more about Aronora‘s new antithrombotic, AB002? Check out the latest Blood Podcast from the American Society of Hematology.

OBI Mentoring Program

Our BioMentor program is in the process of being revamped. Look for more information in the next month!


Upcoming Events

OBI Event: Accelerate Biotech & Digital Health Happy Hour
March 5, 2020
5:30 – 7:00 PM
Join the Waiting List. Free to attend.

OBI Event: Lunch & Learn – Aus-Trial-ia: Early Phase Clinical Trials in Australia
March 10, 2020
12:00 -1:00 PM
Register now, just a few seats left! Free to attend.

OBI Event: Lunch & Learn – Financial Projections – NOW CFO Financial Series #3
March 24, 2020
12:00 -1:00 PM
Register here. Free to attend.


OEN & OTBC Event: Workshop – Startup 411 – How to Start Your Startup
March 5, 2020
11:30 AM – 2:30 PM
Details here
PSU Event: ProductCamp Portland
March 7, 2020
8:30 AM – 5:30 PM
Register here

Oregon Bioscience Association Event: BIO on the Rocks
March 12, 2020
5:00 – 8:00 PM
Details here
OHSU Event: INVENT and SoPE Panel – Explore Alternative Funding Sources
March 18, 2020
5:00 – 7:00 PM
Register here. Free to attend.
Science Talk Event: Science Talk 20
March 26-27, 2020
Tiffany Center in Portland
Details here

OHSU Event: Invent-a-thon
May 1-3, 2020
Portland, OR
Details here

BIO International Event: BIO International Convention
June 8-11, 2020
San Diego, CA
Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology event. Apply now.

OBI & OTRADI 2019 End of Year Newsletter

Congratulations to OBI/OTRADI graduate AbSci for starting off the new year with a $10 million funding round and more growth on the horizon!

 


Thank you for your support of
OBI & OTRADI over the past year!


From 2015 to 2019, OBI Client Companies have:


2019 OBI Client Company Wins

  • Aronora has completed a first-in-human clinical trial of their unique FXI inhibitor. 
  • Aronora announced a $9M+ deal for drug royalties from their novel stroke, clots and heart disease products.
  • Aronora was just awarded a new Fast Track Phase I/II SBIR grant from the NIH for $2.5 million to help support the phase 2 clinical trial of AB002 (E-WE thrombin).
  • Aronora has started a phase 2 clinical trial of AB002, a novel recombinant antithrombotic and anti-inflammatory enzyme. This is their third product candidate, in addition to AB012 and AB023, that had passed phase one. Information on this trial is available here.
  • Aronora was awarded an SBIR matching grant from Business Oregon at the end of 2019.

  • Floragenex saw a 13% increase in sales in 2019.
  • Floragenex tested and validated operational plans to improve:
    • Efficiency of lab processing by 5%
    • Lab throughput by 15%
    • Reduce cost by 5%

  • Hemex Health was invited to present at the RESI Conference during JP Morgan week in San Francisco.
  • Hemex Health was awarded a $150,000 SBIR grant to design and automate an affordable microchip-electrophoresis for sickle cell disease using a test cartridge that can be used in Hemex Health’s portable, easy-to-use analysis equipment.
  • Hemex Health was invited to Ghana to discuss therapy for sickle cell patients. They also toured Korle Bu Teaching Hospital, which has been working to institute sickle cell screening for all newborns.
  • Hemex Health won a $45K Catalyzing Pediatric Innovation Grant from CTIP (Consortium for Technology & Innovation in Pediatrics). The Grant will fund a study in Ghana to determine if a large number of infants can be screened efficiently for sickle cell disease during the vaccination process. Hemex presented at the CTIP Symposium held in Los Angeles.

  • OmnEcoil performed initial imaging-only testing of the OmnEcoil device on 7 patients.
  • OmnEcoil finalized device design and prototype manufacturing after their initial patient testing.
  • OmnEcoil obtained a Business Oregon SBIR matching grant of $50,000
  • OmnEcoil submitted a pending $1.5M NIH grant application to fund a clinical trial of the device (both prostate imaging and biopsy) in ~40 patients.

  • ProMedix was awarded a $100,000 Enhanced Phase 0 Grant for their medical device to measure dehydration.
  • ProMedix received an investment from Ideaship LLC, which is a patent equity firm, to further establish their patent portfolio.

  • Sirona Dx expanded pharma/biotech client base from 10 to 33
  • Sirona Dx launched the Immune Portrait TME panel, enabling comprehensive analysis of the tumor microenvironment at sub-cellular resolution
  • Sirona Dx expanded capabilities with addition of secure server and document control room to meet requirements of pharma clients
  • Sirona Dx expanded executive leadership team with key strategic hires including:
    • James Rader, Chief Financial Officer
    • Camille B. Troup, Ph.D. Chief Technology Officer
    • Anup Madan, Ph.D. Chief Operating Officer
    • Ken J. Pennline, Ph.D. (RED Consulting), Business Strategy Advisor

  • StoneStable was awarded a $49,930 STTR grant for stabilization of influenza vaccine by silica-coating. The company will conduct additional experiments to demonstrate efficacy of silica-coated flu vaccines that are much more stable than existing means.
  • SUTUREGARD Medical was chosen from many startups to participate in the Innovation Pitch Competition and JP Morgan/RESI in San Francisco January 8th.
  • SUTUREGARD presented at the Med Tech Monday in Costa Mesa on January 28th.
  • SUTUREGARD completed round 2 of Willamette Valley Capital’s pitch series.
  • SUTUREGARD participated in a surgical trade show in Las Vegas on February 3rd.
  • SUTUREGARD has completed their seed round. Kaiser Permanente has approved their device for a 3-month product trial and surgeons from multiple specialties will be involved in this clinical trial.
  • SUTUREGARD in introducing another Class I product, the HEMIGARDTM.
  • SUTUREGARD now has 4 patents and 7 pending patents including international submissions.
  • SUTUREGARD has partnered with OPERATION SMILE, the most prestigious global plastic surgery organization serving the underprivileged peoples of the world.
  • SUTUREGARD has partnered with 9 sales consultants, covering the sunbelt regions of the US and all have existing relationships and accounts in SUTUGARD’s target specialties (dermatology, Mohs, general surgery and plastics).
  • WebMarkets has updated SUTUREGARD’s website and is working on optimizing their SEO. Check out their new website (www.suturegard.com) and store (www.suturegard.store).
  • SUTUREGARD has finalized their supply chain. The SUTUREGARD ISR is manufactured by Molded Devices Inc in Tempe, AZ, and the HEMIGARD by MBK Adhesives in Chatsworth, CA. Both products are sterilized and packaged by DemeTECH in Miami Lakes, FL.  SUTUREGARD has partnered with Preferred Depot in Tustin, CA for domestic order fulfillment. 
  • SUTUREGARD recently recently returned from MEDICA, the worlds’ largest MedTech exposition, held this November 18-21 in Dusseldorf Germany! Thank you to Business Oregon for the support!

  • Virogenomics BioDevelopment was awarded a $99,173 SBIR Phase II Matching Grant to work on protein therapeutic treatments for multiple sclerosis, stroke and meth addiction.
  • Virogenomics BioDevelopment was awarded a phase 1 sttr in March DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder”, collaborating with Jennifer Loftis and Marilyn Huckans, at OHSU & the VA. $300k
  • Virogenomics BioDevelopment was awarded a phase I SBIR in September, “Developing novel fibrillin biomarkers for aortic disease”, collaborating with Lynn Sakai, OHSU & Shriner’s Children’s Hospital. $268k
  • Virogenomics BioDevelopment applied for and was accepted into the NIH Commercialization Accelerator Program (CAP) program, as part of our ongoing Phase II STTR work for “Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects”.  The NIH CAP program provides mentoring and consultants to advise and help overcome hurdles to commercialization. 

OBI WELCOMED ELEVEN
NEW STARTUPS TO OUR INCUBATOR IN 2019


Click here to learn more about our new companies.

 


Upcoming Events


 OBI EVENT:
Lunch & Learn
The Space Race: Find and Equip Lab Space Quickly and Cost Effectively
February 20, 2020
12:00-1:00 PM
Register Now!
 

OBI EVENT: Accelerate Biotech & Digital Health Happy Hour
March 5, 2020
 5:30-7:00 PM
Register Now!
 


TAO EVENT: PDX Lunch & Learn – The Ultimate Guide to Communication & Management Across Generations
February 12, 2020
11:30 AM – 1:00 PM
Details Here

 

OEN EVENT: PubTalk –  Picking the Right Incubator, Accelerator, or Co-Working Space
February 12, 2020
5:15 – 7:00 PM
Details Here
 
 

OEN EVENT: PubTalk – Learning From Failure
February 19, 2020
5:15 – 7:00 PM
Details Here
 
 

BIOCOM EVENT: Biocom’s Global Life Science Partnering Conference
February 25-27, 2020
San Diego, CA
Details Here
 
 

OEN & OTBC EVENT: Workshop – Startup 411 – How to Start Your Startup
March 5, 2020
11:30 AM – 2:30 PM
Details Here
 
 

OREGON BIOSCIENCE ASSOCIATION EVENT: BIO on the Rocks
March 12, 2020
5:00 – 8:00 PM
Details Here
 



Applications NOW OPEN for
Springboard Enterprises’ 2020 Health Innovation Hub: Life Sciences

Springboard is now recruiting women-led life science and healthcare companies seeking growth funding and connections to experts and strategic partners for product development and expansion. Areas of focus for the program include (but are not limited to) drugs, therapeutics, diagnostics, medtech, and medical devices.

The 2020 Health Hub programming has a special focus on women’s health innovation. Applications will be open through February 19th-24th (priority deadline February 19).

Apply Now!